WO2002059110A1 - Pyrimidineamines as angiogenesis modulators - Google Patents

Pyrimidineamines as angiogenesis modulators Download PDF

Info

Publication number
WO2002059110A1
WO2002059110A1 PCT/US2001/049367 US0149367W WO02059110A1 WO 2002059110 A1 WO2002059110 A1 WO 2002059110A1 US 0149367 W US0149367 W US 0149367W WO 02059110 A1 WO02059110 A1 WO 02059110A1
Authority
WO
WIPO (PCT)
Prior art keywords
methyl
hydrogen
amino
indazol
alkyl
Prior art date
Application number
PCT/US2001/049367
Other languages
French (fr)
Inventor
Amogh Boloor
Mui Cheung
Ronda Davis
Philip Anthony Harris
Kevin Hinkle
Robert Anthony Mook, Jr.
Jeffery Alan Stafford
James Marvin Veal
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26946028&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2002059110(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to DE122010000038C priority Critical patent/DE122010000038I1/en
Priority to CNB018227503A priority patent/CN1307173C/en
Priority to NZ526542A priority patent/NZ526542A/en
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Priority to JP2002559412A priority patent/JP4253188B2/en
Priority to CA2432000A priority patent/CA2432000C/en
Priority to KR1020037008349A priority patent/KR100847169B1/en
Priority to DK01994315T priority patent/DK1343782T3/en
Priority to PL363243A priority patent/PL214667B1/en
Priority to AT01994315T priority patent/ATE430742T1/en
Priority to AU2002246723A priority patent/AU2002246723B2/en
Priority to SI200130922T priority patent/SI1343782T1/en
Priority to IL15630601A priority patent/IL156306A0/en
Priority to DE60138645T priority patent/DE60138645D1/en
Priority to EP01994315A priority patent/EP1343782B1/en
Priority to BR0116452-0A priority patent/BR0116452A/en
Priority to US10/451,305 priority patent/US7105530B2/en
Priority to MXPA03005696A priority patent/MXPA03005696A/en
Priority to HUP0400691A priority patent/HU230574B1/en
Publication of WO2002059110A1 publication Critical patent/WO2002059110A1/en
Priority to IL156306A priority patent/IL156306A/en
Priority to ZA2003/04482A priority patent/ZA200304482B/en
Priority to NO20032831A priority patent/NO325987B1/en
Priority to HK04101322.3A priority patent/HK1059926A1/en
Priority to US11/383,229 priority patent/US7262203B2/en
Priority to US11/830,024 priority patent/US7858626B2/en
Priority to US11/830,608 priority patent/US8114885B2/en
Priority to CY20091100644T priority patent/CY1109160T1/en
Priority to US12/609,398 priority patent/US20100105712A1/en
Priority to LU91710C priority patent/LU91710I2/en
Priority to CY2010014C priority patent/CY2010014I1/en
Priority to BE2010C030C priority patent/BE2010C030I2/fr
Priority to FR10C0037C priority patent/FR10C0037I2/en
Priority to NO2010020C priority patent/NO2010020I1/en
Priority to US13/545,029 priority patent/US20120277258A1/en
Priority to NO2022001C priority patent/NO2022001I1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/30—Halogen atoms or nitro radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Definitions

  • the present invention relates to pyrimidine derivatives, compositions and medicaments containing the same, as well as processes for the preparation and use of such compounds, compositions and medicaments.
  • pyrimidine derivatives are useful in the treatment of diseases associated with inappropriate or pathological angiogenesis.
  • angiogenesis is the development of new blood vessels from the preexisting vasculature.
  • Angiogenesis is defined herein as involving: (i) activation of endothelial cells; (ii) increased vascular permeability; (iii) subsequent dissolution of the basement membrane and extravasation of plasma components leading to formation of a provisional fibrin gel extracellular matrix; (iv) proliferation and mobilization of endothelial cells; (v) reorganization of mobilized endothelial cells to form functional capillaries; (vi) capillary loop formation; and (vi) deposition of basement membrane and recruitment of perivascular cells to newly formed vessels.
  • Normal angiogenesis is active during tissue growth from embryonic development through maturity and then enters a period of relative quiescence during adulthood.
  • angiogenesis is also activated during wound healing, and at certain stages of the female reproductive cycle. Inappropriate or pathological angiogenesis has been associated with several disease states including various retinopathies, ischemic disease, atherosclerosis, chronic inflammatory disorders, and cancer. The role of angiogenesis in disease states is discussed, for instance, in Fan et al, Trends in Pharmacol Sci. 16:54-66; Shawver et al, DDT Vol. 2, No. 2 February 1997; Folkmann, 1995, Nature Medicine 1 :27-31.
  • VEGF vascular endothelial growth factor
  • VEGFRs vascular endothelial growth factor receptor(s)
  • VEGF is a polypeptide, which has been linked to inappropriate or pathological angiogenesis (Pinedo, H.M. et al The Oncologist, Vol.5, No. 90001 , 1 -2, April 2000).
  • VEGFR(s) are protein tyrosine kinases (PTKs) that catalyze the phosphorylation of specific tyrosine residues in proteins that are involved in the regulation of cell growth, differentiation, and survival.
  • PTKs protein tyrosine kinases
  • VEGFR1 Flk-1 and KDR
  • VEGFR3 Flt-4
  • VEGFR2 is a transmembrane receptor PTK expressed primarily in endothelial cells.
  • VEGF vascular endothelial growth factor-2
  • VEGF expression may be constitutive to tumor cells and can also be upregulated in response to certain stimuli.
  • One such stimulus is hypoxia, where VEGF expression is upregulated in both tumor and associated host tissues.
  • the VEGF ligand activates VEGFR2 by binding to its extracellular VEGF binding site. This leads to receptor dimerization of VEGFRs and autophosphorylation of tyrosine residues at the intracellular kinase domain of VEGFR2.
  • the kinase domain operates to transfer a phosphate from ATP to the tyrosine residues, thus providing binding sites for signaling proteins downstream of VEGFR-2 leading ultimately to angiogenesis.
  • antagonism of the VEGFR2 kinase domain would block phosphorylation of tyrosine residues and serve to disrupt initiation of angiogenesis.
  • VEGFR2 kinase domain inhibition at the ATP binding site of the VEGFR2 kinase domain would prevent binding of ATP and prevent phosphorylation of tyrosine residues.
  • Such disruption of the pro-angiogenesis signal transduction pathway associated with VEGFR2 should therefore inhibit tumor angiogenesis and thereby provide a potent treatment for cancer or other disorders associated with inappropriate angiogenesis.
  • the present inventors have discovered novel pyrimidine derivative compounds, which are inhibitors of VEGFR-2 kinase activity. Such pyrimidine derivatives are useful in the treatment of disorders, including cancer, associated with inappropriate angiogenesis.
  • Xi is hydrogen, C1-C4 alkyl, C ⁇ -C 4 haloalkyl, or C ⁇ -C 4 hydroxyalkyl
  • X 2 is hydrogen, G-C 4 alkyl, C ⁇ -C 4 haloalkyl, C(0)R 1 , or aralkyl
  • X3 is hydrogen or halogen
  • X 4 is hydrogen, C1-C4 alkyl, C1-C4 haloal y ⁇ , heteroaralkyl, cyanoalkyl, -(CH2)pC ⁇ C(CH 2 )tH, or C3-C7 cycloalkyl; p is 1, 2, or 3; t is 0 or 1
  • W is N or C-R, wherein R is hydrogen, halogen, or cyano;
  • Qi is hydrogen, halogen, C1-C2 haloalkyl. C1-C2 alkyl, C1-C2 alkoxy, or C ⁇ -C2 haloalkoxy; Q2 is A 1 or A 2 ;
  • Q3 is A 1 when Ch is A 2 and Q 3 is A 2 when Q2 is A 1 ;
  • a 1 is hydrogen, halogen, C1-C3 alkyl, C1-C3 haloalkyl, -OR 1
  • a 2 is the group defined by -(Z) m -(Z 1 )-(Z 2 ), wherein Z is CH2 and m is 0, 1, 2, or 3, or Z is NR 2 and m is 0 or 1, or Z is oxygen and m is 0 or 1 , or
  • Z is CH 2 NR 2 and m is 0 or 1 ;
  • Z 1 is S(0) 2 , S(0), or C(0); and
  • Z 2 is C1-C4 alkyl, NR 3 R 4 , aryl, arylamino, aralkyl, aralkoxy, or heteroaryl,
  • R 1 is Ci-C+alkyl;
  • R 2 , R 3 , and R 4 are each independently selected from hydrogen, C ⁇ -C 4 alkyl, C3-C7 cycloalkyl,
  • R 5 is Ci-C alkyl, or C3-C7 cycloalkyl; and when Z is oxygen then Z 1 is S(0)2 and when D is
  • X2 is C1-C4 alkyl, G-C haloalkyl, C(0)R 1 , or aralkyl.
  • X1 is hydrogen, C1-C4 alkyl, C1-C haloalkyl, or C ⁇ -C4 hydroxyalkyl
  • X2 is hydrogen, G-Gtalkyl.
  • X3 is hydrogen or halogen
  • X4 is hydrogen, C1-C4 alkyl, C1-C4 haloalkyl, heteroaralkyl, cyanoalkyl, -(CH 2 )pC ⁇ C(CH2)tH, or C3-C7 cycloalkyl; p is 1 , 2, or 3; t is 0 or 1 ;
  • W is N or C-R, wherein R is hydrogen, halogen, or cyano;
  • Qi is hydrogen, halogen, C1-C2 haloalkyl, C1-C2 alkyl, C1-C2 alkoxy, or G-C ⁇ haloalkoxy;
  • Q2 is A 1 or A 2 ;
  • Q3 is A 1 when Q2 is A 2 and Q 3 is A 2 when Q2 is A 1 ;
  • a 1 is hydrogen, halogen, C1-C3 alkyl, C1-C3 haloalkyl, -OR 1
  • a 2 is the group defined by -(Z)m-(Z 1 )-(Z 2 ), wherein
  • Z is CH2 and m is 0, 1, 2, or 3, or
  • Z is NR 2 and m is 0 or 1, or
  • Z is oxygen and m is 0 or 1, or
  • Z is CH 2 NR 2 and m is O or 1 ;
  • Z 1 is S(0) 2 , S(0), or C(0)
  • Z 2 is C1-C4 alkyl, NR 3 R ⁇ aryl, arylamino, aralkyl, aralkoxy, or heteroaryl, R 1 is C ⁇ -C 4 alkyl;
  • R 2 , R 3 , and R 4 are each independently selected from hydrogen, C1-C4 alkyl, C3-C7 cycloalkyl, S(0) 2 R 5 , and -C(0)R 5 ;
  • R 5 is C1-C4 alkyl, or C3-C7 cycloalkyl; and when Z is oxygen then Z 1 is S(0)2.
  • Xi is hydrogen, G-C 4 alkyl, C1-C haloalkyl, or G-C4 hydroxyalkyl
  • X2 is C1-C4 alkyl, G-C 4 haloalkyl, or C(0)R 1 ;
  • X3 is hydrogen or halogen;
  • X 4 is hydrogen, C1-C4 alkyl, G-C haloalkyl, heteroaralkyl, cyanoalkyl, -(CH 2 )pC ⁇ C(CH2)tH, or C3-C7 cycloalkyl; p is 1 , 2, or 3; t is 0 or 1 ;
  • W is N or C-R, wherein R is hydrogen, halogen, or cyano;
  • Qi is hydrogen, halogen, C1-C2 haloalkyl, C1-C2 alkyl, C1-C2 alkoxy, or G-C2 haloalkoxy;
  • Q 2 is A 1 or A 2 ;
  • Q 3 is A 1 when Ck is A 2 and Q3 is A 2 when Q2 is A 1 ;
  • a 1 is hydrogen, halogen, C1-C3 alkyl, C1-C3 haloalkyl, -OR 1
  • a 2 is the group defined by -(Z)m-(Z 1 )-(Z 2 ), wherein Z is CH2 and m is 0, 1 , 2, or 3, or Z is NR 2 and m is 0 or 1 , or Z is oxygen and m is 0 or 1 , or Z 1 is S(0) 2 , S(0), or C(0); and
  • Z 2 is C1-C4 alkyl, NR 3 R 4 , aryl, arylamino, aralkyl, aralkoxy, or heteroaryl, R 1 is Ci-C* alkyl ; R 2 , R 3 , and R 4 are each independently selected from hydrogen, C1-C alkyl, C3-C7 cycloalkyl, - S(0) 2 R 5 , and -C(0)R 5 ; R 5 is C1-C4 alkyl, or C3-C7 cycloalkyl; and when Z is oxygen then Z 1 is S(0)2.
  • Xi is hydrogen, C1-C4 alkyl, C1-C4 haloalkyl, or G-C4 hydroxyalkyl
  • X2 is hydrogen, C,-C 4 alkyl, C1-C4 haloalkyl, or C(0)R ⁇ or aralkyl
  • X3 is hydrogen or halogen
  • X4 is hydrogen, C1-C4 alkyl, C1-C4 haloalkyl, heteroaralkyl, cyanoalkyl, -(CH2) P C ⁇ C(CH 2 )tH, or C3-C7 cycloalkyl; p is 1 , 2, or 3; t is 0 or 1 ;
  • W is N or C-R, wherein R is hydrogen, halogen, or cyano;
  • Qi is hydrogen, halogen, C1-C2 haloalkyl, C1-C2 alkyl, C1-C2 alkoxy, or G-C2 haloalkoxy;
  • Q 2 is A' or A 2 ;
  • Q3 is A 1 when Q2 is A 2 and Q 3 is A 2 when Q2 is A 1 ;
  • a 1 is hydrogen, halogen, C1-C3 alkyl, C1-C3 haloalkyl, -OR 1 , and i
  • a 2 is the group defined by -(Z) m -(Z 1 )-(Z 2 ), wherein Z is CH2 and m is 0, 1 , 2, or 3, or Z is NR 2 and m is 0 or 1, or Z is oxygen and m is 0 or 1 , or Z 1 is S(0) 2 , S(0), or C(O); and
  • Z 2 is C1-C4 alkyl, NR 3 R 4 , aryl, arylamino, aralkyl, aralkoxy, or heteroaryl, R 1 is C1-C4 alkyl; R 2 , R 3 , and R 4 are each independently selected from hydrogen, G-C 4 alkyl, C3-C7 cycloalkyl, -
  • R 5 is C ⁇ -C 4 alkyl, or C3-C7 cycloalkyl; and when Z is oxygen then Z 1 is S(0
  • a pharmaceutical composition including a therapeutically effective amount of a compound of formula (1) or a salt, solvate, or a physiologically functional derivative thereof and one or more of pharmaceutically acceptable carriers, diluents and excipients.
  • a method of treating a disorder in a mammal, said disorder being mediated by inappropriate VEGFR2 activity including: administering to said mammal a therapeutically effective amount of a compound of formula (I) or a salt, solvate or a physiologically functional derivative thereof.
  • a compound of formula (I), or a salt, solvate, or a physiologically functional derivative thereof for use in therapy is provided.
  • a method of treating a disorder in a mammal including: administering to said mammal therapeutically effective amounts of (i) a compound of formula (I), or a salt, solvate or physiologically functional derivative thereof and (ii) an agent to inhibit growth factor receptor function.
  • a method of treating a disorder in a mammal including: administering to said mammal a therapeutically effective amount of a compound of formula (I), or a salt, solvate or physiologically functional derivative thereof.
  • a method of treating cancer in a mammal including administering to said mammal a therapeutically effective amount of a compound of formula (I), or salt, solvate or physiologically functional derivative thereof.
  • a method of treating cancer in a mammal including administering to said mammal therapeutically effective amounts of (i) a compound of formula (I), or salt, solvate or physiologically functional derivative thereof and (ii) at least one additional anti-cancer therapy.
  • the term "effective amount” means that amount of a drug or pharmaceutical agent that will elicit the biological or medical response of a tissue, system, animal or human that is being sought, for instance, by a researcher or clinician.
  • therapeutically effective amount means any amount which, as compared to a corresponding subject who has not received such amount, results in improved treatment, healing, prevention, or amelioration of a disease, disorder, or side effect, or a decrease in the rate of advancement of a disease or disorder.
  • the term also includes within its scope amounts effective to enhance normal physiological function.
  • lower refers to a group having between one and six carbons.
  • alkyl refers to a straight or branched chain hydrocarbon having from one to twelve carbon atoms, optionally substituted with substituents selected from the group consisting of lower alkyl, lower alkoxy, lower alkylsulfanyl, lower alkylsulfenyl, lower alkylsulfonyl, oxo, mercapto, amino optionally substituted by alkyl, carboxy, carbamoyl optionally substituted by alkyl, aminosulfonyl optionally substituted by alkyl, nitro, or lower perfluoroalkyl, multiple degrees of substitution being allowed.
  • substituents selected from the group consisting of lower alkyl, lower alkoxy, lower alkylsulfanyl, lower alkylsulfenyl, lower alkylsulfonyl, oxo, mercapto, amino optionally substituted by alkyl, carboxy, carbamoyl optionally substituted by alkyl, aminosulfonyl
  • C1-C4 alkyl refers to an alkyl group, as defined above, which contains at least 1 , and at most 4, carbon atoms.
  • Examples of "G-C 4 alkyl” groups useful in the present invention include, but are not limited to, methyl, ethyl, propyl, isopropyl, isobutyl and n-butyl.
  • C1-C2 alkyl and C1-C3 alkyl refer to an alkyl group, as defined above, which contains at least 1 , and at most 2 and 3, carbon atoms respectively.
  • Examples of “C1-C2 alkyl” and “C1-C3 alkyl” groups useful in the present invention include, methyl, ethyl, n-propyl and isopropyl.
  • alkylene refers to a straight or branched chain divalent hydrocarbon radical having from one to ten carbon atoms, optionally substituted with substituents selected from the group which includes lower alkyl, lower alkoxy, lower alkylsulfanyl, lower alkylsulfenyl, lower alkylsulfonyl, oxo, hydroxy, mercapto, amino optionally substituted by alkyl, carboxy, carbamoyl optionally substituted by alkyl, aminosulfonyl optionally substituted by alkyl, nitro, cyano, halogen and lower perfluoroalkyl, multiple degrees of substitution being allowed.
  • Examples of “alkylene” as used herein include, but are not limited to, methylene, ethylene, n-propylene, n-butylene, and the like.
  • C1-C3 alkylene and C1-C4 alkylene refer to an alkylene group, as defined above, which contains at least 1 , and at most 3 or 4, carbon atoms respectively.
  • Examples of “C1-C3 alkylene” groups useful in the present invention include, but are not limited to, methylene, ethylene, and n-propylene.
  • halogen or “halo” refer to fluoro (-F), chloro (-CI), bromo (-Br), or iodo (-1).
  • C ⁇ -C 4 haloalkyl refers to a straight or branched chain hydrocarbon containing at least 1 , and at most 4, carbon atoms substituted with at least one halogen, halogen being as defined herein.
  • Examples of branched or straight chained "C1-C4 haloalkyl” groups useful in the present invention include, but are not limited to, methyl, ethyl, propyl, isopropyl, isobutyl and n-butyl substituted independently with one or more halogens, e.g., fluoro, chloro, bromo and iodo.
  • C1-C2 haloalkyl and “C1-C3 haloalkyl” refer to a straight or branched chain hydrocarbon containing at least 1 , and at most 2 and 3, carbon atoms respectively substituted with at least one halogen, halogen being as defined herein.
  • Examples of branched or straight chained “C1-C2 haloalkyl” and “C1-C3 haloalkyl” groups useful in the present invention include, but are not limited to, methyl, ethyl, n-propyl, and isopropyl substituted independently with one or more halogens, e.g., fluoro, chloro, bromo and iodo.
  • hydroxy refers to the group -OH.
  • G-C4 hydroxyalkyl refers to a straight or branched chain hydrocarbon containing at least 1 , and at most 4, carbon atoms substituted with at least one hydroxy, hydroxy being as defined herein.
  • Examples of branched or straight chained "C ⁇ -C4 hydroxyalkyl” groups useful in the present invention include, but are not limited to, methyl, ethyl, propyl, isopropyl, isobutyl and n-butyl substituted independently with one or more hydroxy groups.
  • C3-C7 cycloalkyl refers to a non-aromatic cyclic hydrocarbon ring having from three to seven carbon atoms, which optionally includes a C1-C4 alkylene linker through which it may be attached.
  • Exemplary "C3-C7 cycloalkyl” groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl.
  • heterocyclic or the term “heterocyclyl” refers to a three to twelve-membered non-aromatic ring being unsaturated or having one or more degrees of unsaturation containing one or more heteroatomic substitutions selected from S, SO, SO2, 0, or N, optionally substituted with substituents selected from the group consisting of lower alkyl, lower alkoxy, lower alkylsulfanyl, lower alkylsulfenyl, lower alkylsulfonyl, oxo, hydroxy, mercapto, amino optionally substituted by alkyl, carboxy, carbamoyl optionally substituted by alkyl, aminosulfonyl optionally substituted by alkyl, nitro, cyano, halogen, or lower perfluoroalkyl, multiple degrees of substitution being allowed.
  • Such a ring may be optionally fused to one or more of another "heterocyclic" ring(s) or cycloalkyl ring(s).
  • heterocyclic include, but are not limited to, tetrahydrofuran, pyran, 1 ,4- dioxane, 1 ,3-dioxane, piperidine, pyrrolidine, morpholine, tetrah ⁇ drothiopyran, tetrahydrothiophene, and the like.
  • aryl refers to an optionally substituted benzene ring or to an optionally substituted benzene ring system fused to one or more optionally substituted benzene rings to form, for example, anthracene, phenanthrene, or napthalene ring systems.
  • Exemplary optional substituents include lower alkyl, lower alkoxy, lower alkylsulfanyl, lower alkylsulfenyl, lower alkylsulfonyl, oxo, hydroxy, mercapto, amino optionally substituted by alkyl, carboxy, tetrazolyl, carbamoyl optionally substituted by alkyl, aminosulfonyl optionally substituted by alkyl, acyl, aroyl, heteroaroyl, acyloxy, aroyloxy, heteroaroyloxy, alkoxycarbonyl, nitro, cyano, halogen, lower perfluoroalkyl, heteroaryl, or aryl, multiple degrees of substitution being allowed.
  • aryl include, but are not limited to, phenyl, 2-naphthyl, 1-naphthyl, biphenyl, as well as substituted derivatives thereof.
  • aralkyl refers to an aryl or heteroaryl group, as defined herein including both unsubstituted and substituted versions thereof, attached through a lower alkylene linker, wherein lower alkylene is as defined herein.
  • heteroaralkyl is included within the scope of the term “aralkyl”.
  • heteroaralkyl is defined as a heteroaryl group, as defined herein, attached through a lower alkylene linker, lower alkylene is as defined herein.
  • aralkyl including “heteroaralkyl”
  • examples of “aralkyl”, including “heteroaralkyl” include, but are not limited to, benzyl, phenylpropyl, 2-pyridinylmethyl, 4-pyridinylmethyl, 3-isoxazolylmethyl, 5-methyl-3-isoxazolylmethyl, and 2-imidazoyly ethyl.
  • arylamino refers to an aryl or heteroaryl group, as defined herein, attached through an amino group -NR 2 -, wherein R 2 is as defined herein.
  • heteroaryl refers to a monocyclic five to seven membered aromatic ring, or to a fused bicyclic aromatic ring system comprising two of such monocyclic five to seven membered aromatic rings.
  • These heteroaryl rings contain one or more nitrogen, sulfur, and/or oxygen heteroatoms, where N-oxides and sulfur oxides and dioxides are permissible heteroatom substitutions and may be optionally substituted with up to three members selected from a group consisting of lower alkyl, lower alkoxy, lower alkylsulfanyl, lower alkylsulfenyl, lower alkylsulfonyl, oxo, hydroxy, mercapto, amino optionally substituted by alkyl, carboxy, tetrazolyl, carbamoyl optionally substituted by alkyl, aminosulfonyl optionally substituted by alkyl, acyl, aroyl, heteroaroyl, acyloxy, aroyloxy,
  • heteroaryl groups used herein include furan, thiophene, pyrrole, imidazole, pyrazole, triazole, tetrazole, thiazole, oxazole, isoxazole, oxadiazole, thiadiazole, isothiazole, pyridine, pyridazine, pyrazine, pyrimidine, quinoline, isoquinoline, benzofuran, benzothiophene, indole, indazole, and substituted versions thereof.
  • alkoxy refers to the group RaO-, where Ra is alkyl as defined above and the term “C1-C2 alkoxy” refers to the group RaO-, where Ra is C1-C2 alkyl as defined above.
  • haloalkoxy refers to the group RaO-, where Ra is haloalkyl as defined above and the term “C1-C2 haloalkoxy” refers to the group RaO-, where Ra is C1-C2 halolkyl as defined above.
  • alkylsulfanyl refers to the group RaS-, where Ra is alkyl as defined above.
  • alkylsulfenyl refers to the group RaS(O)-, where Ra is alkyl as defined above.
  • alkylsulfonyl refers to the group RaS ⁇ 2-, where Ra is alkyl as defined above.
  • mercapto refers to the group -SH.
  • cyano refers to the group -CN.
  • cyanoalkyl refers to the group -RaCN wherein Ra is C1-C3 alkylene as defined above.
  • exemplary "cyanoalkyl” groups useful in the present invention include, but are not limited to, cyanomethyl, cyanoethyl, and cyanopropyl.
  • aminosulfonyl refers to the group
  • carbamoyl refers to the group -C(0)NH2.
  • sulfanyl shall refer to the group -S-.
  • sulfenyl shall refer to the group -S(0)-.
  • sulfonyl shall refer to the group -S(0)2- or -SO2- or - S(0 2 ).
  • acyl refers to the group RaC(O)-, where Ra is alkyl, cycloalkyl, or heterocyclyl as defined herein.
  • aroyl refers to the group RaC(O)- , where Ra is aryl as defined herein.
  • heteroaroyl refers to the group RaC(O)- , where Ra is heteroaryl as defined herein.
  • alkoxycarbonyl refers to the group RaOC(O)-, where Ra is alkyl as defined herein.
  • acyloxy refers to the group RaC(0)0- , where Ra is alkyl, cycloalkyl, or heterocyclyl as defined herein.
  • aroyloxy refers to the group RaC(0)0- , where Ra is aryl as defined herein.
  • heteroaroyloxy refers to the group RaC(0)0- , where Ra is heteroaryl as defined herein.
  • the term "optionally” means that the subsequently described event(s) may or may not occur, and includes both event(s), which occur, and events that do not occur.
  • physiologically functional derivative refers to any pharmaceutically acceptable derivative of a compound of the present invention, for example, an ester or an amide, which upon administration to a mammal is capable of providing (directly or indirectly) a compound of the present invention or an active metabolite thereof.
  • physiologically functional derivatives are clear to those skilled in the art, without undue experimentation, and with reference to the teaching of Burger's Medicinal Chemistry And Drug Discovery, 5 th Edition, Vol 1 : Principles and Practice, which is incorporated herein by reference to the extent that it teaches physiologically functional derivatives.
  • solvate refers to a complex of variable stoichiometry formed by a solute (in this invention, a compound of formula (I), (II), (III), or (IV) or a salt or physiologically functional derivative thereof) and a solvent.
  • solvents for the purpose of the invention may not interfere with the biological activity of the solute.
  • suitable solvents include, but are not limited to, water, methanol, ethanol and acetic acid.
  • the solvent used is a pharmaceutically acceptable solvent.
  • suitable pharmaceutically acceptable solvents include water, ethanol and acetic acid. Most preferably the solvent used is water.
  • the compounds of formulae (I), (II), (III), or (IV) may have the ability to crystallize in more than one form, a characteristic, which is known as polymorphism, and it is understood that such polymorphic forms (“polymorphs") are within the scope of formulae (I), (II), (III), and (IV).
  • Polymorphism generally can occur as a response to changes in temperature or pressure or both and can also result from variations in the crystallization process. Polymorphs can be distinguished by various physical characteristics known in the art such as x-ray diffraction patterns, solubility, and melting point.
  • substituted refers to substitution with the named substituent or substituents, multiple degrees of substitution being allowed unless otherwise stated.
  • the compounds described herein may contain one or more chiral atoms, or may otherwise be capable of existing as two enantiomers. Accordingly, the compounds of this invention include mixtures of enantiomers as well as purified enantiomers or enantiomerically enriched mixtures. Also included within the scope of the invention are the individual isomers of the compounds represented by formula (I), (II), (III), and (IV) above as well as any wholly or partially equilibrated mixtures thereof. The present invention also covers the individual isomers of the compounds represented by the formulas above as mixtures with isomers thereof in which one or more chiral centers are inverted.
  • the compounds of Formula (I), (II), (III), or (IV) may form tautomers. It is understood that all tautomers and mixtures of tautomers of the compounds of the present invention, more specifically, the compounds of formula (III) are included within the scope of the compounds of the present invention, including the compounds of formula (III).
  • D is:
  • D is
  • D is attached to the indicated nitrogen of Formula (I) through the bond of D having an unfilled valence and being indicated by " '.
  • the appropriate attachment is further illustrated in Formulae (II), (III), or (IV) and in the working examples recited below.
  • Xi is hydrogen or G- 4 alkyl. In a preferred embodiment, Xi is methyl or ethyl. In a more preferred embodiment, Xi is methyl.
  • X2 is hydrogen or G-4 alkyl. In a preferred embodiment, X2 is hydrogen or methyl. In a more preferred embodiment, X2 is hydrogen. In another preferred embodiment, X2 is methyl.
  • X3 is halogen. In a preferred embodiment, X3 is hydrogen.
  • X4 is hydrogen, G-G- alkyl, cyanoalkyl, or ' -(CH2) P C ⁇ C(CH 2 )tH.
  • X 4 is hydrogen, methyl, ethyl, isopropyl, cyanomethyl, or - (CH2) P C ⁇ C(CH2)tH, wherein p is 1 and t is 0.
  • X 4 is methyl.
  • Xi is methyl or ethyl
  • X2 is hydrogen or methyl
  • X 3 is hydrogen or halogen
  • X 4 is hydrogen, methyl, ethyl, isopropyl, cyanomethyl, or - (CH2) P C ⁇ C(CH2)tH, wherein p is 1 and t is 0.
  • Xi is methyl, X2 is hydrogen, X3 is hydrogen, and X 4 is methyl. In another preferred embodiment, Xi is methyl, X2 is methyl, X3 is hydrogen, and X is methyl.
  • D is:
  • Xi is methyl
  • X2 is hydrogen
  • X3 is hydrogen
  • X4 is methyl
  • D is
  • Xi is methyl
  • X2 is methyl
  • X3 is hydrogen
  • X is methyl
  • W is N. In another embodiment W is C-R wherein R is H, F, or
  • W is N, C-H, C-F, or C-CN. In a more preferred embodiment, W is C-F or C-H. In a most preferred embodiment, W is C-H.
  • Qi is hydrogen, halogen, C1-C2 alkyl or C1-C2 alkoxy. In a preferred embodiment, Qi is hydrogen, chlorine, methyl, or methoxy.
  • Q2 is A 1 and Q3 is A 2 . In an alternative embodiment, Q2 is A 2 and Qs is A 1 . In one embodiment, Q2 is A 2 and Q3 is A 1 , wherein A 1 is hydrogen, halogen, or C1-C3 haloalkyl and A 2 is the group defined by -(Z)m-(Z 1 )-(Z 2 ), wherein Z is CH2 and m is 0, 1 , 2, or 3, or Z is NR 2 and m is 0 or 1 , or Z is CH2NR 2 and m is 0 or 1 ; Z 1 is S(0) 2 , S(0), or C(0); and Z 2 is G-C 4 alkyl or NR 3 R 4 and wherein R 2 , R 3 , and R 4 are each independently selected from H or G-C 4 alkyl.
  • Q2 is A 2 and Q3 is A 1 , wherein A 1 is hydrogen or chlorine and A 2 is the group defined by -(Z) m -(Z 1 )-(Z 2 ), wherein Z is CH2 and m is 0, 1 , 2, or 3; Z 1 is S(0) 2 ; and Z 2 is G-C 4 alkyl.
  • Q2 is A 1 and Q3 is A 2 , wherein A 1 is hydrogen, halogen, or C1-C3 alkyl and A 2 is the group defined by - ⁇ l)m-[Z ] )- ⁇ Z 2 ), wherein Z is CH2 and m is 0, 1 , 2, or 3, or Z is NR 2 and m is 0 or 1 , or Z is CH2NR 2 and m is 0 or 1 ; Z 1 is S(0) 2 , S(0), or C(0); and Z 2 is C1-C4 alkyl or NR 3 R 4 , and wherein R 2 , R 3 , and R 4 are each independently selected from H or C1-C4 alkyl.
  • Q2 is A 1 and Q3 is A 2 , wherein A 1 is hydrogen, methyl, or chlorine and A 2 is the group defined by -(Z) m -(Z 1 )-(Z 2 ), wherein Z is CH2 and m is 0, 1 , 2, or 3; Z 1 is S(0) 2 ; and Z 2 is G-G alkyl or NR 3 R 4 , wherein R 3 and R 4 are each independently selected from hydrogen or G-G alkyl.
  • Xi is hydrogen or C1-4 alkyl
  • X2 is hydrogen or G-4 alkyl
  • X3 is hydrogen or halogen
  • X is hydrogen, G-C 4 alkyl, cyanoalkyl, or -(CH2) P C ⁇ C(CH2)tH
  • W is N
  • Qi is hydrogen, halogen, C1-C2 alkyl or C1-C2 alkoxy
  • Xi is hydrogen or C1-4 alkyl
  • X2 is hydrogen or C1-4 alkyl
  • X3 is hydrogen or halogen
  • X 4 is hydrogen, G-G alkyl, cyanoalkyl, or -(CH2) P C ⁇ €(CH2)tH
  • W is C-R wherein R is H, F, Cl, or CN
  • Qi is hydrogen, halogen, G-G alkyl or C1-C2 alkoxy
  • Q2 is A 2 and Q3 is A 1 , wherein A 1 is hydrogen, halogen, or G-G haloalkyl and A 2 is the group defined by -(Z)m-(Z 1 )-(Z 2 ), wherein Z is CH2 and m is 0, 1, 2, or 3, or Z is NR 2 and m is 0 or 1 , or Z is CH2NR 2 and m is 0 or 1 ;
  • Z 1 is S(0) 2 or C(0); and
  • Z 2 is G-G alkyl or
  • Xi is hydrogen or G- 4 alkyl
  • X2 is hydrogen or G-4 alkyl
  • X3 is hydrogen or halogen
  • X 4 is hydrogen, G-G alkyl, cyanoalkyl, or -(CH2) P C ⁇ C(CH 2 )tH
  • W is N
  • Qi is hydrogen, halogen, C1-C2 alkyl or G-G alkoxy
  • Q2 is A 1 and Q 3 is A 2 , wherein A 1 is hydrogen, halogen, or G-G alkyl and A 2 is the group defined by -(Z)m-(Z 1 )-(Z 2 ), wherein Z is CH2 and m is 0, 1 , 2, or 3, or Z is NR 2 and m is 0 or 1 , or Z is CH2NR 2 and m is 0 or 1 ;
  • Z 1 is S(0) 2 , S(0), or C(O); and
  • Z 2 is G-G alkyl or NR 3 R 4 , and
  • Xi is hydrogen or G- 4 alkyl
  • X2 is hydrogen or C1-4 alkyl
  • X3 is hydrogen or halogen
  • X 4 is hydrogen, G-G alkyl, cyanoalkyl, or -(CH2) P C ⁇ C(CH2)tH
  • W is C-R wherein R is H, F, Cl, or CN
  • Qi is hydrogen, halogen, G-G alkyl or G-G alkoxy
  • Q2 is A 1 and Q3 is A 2 , wherein A 1 is hydrogen, halogen, or G-G alkyl' and A 2 is the group defined by -(Z)m-(Z 1 )-(Z 2 ), wherein Z is CH2 and m is 0, 1 , 2, or 3, or Z is NR 2 and m is 0 or 1 , or Z is CH2NR 2 and m is 0 or 1 ( ;
  • Z 1 is S(0) 2 , S(0), or C(0); and
  • Z 2 is G-G
  • Xi is methyl or ethyl
  • X2 is hydrogen or methyl
  • X3 is hydrogen
  • X 4 is hydrogen, methyl, ethyl, isopropyl, cyanomethyl, or -(CH2) P C ⁇ C(CH2)tH, wherein p is 1 and t is 0.
  • W is N, C-H, C-F, C-CN
  • Qi is hydrogen, chlorine, or methoxy
  • Q2 is A 1 and Q 3 is A 2 , wherein A 1 is hydrogen, methyl, or chlorine and A 2 is the group defined by -(Z)m-(Z 1 )-(Z 2 ), wherein Z is CH2 and m is 0, 1 , 2, or 3, or Z is NR 2 and m is 0 or 1 , or Z is CH2NR 2 and m is 0 or 1 ;
  • Z 1 is S(0) 2 , S(0), or C(0); and
  • Z 2 is G-G alkyl or NR 3 R ⁇ and where
  • Xi is methyl or ethyl
  • X2 is hydrogen or methyl
  • X3 is hydrogen
  • X 4 ' ⁇ s hydrogen, methyl, ethyl, isopropyl, cyanomethyl, or -(CH2) C ⁇ C(CH2)tH, wherein p is 1 and t is 0.
  • W is C-H or C-F
  • Qi is hydrogen, chlorine, methyl, or methoxy
  • Q2 is A 1 and Q 3 is A 2 , wherein A 1 is hydrogen, methyl, or chlorine and A 2 is the group defined by -(Z)m- (Z 1 )-(Z 2 ), wherein Z is CH2 and m is 0, 1 , 2, or 3, or Z is NR 2 and m is 0 or 1 , or Z is CH2NR 2 and m is 0 or 1 ;
  • Z 1 is S(0) 2 , S(0), or C(0); and
  • Z 2 is G-C 4 alkyl or NR 3 R ⁇ and
  • D is:
  • Xi is methyl; X2 is methyl; X3 is hydrogen; and X4 is methyl; W is C-H; Qi is hydrogen, chlorine, methyl, or methoxy; Q2 is A 1 and Q3 is A 2 , wherein A 1 is hydrogen, methyl, or chlorine and A 2 is the group defined by -(Z)m-(Z 1 )-(Z 2 ), wherein Z is CH2 and m is 0, 1 , 2, or 3, or Z is NR 2 and m is 0 or 1 , or Z is CH2NR 2 and m is 0 or 1 ; Z 1 is S(0) 2 , S(0), or C(0); and Z 2 is G-G alkyl or NR 3 R ⁇ and wherein R 2 , R 3 , and R 4 are each independently selected from hydrogen or G-Galkyl.
  • D is and Xi is methyl; X2 is methyl; X3 is hydrogen; and X 4 is methyl; W is C-H; Qi is hydrogen, chlorine, methyl, or methoxy; Q2 is A 1 and Q3 is A 2 , wherein A 1 is hydrogen, methyl, or chlorine and A 2 is the group defined by -(Z) m -(Z 1 )-(Z 2 ), wherein Z is CH2 and m is 0, 1 , 2, or 3, or Z is NR 2 and m is 0 or 1 , or Z is CH2NR 2 and m is 0 or 1 ; Z 1 is S(0) 2 , S(0), or C(0); and Z 2 is G-G alkyl or NR 3 R 4 , and wherein R 2 , R 3 , and R are each independently selected from hydrogen or G-Galkyl.
  • the salts of the present invention are pharmaceutically acceptable salts.
  • Salts encompassed within the term “pharmaceutically acceptable salts” refer to non-toxic salts of the compounds of this invention.
  • Salts of the compounds of the present invention may comprise acid addition salts derived from a nitrogen on a substituent in the compound of formula (I).
  • Representative salts include the following salts: acetate, benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, bromide, calcium edetate, camsylate, carbonate, chloride, clavulanate, citrate, dihydrochloride, edetate, edisylate, estolate, esylate, fumarate, gluceptate, gluconate, glutamate, glycollylarsanilate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, hydroxynaphthoate, iodide, isethionate, lactate, lactobionate, laurate, malate, maleate, mandelate, mesylate, methylbromide, methylnitrate, methylsulfate, monopotassium maleate, mucate, napsylate, nitrate, N-methylglucamine, oxa
  • compositions which include therapeutically effective amounts of compounds of the formula (I) and salts, solvates and physiological functional derivatives thereof, and one or more pharmaceutically acceptable carriers, diluents, or excipients.
  • the compounds of the formula (I) and salts, solvates and physiological functional derivatives thereof, are as described above.
  • the carrier(s), diluent(s) or excipient(s) must be acceptable in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
  • a process for the preparation of a pharmaceutical formulation including admixing a compound of the formula (I), or salts, solvates and physiological functional derivatives thereof, with one or more pharmaceutically acceptable carriers, diluents or excipients.
  • compositions may be presented in unit dose forms containing a predetermined amount of active ingredient per unit dose.
  • a unit may contain, for example, 0.5mg to 1g, preferably 1 mg to 700mg, of a compound of the formula (I) depending on the condition being treated, the route of administration and the age, weight and condition of the patient.
  • Preferred unit dosage formulations are those containing a daily dose or sub-dose, as herein above recited, or an appropriate fraction thereof, of an active ingredient.
  • such pharmaceutical formulations may be prepared by any of the methods well known in the pharmacy art.
  • compositions may be adapted for administration by any appropriate route, for example by the oral (including buccal or sublingual), rectal, nasal, topical (including buccal, sublingual or transdermal), vaginal or parenteral (including subcutaneous, intramuscular, intravenous or intradermal) route.
  • Such formulations may be prepared by any method known in the art of pharmacy, for example by bringing into association the active ingredient with the carrier(s) or excipient(s).
  • compositions adapted for oral administration may be presented as discrete units such as capsules or tablets; powders or granules; solutions or suspensions in aqueous or non-aqueous liquids; edible foams or whips; or oil-in-water liquid emulsions or water-in-oil liquid emulsions.
  • the active drug component can be combined with an oral, non-toxic pharmaceutically acceptable inert carrier such as ethanol, glycerol, water and the like.
  • an oral, non-toxic pharmaceutically acceptable inert carrier such as ethanol, glycerol, water and the like.
  • Powders are prepared by comminuting the compound to a suitable fine size and mixing with a similarly comminuted pharmaceutical carrier such as an edible carbohydrate, as, for example, starch or mannitol. Flavoring, preservative, dispersing and coloring agent can also be present
  • Capsules are made by preparing a powder mixture as described above, and filling formed gelatin sheaths.
  • Glidants and lubricants such as colloidal silica, talc, magnesium stearate, calcium stearate or solid polyethylene glycol can be added to the powder mixture before the filling operation.
  • a disintegrating or solubilizing agent such as agar-agar, calcium carbonate or sodium carbonate can also be added to improve the availability of the medicament when the capsule is ingested.
  • suitable binders include starch, gelatin, natural sugars such as glucose or beta-lactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth or sodium alginate, carboxymethylcellulose, polyethylene glycol, waxes and the like.
  • Lubricants used in these dosage forms include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and the like.
  • Disintegrators include, without limitation, starch, methyl cellulose, agar, bentonite, xanthan gum and the like.
  • Tablets are formulated, for example, by preparing a powder mixture, granulating or slugging, adding a lubricant and disintegrant and pressing into tablets.
  • a powder mixture is prepared by mixing the compound, suitably comminuted, with a diluent or base as described above, and optionally, with a binder such as carboxymethylcellulose, an aliginate, gelatin, or polyvinyl pyrrolidone, a solution retardant such as paraffin, a resorption accelerator such as a quaternary salt and/or an absorption agent such as bentonite, kaolin or dicalcium phosphate.
  • a binder such as carboxymethylcellulose, an aliginate, gelatin, or polyvinyl pyrrolidone
  • a solution retardant such as paraffin
  • a resorption accelerator such as a quaternary salt
  • an absorption agent such as bentonite, kaolin or dicalcium phosphate.
  • the powder mixture can be granulated by wetting with a binder such as syrup, starch paste, acadia mucilage or solutions of cellulosic or polymeric materials and forcing through a screen.
  • a binder such as syrup, starch paste, acadia mucilage or solutions of cellulosic or polymeric materials and forcing through a screen.
  • the powder mixture can be run through the tablet machine and the result is imperfectly formed slugs broken into granules.
  • the granules can be lubricated to prevent sticking to the tablet forming dies by means of the addition of stearic acid, a stearate salt, talc or mineral oil.
  • the lubricated mixture is then compressed into tablets.
  • the compounds of the present invention can also be combined with a free flowing inert carrier and compressed into tablets directly without going through the granulating or slugging steps.
  • a clear or opaque protective coating consisting of a sealing coat of shellac, a coating of
  • Oral fluids such as solution, syrups and elixirs can be prepared in dosage unit form so that a given quantity contains a predetermined amount of the compound.
  • Syrups can be prepared by dissolving the compound in a suitably flavored aqueous solution, while elixirs are prepared through the use of a non-toxic alcoholic vehicle.
  • Suspensions can be formulated by dispersing the compound in a non-toxic vehicle.
  • Solubilizers and emulsifiers such as ethoxylated isostearyl alcohols and polyoxy ethylene sorbitol ethers, preservatives, flavor additives such as peppermint oil or natural sweeteners or saccharin or other artificial sweeteners, and the like can also be added.
  • dosage unit formulations for oral administration can be microencapsulated.
  • the formulation can also be prepared to prolong or sustain the release as for example by coating or embedding particulate material in polymers, wax or the like.
  • the compounds of formula (I) and salts, solvates and physiological functional derivatives thereof can also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles.
  • liposomes can be formed from a variety of phosphohpids, such as cholesterol, stearylamine or phosphatidylcholines.
  • the compounds of formula (I) and salts, solvates and physiological functional derivatives thereof may also be delivered by the use of monoclonal antibodies as individual carriers to which the compound molecules are coupled.
  • the compounds may also be coupled with soluble polymers as targetable drug carriers.
  • Such polymers can include polyvinylpyrrolidone, pyran copolymer, polyhydroxypropylmethacrylamide-phenol, polyhydroxyethylaspartamidephenol, or polyethyleneoxidepolylysine substituted with palmitoyl residues.
  • the compounds may be coupled to a class of biodegradable polymers useful in achieving controlled release of a drug, for example, polylactic acid, polepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates and cross-linked or amphipathic block copolymers of hydrogels.
  • a class of biodegradable polymers useful in achieving controlled release of a drug, for example, polylactic acid, polepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates and cross-linked or amphipathic block copolymers of hydrogels.
  • compositions adapted for transdermal administration may be presented as discrete patches intended to remain in intimate contact with the epidermis of the recipient for a prolonged period of time.
  • the active ingredient may be delivered from the patch by iontophoresis as generally described in Pharmaceutical Research, 3(6), 318 (1986).
  • compositions adapted for topical administration may be formulated as ointments, creams, suspensions, lotions, powders, solutions, pastes, gels, sprays, aerosols or oils.
  • the formulations are preferably applied as a topical ointment or cream.
  • the active ingredient may be employed with either a paraffinic or a water-miscible ointment base.
  • the active ingredient may be formulated in a cream with an oil-in-water cream base or a water-in-oil base.
  • Pharmaceutical formulations adapted for topical administrations to the eye include eye drops wherein the active ingredient is dissolved or suspended in a suitable carrier, especially an aqueous solvent.
  • compositions adapted for topical administration in the mouth include lozenges, pastilles and mouth washes.
  • compositions adapted for rectal administration may be presented as suppositories or as enemas.
  • compositions adapted for nasal administration wherein the carrier is a solid include a coarse powder having a particle size for example in the range 20 to 500 microns which is administered in the manner in which snuff is taken, i.e., by rapid inhalation through the nasal passage from a container of the powder held close up to the nose.
  • Suitable formulations wherein the carrier is a liquid, for administration as a nasal spray or as nasal drops, include aqueous or oil solutions of the active ingredient.
  • Fine particle dusts or mists which may be generated by means of various types of metered, dose pressurised aerosols, nebulizers or insufflators.
  • compositions adapted for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or spray formulations.
  • compositions adapted for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents.
  • the formulations may be presented in unit-dose or multi-dose containers, for example sealed ampules and vials, and may be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example water for injections, immediately prior to use.
  • Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets.
  • formulations may include other agents conventional in the art having regard to the type of formulation in question, for example those suitable for oral administration may include flavouring agents.
  • a therapeutically effective amount of a compound of the present invention will depend upon a number of factors including, for example, the age and weight of the animal, the precise condition requiring treatment and its severity, the nature of the formulation, and the route of administration, and will ultimately be at the discretion of the attendant physician or veterinarian.
  • an effective amount of a compound of formula (I) for the treatment of neoplastic growth, for example colon or breast carcinoma will generally be in the range of 0.1 to 100 mg/kg body weight of recipient (mammal) per day and more usually in the range of 1 to 10 mg/kg body weight per day.
  • the actual amount per day would usually be from 70 to 700 mg and this amount may be given in a single dose per day or more usually in a number (such as two, three, four, five or six) of sub-doses per day such that the total daily dose is the same.
  • An effective amount of a salt or solvate, or physiologically functional derivative thereof may be determined as a proportion of the effective amount of the compound of formula (I) per se. It is envisaged that similar dosages would be appropriate for treatment of the other conditions referred to above.
  • Combination therapies according to the present invention thus comprise the administration of at least one compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, or a physiologically functional derivative thereof, and the use of at least one other cancer treatment method.
  • combination therapies according to the present invention comprise the administration of at least one compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, or a physiologically functional derivative thereof, and at least one other pharmaceutically active agent, preferably an anti-neoplastic agent.
  • the compound(s) of formula (I) and the other pharmaceutically active agent(s) may be administered together or separately and, when administered separately this may occur simultaneously or sequentially in any order.
  • the amounts of the compound(s) of formula (I) and the other pharmaceutically active agent(s) and the relative timings of administration will be selected in order to achieve the desired combined therapeutic effect.
  • the compounds of the Formula (I) or salts, solvates, or physiologically functional derivatives thereof and at least one additional cancer treatment therapy may be employed in combination concomitantly or sequentially in any therapeutically appropriate combination with such other anti-cancer therapies.
  • the other anticancer therapy is at least one additional chemotherapeutic therapy including administration of at least one anti-neoplastic agent.
  • the administration in combination of a compound of formula (I) or salts, solvates, or physiologically functional derivatives thereof with other anti-neoplastic agents may be in combination in accordance with the invention by administration concomitantly in (1) a unitary pharmaceutical composition including both compounds or (2) separate pharmaceutical compositions each including one of the compounds.
  • the combination may be administered separately in a sequential manner wherein one anti-neoplastic agent is administered first and the other second or vice versa. Such sequential administration may be close in time or remote in time.
  • Anti-neoplastic agents may induce anti-neoplastic effects in a cell-cycle specific manner, i.e., are phase specific and act at a specific phase of the cell cycle, or bind DNA and act in a non cell-cycle specific manner, i.e., are non-cell cycle specific and operate by other mechanisms.
  • Anti-neoplastic agents useful in combination with the compounds and salts, solvates or physiologically functional derivatives thereof of formula 1 include the following:
  • cell cycle specific anti-neoplastic agents including, but not limited to, diterpenoids such as paclitaxel and its analog docetaxel; vinca alkaloids such as vinblastine, vincristine, vindesine, and vinorelbine; epipodophyllotoxins such as etoposide and teniposide; fluoropyrimidines such as 5-fluorouracil and fluorodeoxyuridine ; antimetabolites such as allopurinol, fludurabine, methotrexate, cladrabine, cytarabine, mercaptopurine and thioguanine; and camptothecins such as 9-amino camptothecin, irinotecan, CPT-11 and the various optical forms of 7-(4-methylpiperazino-methylene)- 10,1 1 -ethylenedioxy-20-camptothecin;
  • diterpenoids such as paclitaxel and its analog docetaxel
  • vinca alkaloids such
  • cytotoxic chemotherapeutic agents including, but not limited to, alkylating agents such as melphalan, chlorambucil, cyclophosphamide, mechlorethamine, hexamethylmelamine, busulfan, carmustine, lomustine, and dacarbazine; anti-tumour antibiotics such as doxorubicin, daunomycin, epirubicin, idarubicin, mitomycin-C, dacttinomycin and mithramycin; and platinum coordination complexes such as cisplatin, carboplatin, and oxaliplatin; and
  • anti-estrogens such as tamoxifen, toremifene, raloxifene, droloxifene and iodoxyfene
  • progestrogens such as megestrol acetate
  • aromatase inhibitors such as anastrozole, letrazole, vorazole, and exemestane
  • antiandrogens such as flutamide, nilutamide, bicalutamide, and cyproterone acetate
  • LHRH agonists and antagagonists such as goserelin acetate and luprolide, testosterone 5 ⁇ -dihydroreductase inhibitors such as finasteride
  • metalloproteinase inhibitors such as marimastat
  • antiprogestogens urokinase plasminogen activator receptor function inhibitors
  • cyclooxygenase type 2 (COX-2) inhibitors such as celecoxi
  • the compounds of formula (I) and salts, solvates and physiological functional derivatives thereof, are believed to have anticancer activity as a result of inhibition of the protein kinase VEGFR2 and its effect on selected cell lines whose growth is dependent on VEGFR2 protein kinase activity.
  • the present invention thus also provides compounds of formula (I) and pharmaceutically acceptable salts or solvates thereof, or physiologically functional derivatives thereof, for use in medical therapy, and particularly in the treatment of disorders mediated by inappropriate VEGFR2 activity.
  • the inappropriate VEGFR2 activity referred to herein is any VEGFR2 activity that deviates from the normal VEGFR2 activity expected in a particular mammalian subject.
  • Inappropriate VEGFR2 activity may take the form of, for instance, an abnormal increase in activity, or an aberration in the timing and or control of VEGFR2 activity.
  • Such inappropriate activity may result then, for example, from overexpression or mutation of the protein kinase or ligand leading to inappropriate or uncontrolled activation of the receptor.
  • unwanted VEGFR2 activity may reside in an abnormal source, such as a malignancy. That is, the level of VEGFR2 activity does not have to be abnormal to be considered inappropriate, rather the activity derives from an abnormal source.
  • the inappropriate angiogenesis referred to herein is any angiogenic activity that deviates from the normal angiogenic activity expected in a particular mammalian subject.
  • Inappropriate angiogenesis may take the form of, for instance, an abnormal increase in activity, or an aberration in the timing and or control of angiogenic activity.
  • Such inappropriate activity may result then, for example, from overexpression or mutation of a protein kinase or ligand leading to inappropriate or uncontrolled activation of angiogenesis.
  • unwanted angiogenic activity may reside in an abnormal source, such as a malignancy. That is, the level of angiogenic activity does not have to be abnormal to be considered inappropriate, rather the activity derives from an abnormal source.
  • the present invention is directed to methods of regulating, modulating, or inhibiting VEGFR2 for the prevention and/or treatment of disorders related to unregulated VEGFR2 activity.
  • the compounds of the present invention can also be used in the treatment of certain forms of cancer.
  • the compounds of the present invention can be used to provide additive or synergistic effects with certain existing cancer chemotherapies and radiation, and/or be used to restore effectiveness of certain existing cancer chemotherapies and radiation.
  • the compounds of the present invention are also useful in the treatment of one or more diseases afflicting mammals which are characterized by cellular proliferation in the area of disorders associated with neo-vascularization and/or vascular permeability including blood vessel proliferative disorders including arthritis and restenosis; fibrotic disorders including hepatic cirrhosis and atherosclerosis; mesangial cell proliferative disorders include glomerulonephritis, diabetic nephropathy, malignant nephrosclerosis, thrombotic microangiopathy syndromes, proliferative retinopathies, organ transplant rejection and glomerulopathies; and metabolic disorders include psoriasis, diabetes mellitus, chronic wound healing, inflammation and neurodegenerative diseases.
  • a further aspect of the invention provides a method of treatment of a mammal suffering from a disorder mediated by inappropriate VEGFR2 activity, including susceptible malignancies, which includes administering to said subject an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt, solvate, or a physiologically functional derivative thereof.
  • the disorder is cancer.
  • a further aspect of the invention provides a method of treatment of a mammal suffering from cancer, which includes administering to said subject an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, or a physiologically functional derivative thereof.
  • a further aspect of the present invention provides the use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, or a physiologically functional derivative thereof, in the preparation of a medicament for the treatment of a disorder characterized by inappropriate VEGFR2 activity.
  • the disorder is cancer.
  • a further aspect of the present invention provides the use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, or a physiologically functional derivative thereof, in the preparation of a medicament for the treatment of cancer and malignant tumours.
  • the mammal requiring treatment with a compound of the present invention is typically a human being.
  • therapeutically effective amounts of the compounds of formula (I) or salts, solvates or physiologically derived derivatives thereof and agents which inhibit growth factor receptor function may be administered in combination to a mammal for treatment of a disorder mediated by inappropriate VEGFR2 activity, for instance in the treatment of cancer.
  • growth factor receptors include, for example, EGFR, PDGFR, erbB2, erbB4, VEGFR, and/or TIE-2.
  • Growth factor receptors and agents that inhibit growth factor receptor function are described, for instance, in Kath, John C, Exp. Opin. Ther. Patents (2000) 10(6):803-818 and in Shawver et al DDT Vol 2, No. 2 February 1997.
  • the compounds of the Formula (I) or salts, solvates, or physiologically functional derivatives thereof and the agent for inhibiting growth factor receptor function may be employed in combination concomitantly or sequentially in any therapeutically appropriate combination.
  • the combination may be employed in combination in accordance with the invention by administration concomitantly in (1) a unitary pharmaceutical composition including both compounds or (2) separate pharmaceutical compositions each including one of the compounds.
  • the combination may be administered separately in a sequential manner wherein one is administered first and the other second or vice versa. Such sequential administration may be close in time or remote in time.
  • a method of treating a disorder in a mammal, said disorder being mediated by inappropriate angiogenesis including: administering to said mammal a therapeutically effective amount of a compound of formula (I), or a salt, solvate or physiologically functional derivative thereof.
  • the inappropriate angiogenic activity is due to at least one of inappropriate VEGFR1 , VEGFR2, VEGFR3, or TIE-2 activity.
  • the inappropriate angiogenesis is due to inappropriate VEGFR2 and TIE-2 activity.
  • the method further includes administering a therapeutically effective amount of a TIE-2 inhibitor along with the compounds of formula (I) or salts, solvates or physiologically functional derivatives thereof.
  • the disorder is cancer.
  • a compound of formula (I), or a salt, solvate or physiologically functional derivative thereof in the preparation of a medicament for use in treating a disorder in a mammal, said disorder being characterized by inappropriate angiogenesis.
  • the inappropriate angiogenic activity is due to at least one of inappropriate VEGFR1 , VEGFR2, VEGFR3 or TIE-2 activity.
  • the inappropriate angiogenic activity is due to inappropriate VEGFR2 and TIE-2 activity.
  • the use further includes use of a TIE-2 inhibitor to prepare said medicament.
  • the combination of a compound of formula (I) or salts, solvates, or physiologically functional derivatives with a TIE-2 inhibitor may be employed in combination in accordance with the invention by administration concomitantly in (1) a unitary pharmaceutical composition including both compounds or (2) separate pharmaceutical compositions each including one of the compounds.
  • the combination may be administered separately in a sequential manner wherein one is administered first and the other second or vice versa. Such sequential administration may be close in time or remote in time.
  • the compounds of this invention may be made by a variety of methods, including standard chemistry. Any previously defined variable will continue to have the previously defined meaning unless otherwise indicated. Illustrative general synthetic methods are set out below and then specific compounds of the invention are prepared in the working Examples.
  • chloropyrimidine B is treated with di-t-butyl- dicarbonate to affect BOC protection at N1 of the indazole (Scheme 2).
  • N- alkylation under standard conditions affords the N 4 -alkyl-2-chloropyrimidine D, which is treated with an arylamine C in a similar fashion as above to provide the compound of Formula (II), wherein X4 is not hydrogen.
  • BOC deprotection is not fully facilitated in the displacement reaction and the initial reaction product is further exposed to TFA or HCI to afford the desired product.
  • benzylamine can be condensed with an alkyl- or arylsulfonyl chloride under suitable conditions (e.g., triethylamine, CH2CI2) to provide a sulfonamide F.
  • suitable conditions e.g., triethylamine, CH2CI2
  • the NO2 moiety of F can be reduced using SnCI ⁇ /conc. HCI or by hydrogenation (e.g., 10°/o Pd/C in methanol) to provide the desired aniline.
  • Other embodiments of the present invention can be derived from anilines that are prepared as shown in Scheme 6.
  • a nitro-substituted benzyl chloride G is converted to a sodium benzylsulfonate salt H by reaction at elevated temperature with Na2S ⁇ 3 in a H2 ⁇ /dioxane mixture.
  • Treatment of H with SOCI2 (cat. DMF/CH2CI2) provides the corresponding sulfonylchloride I, which can be treated with an amine to provide a sulfonamide J.
  • Reduction of the nitro group in J can be accomplished in similar fashion as described above in Scheme 5.
  • Scheme 7 depicts the synthesis of other anilines of structure C that are useful in the preparation of compounds of Formula (I).
  • An appropriate thiolate anion undergoes a displacement reaction with a nitro-substituted benzyl chloride G to provide a benzylic sulfide K.
  • Oxidation of the sulfide, for example with mCPBA, provides the corresponding sulfone, which is then reduced by standard methods to the desired aniline C.
  • Scheme 8 depicts the synthesis of other anilines of structure C that are useful in the preparation of compounds of Formula (I).
  • the 2-methoxyacetanilide undergoes chlorosulfonylation under standard conditions to provide the expected arylsulfonyl chloride L Animation of L with an amine affords a sulfonamide, which is hydrolyzed under appropriate conditions to provide the desired aniline C for use in the synthesis of compounds of Formula (I).
  • Scheme 9 depicts the synthesis of other anilines of structure C that are useful in the preparation of compounds of Formula (I).
  • the para-methoxy sulfenimide M can be prepared as described in the prior art. Mitsunobu-type substitution with an alcohol provides the phenyl sulfide N. (In certain cases, one who is skilled in the art will recognize that the same phenylsulfide N can be derived by alkylation of the para-methoxy thiophenoxide anion with an alkyl halide.) Oxidation of sulfide N affords a sulfone 0, which undergoes nitration to provide the methoxynitrosulfone P. Methoxynitrosulfone P is reduced as already described by the earlier scheme to the aniline C.
  • Scheme 10 depicts the synthesis of compounds of Formula (III).
  • a substituted 6- nitroindazole Q undergoes alkylation by an appropriate alkylating agent (e.g., trimethyloxonium tetraflouroborate, triethyloxonium tetrafluoroborate, benzyl halide) to provide the N2-alkylated nitroindazole R.
  • Reduction of the nitro group using standard conditions e.g., SnC , aqueous acid or 10°/o Pd/C, methanol, ammonium formate
  • 2,4-dichloropyrimidine provides the chloropyrimidine S.
  • Alkylation of the bisaryl amine nitrogen under appropriate alkylation conditions e.g., Mel, CS2CO3, DMF
  • affords intermediate T which undergoes subsequent condensation with an appropriately substituted aniline to provide the compound of Formula (III).
  • M molar
  • mM millimolar
  • i. v. intravenous
  • Hz Hertz
  • T r retention time
  • RP reverse phase
  • TEA triethylamine
  • TFA trifluoroacetic acid
  • TFAA trifluoroacetic anhydride
  • THF tetrahydrofuran
  • DCE dichloroethane
  • DMF ⁇ /, ⁇ /-dimethylformamide
  • DMPU ⁇ /, ⁇ /'-dimethylpropyleneurea
  • CDI 1,1-carbonyldiimidazole
  • IBCF isobutyl chloroformate
  • HOAc acetic acid
  • HOSu JV-hydroxysuccinimide
  • HOBT 1-hydroxybenzotriazole
  • tnCPBA metal-chloroperbenzoic acid
  • EDC ethylcarbodii ide hydrochloride
  • BOC ter -butyloxycarbonyl
  • FMOC 9-fluorenylmethoxycarbonyl
  • TIPS triisopropylsilyl
  • TBS f-butyldimethylsilyl
  • BOP bis(2-oxo-3-oxazolidinyl)phosphinic chloride
  • NMR spectra were recorded on a Varian VXR-300, a Varian Unity-300, a Varian Unity-400 instrument, or a General Electric QE-300. Chemical shifts are expressed in parts per million (ppm, ⁇ units). Coupling constants are in units of hertz (Hz). Splitting patterns describe apparent multiplicities and are designated as s (singlet), d (doublet), t (triplet), q
  • Methyl-2-pyrrolidinone 80 mL were combined. The flask was sealed and heated to 120 degrees C overnight. The reaction was monitored by TLC. When reaction was judged to be complete based upon consumption of 2-fluoro-5-nitroaniline, it was cooled to room temperature and poured into 2-3 times the total reaction volume of water. When a precipitate was formed, it was filtered and dried. The product was carried on without purification.
  • the solid was filtered and washed with ethyl acetate (2 x 4 mL), acetonitrile (4 mL), and ethyl ether (4 mL) and dried under vacuum to give N 2 -(3-methyl- l H-indazol-6-yl)-N 4 - ⁇ 3-[(methylsulfonyl)methyl]phenyl ⁇ -1 ,3,5-triazine-2,4-diamine hydrochloride as a solid.
  • the solid was purified by C-18 RP-HPLC using an acetonitrile/water gradient containing 0.5% trifluoroacetic acid buffer.
  • the hydrochloride salts are obtained in sufficient purity.
  • the amine hydrochloride salts are purified either by Reverse Phase High Pressure Liquid Chromatography (RPHPLC), or by normal phase chromatography by loading the solids on 1 gram of silica gel. The silica gel mixture is then loaded on top of a column of silica gel and eluted with a chloroform/ethyl acetate to methanol/ethyl acetate gradient.
  • RPHPLC Reverse Phase High Pressure Liquid Chromatography
  • Example 22-37 and 41-68 were prepared according to the general procedures set forth above in Example 21. In most cases the hydrochloride salts of these examples were readily obtained as described in the experimental above. In certain cases it was more convenient to isolate the final compound as its free base by partitioning with an organic solvent (e.g., ethyl acetate) and an aqueous base (e.g. aqueous sodium bicarbonate). It will be readily apparent to those skilled in the art that the syntheses of these examples will use either of Scheme 1 or Scheme 2 described above, depending on group X 4 , the nature of which defines the alkylating agent whose use is described in Scheme 2. The NMR data characterizing these examples describe either the salt form or the free base form.
  • organic solvent e.g., ethyl acetate
  • aqueous base e.g. aqueous sodium bicarbonate
  • A/ 4 -(2,3-dimethyl-2f/-indazol-6-yl)- ⁇ / 4 -methyl- ⁇ / 2 - ⁇ 3-[(methylsulfonyl)methyl]phenyl ⁇ - 2,4-pyrimidinediamine o a solution of /v 4 -methyl-/V*-(3-methyl-1 /-indazol-6-yl)-/ ⁇ / 2 - ⁇ 3-
  • Example 40 ⁇ 1 -(2,3-dimethyl-2r/-indazol-6-yl)- ⁇ / 2 -[5-(ethylsulfonyl)-2-methoxyphenyl]-/ ⁇ / 4 -methyl- 2,4-pyrimidinediamine
  • Example 72 ⁇ f 1 -(2,3-dimethyl-2f/-indazol-6-yl)- ⁇ f 1 -methyl-/ ⁇ - ⁇ 4- [(methyIsuIfonyl)methyI]phenyl ⁇ pyrimidine-2,4-diamine
  • Example 75 was prepared by the similar procedure set forth at the Example 74 wherein Intermediate Example 18 was used instead of Intermediate Example 17 for the synthesis of Intermediate Example 21.
  • I H NMR 400 MHz, deDMSO
  • Example 76 was prepared according to the general procedure outlined in Example 69 wherein triethyloxonium hexafluorophosphate was used instead of trimethyloxonium tetrafluoroborate in the synthesis of Intermediate Example 1 1.
  • 'H NMR 400 MHz, deDMSO
  • Example 9 (10 g, 0.029 mol) was treated with excess trifluoroacetic acid (20 ml) at rt for 30 min. The reaction mixture was quenched with NaHQ- and extracted with ethyl acetate. The organic layer was separated, and the aqueous layer was thoroughly extracted with EtOAc. The combined organic layer was dried over anhydrous MgS0 , filtered and evaporated to give /V-(2-chloropyrimidin-4-yl)- ⁇ /,3-dimethyl-1 /V- indazol-6-amine as an off-white solid (7.3 g, 100%).
  • the compounds of the present invention elicit important and measurable pharmacological responses.
  • Each of the compounds described in the Examples section bind with high affinity (IC-o ⁇ 1 ⁇ M) to the kinase domain of VEGFR2 receptor, as described by the VEGFR2 HTRF assay below.
  • the exemplified compounds of the present invention also measurably and significantly inhibit the proliferation of endothelial cells that are stimulated for growth by activation with VEGF. Data for inhibition of cell proliferation are provided in Table 1 below.
  • the assays were performed in 96-well black plates. 10 nM hVEGFR2 was used to phosphorylate 0.36 ⁇ M peptide (Biotin-Ahx-EEEEYFELVAKKKK) in the presence of 75 ⁇ M ATP, 5 mM MgCI 2 , 0.3 mM DTT, 0.1 mg/ml BSA, and 0.1 M HEPES (pH 7.5). 10 ⁇ l 0.5 M EDTA was added to reactions as negative controls. The 50 ⁇ l kinase reaction with or without inhibitors in 5% DMS0 was carried out at room temperature for 45 minutes, then stopped by 40 ⁇ l of 125 mM EDTA.
  • Reagent resources Peptide from Synpep (Dublin, CA) ATP, MgCb, DTT. BSA, HEPES, EDTA, DMSO from Sigma Streptavidin-APC from Molecular Probes (Eugene, Oregon) Eu- ⁇ -pY from EGftG Wallac (Gaithersburg, MD) Abbreviations:
  • HUVEC cells and EGM-MV Endothelial cell growth medium - microvascular
  • VEGF and bFGF were purchased from REtD Systems (Minneapolis, MN).
  • Anti-BrdU antibody was obtained from Chemicon International (Temecula, CA).
  • HUVECs were routinely maintained in EGM-MV medium and were used within passage 7.
  • HUVECs were plated at a density of 2500 cells/well in M 199 medium containing 5% FBS (Hyclone) in type I collagen coated plate (Becton Dickinson). The plate was incubated at 37 °C overnight. The medium was removed by aspiration, and test compounds were added to each well in a volume of 0.1 ml/well in serum-free M199 medium. Compound concentrations ranged from 1.5 nM to 30 micromolar. The plate was incubated for 30 min at 37°C.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)

Abstract

Pyrimidine derivatives, which are useful as VEGFR2 inhibitors are described herein. The described invention also includes methods of making such pyrimidine derivatives as well as methods of using the same in the treatment of hyperproliferative diseases.

Description

PYRIMIDINEAMINES AS ANGIOGENESIS MODULATORS
BACKGROUND OF THE INVENTION
The present invention relates to pyrimidine derivatives, compositions and medicaments containing the same, as well as processes for the preparation and use of such compounds, compositions and medicaments. Such pyrimidine derivatives are useful in the treatment of diseases associated with inappropriate or pathological angiogenesis.
The process of angiogenesis is the development of new blood vessels from the preexisting vasculature. Angiogenesis is defined herein as involving: (i) activation of endothelial cells; (ii) increased vascular permeability; (iii) subsequent dissolution of the basement membrane and extravasation of plasma components leading to formation of a provisional fibrin gel extracellular matrix; (iv) proliferation and mobilization of endothelial cells; (v) reorganization of mobilized endothelial cells to form functional capillaries; (vi) capillary loop formation; and (vi) deposition of basement membrane and recruitment of perivascular cells to newly formed vessels. Normal angiogenesis is active during tissue growth from embryonic development through maturity and then enters a period of relative quiescence during adulthood. Normal angiogenesis is also activated during wound healing, and at certain stages of the female reproductive cycle. Inappropriate or pathological angiogenesis has been associated with several disease states including various retinopathies, ischemic disease, atherosclerosis, chronic inflammatory disorders, and cancer. The role of angiogenesis in disease states is discussed, for instance, in Fan et al, Trends in Pharmacol Sci. 16:54-66; Shawver et al, DDT Vol. 2, No. 2 February 1997; Folkmann, 1995, Nature Medicine 1 :27-31.
In cancer the growth of solid tumors has been shown to be dependent on angiogenesis. The progression of leukemias as well as the accumulation of fluid associated with malignant ascites and pleural effusions also involve pro-angiogenic factors. (See Folkmann, J., J. Nat'l. Cancer Inst, 1990, 82, 4-6.) Consequently, the targeting of pro- angiogenic pathways is a strategy being widely pursued in order to provide new therapeutics in these areas of great, unmet medical need. Central to the process of angiogenesis are vascular endothelial growth factor (VEGF) and its receptors, termed vascular endothelial growth factor receptor(s) (VEGFRs), The roles VEGF and VEGFRs play in the vascularization of solid tumors, progression of hematopoietic cancers and modulation of vascular permeability have drawn great interest in the scientific community. VEGF is a polypeptide, which has been linked to inappropriate or pathological angiogenesis (Pinedo, H.M. et al The Oncologist, Vol.5, No. 90001 , 1 -2, April 2000). VEGFR(s) are protein tyrosine kinases (PTKs) that catalyze the phosphorylation of specific tyrosine residues in proteins that are involved in the regulation of cell growth, differentiation, and survival. (A.F. Wilks, Progress in Growth Factor Research, 1990, 2, 97-1 1 1 ; S.A. Courtneidge, Dev. Supp.l, 1993, 57-64; J.A. Cooper, Semin. Cell Biol., 1994, 5(6), 377-387; R.F. Paulson, Semin. Immunol., 1995, 7(4), 267-277; A.C. Chan, Curr. Opin. Immunol., 1996, 8(3), 394-401).
Three PTK receptors for VEGF have been identified: VEGFR1 (Flt-1); VEGFR2 ( Flk-1 and KDR) and VEGFR3 (Flt-4). These receptors are involved in angiogenesis and participate in signal transduction. (Mustonen, T. et al J. Cell Biol. 1995:129:895-898; Ferrara and Davis-Smyth, Endocrine Reviews, 18(l):4-25, 1997; McMahon, G., The Oncologist, Vol. 5, No 90001 , 3-10, April 2000).
Of particular interest is VEGFR2, which is a transmembrane receptor PTK expressed primarily in endothelial cells. Activation of VEGFR-2 by VEGF is a critical step in the signal transduction pathway that initiates tumor angiogenesis. VEGF expression may be constitutive to tumor cells and can also be upregulated in response to certain stimuli. One such stimulus is hypoxia, where VEGF expression is upregulated in both tumor and associated host tissues. The VEGF ligand activates VEGFR2 by binding to its extracellular VEGF binding site. This leads to receptor dimerization of VEGFRs and autophosphorylation of tyrosine residues at the intracellular kinase domain of VEGFR2. The kinase domain operates to transfer a phosphate from ATP to the tyrosine residues, thus providing binding sites for signaling proteins downstream of VEGFR-2 leading ultimately to angiogenesis. (Ferrara and Davis-Smyth, Endocrine Reviews, 18(l):4-25, 1997; McMahon, G., The Oncologist, Vol. 5, No. 90001 , 3-10, April 2000.) Consequently, antagonism of the VEGFR2 kinase domain would block phosphorylation of tyrosine residues and serve to disrupt initiation of angiogenesis. Specifically, inhibition at the ATP binding site of the VEGFR2 kinase domain would prevent binding of ATP and prevent phosphorylation of tyrosine residues. Such disruption of the pro-angiogenesis signal transduction pathway associated with VEGFR2 should therefore inhibit tumor angiogenesis and thereby provide a potent treatment for cancer or other disorders associated with inappropriate angiogenesis.
The present inventors have discovered novel pyrimidine derivative compounds, which are inhibitors of VEGFR-2 kinase activity. Such pyrimidine derivatives are useful in the treatment of disorders, including cancer, associated with inappropriate angiogenesis.
BRIEF SUMMARY OF THE INVENTION
In one aspect of the present invention, there is provided a compound of Formula (I):
Figure imgf000004_0001
(I) or a salt, solvate, or physiologically functional derivative thereof: wherein:
D is
Figure imgf000005_0001
Xi is hydrogen, C1-C4 alkyl, Cι-C4haloalkyl, or Cι-C4hydroxyalkyl; X2 is hydrogen, G-C4 alkyl, Cι-C4 haloalkyl, C(0)R1, or aralkyl; X3 is hydrogen or halogen;
X4 is hydrogen, C1-C4 alkyl, C1-C4 haloal yϊ, heteroaralkyl, cyanoalkyl,
Figure imgf000005_0002
-(CH2)pC≡C(CH2)tH, or C3-C7 cycloalkyl; p is 1, 2, or 3; t is 0 or 1
W is N or C-R, wherein R is hydrogen, halogen, or cyano;
Qi is hydrogen, halogen, C1-C2 haloalkyl. C1-C2 alkyl, C1-C2 alkoxy, or Cι-C2 haloalkoxy; Q2 is A1 or A2;
Q3 is A1 when Ch is A2 and Q3 is A2 when Q2 is A1; wherein
A1 is hydrogen, halogen, C1-C3 alkyl, C1-C3 haloalkyl, -OR1, and A2 is the group defined by -(Z)m-(Z1)-(Z2), wherein Z is CH2 and m is 0, 1, 2, or 3, or Z is NR2and m is 0 or 1, or Z is oxygen and m is 0 or 1 , or
Z is CH2NR2 and m is 0 or 1 ; Z1 is S(0)2, S(0), or C(0); and Z2 is C1-C4 alkyl, NR3R4, aryl, arylamino, aralkyl, aralkoxy, or heteroaryl, R1 is Ci-C+alkyl;
R2, R3, and R4 are each independently selected from hydrogen, Cι-C4 alkyl, C3-C7 cycloalkyl,
S(0)2R5, and -C(0)R5;
R5 is Ci-C alkyl, or C3-C7 cycloalkyl; and when Z is oxygen then Z1 is S(0)2 and when D is
Figure imgf000006_0001
then X2 is C1-C4 alkyl, G-C haloalkyl, C(0)R1, or aralkyl.
In a second aspect of the present invention, there is provided a compound of Formula (II):
Figure imgf000006_0002
or a salt, solvate, or physiologically functional derivative thereof: wherein:
X1 is hydrogen, C1-C4 alkyl, C1-C haloalkyl, or Cι-C4 hydroxyalkyl; X2 is hydrogen, G-Gtalkyl. C1-C4 haloalkyl, C(0)R\ or aralkyl;
X3 is hydrogen or halogen;
X4 is hydrogen, C1-C4 alkyl, C1-C4 haloalkyl, heteroaralkyl, cyanoalkyl,
Figure imgf000006_0003
-(CH2)pC≡C(CH2)tH, or C3-C7 cycloalkyl; p is 1 , 2, or 3; t is 0 or 1 ;
W is N or C-R, wherein R is hydrogen, halogen, or cyano; Qi is hydrogen, halogen, C1-C2 haloalkyl, C1-C2 alkyl, C1-C2 alkoxy, or G-C∑ haloalkoxy;
Q2 is A1 or A2;
Q3 is A1 when Q2 is A2 and Q3 is A2 when Q2 is A1; wherein
A1 is hydrogen, halogen, C1-C3 alkyl, C1-C3 haloalkyl, -OR1, and A2 is the group defined by -(Z)m-(Z1)-(Z2), wherein
Z is CH2 and m is 0, 1, 2, or 3, or
Z is NR2and m is 0 or 1, or
Z is oxygen and m is 0 or 1, or
Z is CH2NR2 and m is O or 1 ;
Z1 is S(0)2, S(0), or C(0); and
Z2 is C1-C4 alkyl, NR3R\ aryl, arylamino, aralkyl, aralkoxy, or heteroaryl, R1 is Cι-C4alkyl;
R2, R3, and R4 are each independently selected from hydrogen, C1-C4 alkyl, C3-C7 cycloalkyl, S(0)2R5, and -C(0)R5;
R5 is C1-C4 alkyl, or C3-C7 cycloalkyl; and when Z is oxygen then Z1 is S(0)2.
In a third aspect of the present invention, there is provided a compound of Formula
Figure imgf000007_0001
or a salt, solvate, or physiologically functional derivative thereof: wherein:
Xi is hydrogen, G-C4 alkyl, C1-C haloalkyl, or G-C4 hydroxyalkyl; X2 is C1-C4 alkyl, G-C4 haloalkyl, or C(0)R1; X3 is hydrogen or halogen;
X4 is hydrogen, C1-C4 alkyl, G-C haloalkyl, heteroaralkyl, cyanoalkyl,
Figure imgf000008_0001
-(CH2)pC≡C(CH2)tH, or C3-C7 cycloalkyl; p is 1 , 2, or 3; t is 0 or 1 ;
W is N or C-R, wherein R is hydrogen, halogen, or cyano;
Qi is hydrogen, halogen, C1-C2 haloalkyl, C1-C2 alkyl, C1-C2 alkoxy, or G-C2 haloalkoxy; Q2 is A1 or A2;
Q3 is A1 when Ck is A2 and Q3 is A2 when Q2 is A1 ; wherein
A1 is hydrogen, halogen, C1-C3 alkyl, C1-C3 haloalkyl, -OR1, and A2 is the group defined by -(Z)m-(Z1)-(Z2), wherein Z is CH2 and m is 0, 1 , 2, or 3, or Z is NR2 and m is 0 or 1 , or Z is oxygen and m is 0 or 1 , or
Figure imgf000008_0002
Z1 is S(0)2, S(0), or C(0); and
Z2 is C1-C4 alkyl, NR3R4, aryl, arylamino, aralkyl, aralkoxy, or heteroaryl, R1 is Ci-C* alkyl ; R2, R3, and R4 are each independently selected from hydrogen, C1-C alkyl, C3-C7 cycloalkyl, - S(0)2R5, and -C(0)R5; R5 is C1-C4 alkyl, or C3-C7 cycloalkyl; and when Z is oxygen then Z1 is S(0)2.
In a fourth aspect of the present invention, there is provided a compound of Formula (IV):
Figure imgf000009_0001
or a salt, solvate, or physiologically functional derivative thereof: wherein:
Xi is hydrogen, C1-C4 alkyl, C1-C4 haloalkyl, or G-C4 hydroxyalkyl; X2 is hydrogen, C,-C4alkyl, C1-C4 haloalkyl, or C(0)R\ or aralkyl; X3 is hydrogen or halogen;
X4 is hydrogen, C1-C4 alkyl, C1-C4 haloalkyl, heteroaralkyl, cyanoalkyl,
Figure imgf000009_0002
-(CH2)PC≡C(CH2)tH, or C3-C7 cycloalkyl; p is 1 , 2, or 3; t is 0 or 1 ;
W is N or C-R, wherein R is hydrogen, halogen, or cyano;
Qi is hydrogen, halogen, C1-C2 haloalkyl, C1-C2 alkyl, C1-C2 alkoxy, or G-C2 haloalkoxy; Q2 is A' or A2;
Q3 is A1 when Q2 is A2 and Q3 is A2 when Q2 is A1; wherein
A1 is hydrogen, halogen, C1-C3 alkyl, C1-C3 haloalkyl, -OR1, and i
A2 is the group defined by -(Z)m-(Z1)-(Z2), wherein Z is CH2 and m is 0, 1 , 2, or 3, or Z is NR2and m is 0 or 1, or Z is oxygen and m is 0 or 1 , or
Figure imgf000009_0003
Z1 is S(0)2, S(0), or C(O); and
Z2 is C1-C4 alkyl, NR3R4, aryl, arylamino, aralkyl, aralkoxy, or heteroaryl, R1 is C1-C4 alkyl; R2, R3, and R4 are each independently selected from hydrogen, G-C4 alkyl, C3-C7 cycloalkyl, -
S(0)2R5, and -C(0)R5;
R5 is Cι-C4alkyl, or C3-C7 cycloalkyl; and when Z is oxygen then Z1 is S(0
In a fifth aspect of the present invention, there is provided a pharmaceutical composition including a therapeutically effective amount of a compound of formula (1) or a salt, solvate, or a physiologically functional derivative thereof and one or more of pharmaceutically acceptable carriers, diluents and excipients.
In a sixth aspect of the present invention, there is provided a method of treating a disorder in a mammal, said disorder being mediated by inappropriate VEGFR2 activity, including: administering to said mammal a therapeutically effective amount of a compound of formula (I) or a salt, solvate or a physiologically functional derivative thereof.
In a seventh aspect of the present invention, there is provided a compound of formula (I), or a salt, solvate, or a physiologically functional derivative thereof for use in therapy.
In an eighth aspect of the present invention, there is provided the use of a compound of formula (I), or a salt, solvate, or a physiologically functional derivative thereof in the preparation of a medicament for use in the treatment of a disorder mediated by inappropriate VEGFR2 activity.
In a ninth aspect of the present invention, there is provided a method of treating a disorder in a mammal, said disorder being mediated by inappropriate VEGFR2 activity, including: administering to said mammal therapeutically effective amounts of (i) a compound of formula (I), or a salt, solvate or physiologically functional derivative thereof and (ii) an agent to inhibit growth factor receptor function. In an tenth aspect of the present invention, there is provided a method of treating a disorder in a mammal, said disorder being characterized by inappropriate angiogenisis, including: administering to said mammal a therapeutically effective amount of a compound of formula (I), or a salt, solvate or physiologically functional derivative thereof.
In an eleventh aspect of the present invention, there is provided a method of treating cancer in a mammal, including administering to said mammal a therapeutically effective amount of a compound of formula (I), or salt, solvate or physiologically functional derivative thereof.
In a twelvth aspect of the present invention, there is provided a method of treating cancer in a mammal, including administering to said mammal therapeutically effective amounts of (i) a compound of formula (I), or salt, solvate or physiologically functional derivative thereof and (ii) at least one additional anti-cancer therapy.
DETAILED DESCRIPTION OF THE INVENTION
As used herein, the term "effective amount" means that amount of a drug or pharmaceutical agent that will elicit the biological or medical response of a tissue, system, animal or human that is being sought, for instance, by a researcher or clinician. Furthermore, the term "therapeutically effective amount" means any amount which, as compared to a corresponding subject who has not received such amount, results in improved treatment, healing, prevention, or amelioration of a disease, disorder, or side effect, or a decrease in the rate of advancement of a disease or disorder. The term also includes within its scope amounts effective to enhance normal physiological function.
As used herein, the term "lower" refers to a group having between one and six carbons.
As used herein, the term "alkyl" refers to a straight or branched chain hydrocarbon having from one to twelve carbon atoms, optionally substituted with substituents selected from the group consisting of lower alkyl, lower alkoxy, lower alkylsulfanyl, lower alkylsulfenyl, lower alkylsulfonyl, oxo, mercapto, amino optionally substituted by alkyl, carboxy, carbamoyl optionally substituted by alkyl, aminosulfonyl optionally substituted by alkyl, nitro, or lower perfluoroalkyl, multiple degrees of substitution being allowed. Examples of "alkyl" as used herein include, but are not limited to, n-butyl, n-pentyl, isobutyl, and isopropyl, and the like.
As used herein, the term "C1-C4 alkyl" refers to an alkyl group, as defined above, which contains at least 1 , and at most 4, carbon atoms. Examples of "G-C4 alkyl" groups useful in the present invention include, but are not limited to, methyl, ethyl, propyl, isopropyl, isobutyl and n-butyl.
In a like manner, the terms "C1-C2 alkyl" and "C1-C3 alkyl" refer to an alkyl group, as defined above, which contains at least 1 , and at most 2 and 3, carbon atoms respectively. Examples of "C1-C2 alkyl" and "C1-C3 alkyl" groups useful in the present invention include, methyl, ethyl, n-propyl and isopropyl.
As used herein, the term "alkylene" refers to a straight or branched chain divalent hydrocarbon radical having from one to ten carbon atoms, optionally substituted with substituents selected from the group which includes lower alkyl, lower alkoxy, lower alkylsulfanyl, lower alkylsulfenyl, lower alkylsulfonyl, oxo, hydroxy, mercapto, amino optionally substituted by alkyl, carboxy, carbamoyl optionally substituted by alkyl, aminosulfonyl optionally substituted by alkyl, nitro, cyano, halogen and lower perfluoroalkyl, multiple degrees of substitution being allowed. Examples of "alkylene" as used herein include, but are not limited to, methylene, ethylene, n-propylene, n-butylene, and the like.
As used herein, the terms "C1-C3 alkylene" and "C1-C4 alkylene" refer to an alkylene group, as defined above, which contains at least 1 , and at most 3 or 4, carbon atoms respectively. Examples of "C1-C3 alkylene" groups useful in the present invention include, but are not limited to, methylene, ethylene, and n-propylene. As used herein, the terms "halogen" or "halo" refer to fluoro (-F), chloro (-CI), bromo (-Br), or iodo (-1).
As used herein, the term "Cι-C4 haloalkyl" refers to a straight or branched chain hydrocarbon containing at least 1 , and at most 4, carbon atoms substituted with at least one halogen, halogen being as defined herein. Examples of branched or straight chained "C1-C4 haloalkyl" groups useful in the present invention include, but are not limited to, methyl, ethyl, propyl, isopropyl, isobutyl and n-butyl substituted independently with one or more halogens, e.g., fluoro, chloro, bromo and iodo.
In a like manner, the terms "C1-C2 haloalkyl" and "C1-C3 haloalkyl" refer to a straight or branched chain hydrocarbon containing at least 1 , and at most 2 and 3, carbon atoms respectively substituted with at least one halogen, halogen being as defined herein. Examples of branched or straight chained "C1-C2 haloalkyl" and "C1-C3 haloalkyl" groups useful in the present invention include, but are not limited to, methyl, ethyl, n-propyl, and isopropyl substituted independently with one or more halogens, e.g., fluoro, chloro, bromo and iodo.
As used herein, the term "hydroxy" refers to the group -OH.
As used herein, the term "G-C4 hydroxyalkyl" refers to a straight or branched chain hydrocarbon containing at least 1 , and at most 4, carbon atoms substituted with at least one hydroxy, hydroxy being as defined herein. Examples of branched or straight chained "Cι-C4 hydroxyalkyl" groups useful in the present invention include, but are not limited to, methyl, ethyl, propyl, isopropyl, isobutyl and n-butyl substituted independently with one or more hydroxy groups.
As used herein, the term "C3-C7 cycloalkyl" refers to a non-aromatic cyclic hydrocarbon ring having from three to seven carbon atoms, which optionally includes a C1-C4 alkylene linker through which it may be attached. Exemplary "C3-C7 cycloalkyl" groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl. As used herein, the term "heterocyclic" or the term "heterocyclyl" refers to a three to twelve-membered non-aromatic ring being unsaturated or having one or more degrees of unsaturation containing one or more heteroatomic substitutions selected from S, SO, SO2, 0, or N, optionally substituted with substituents selected from the group consisting of lower alkyl, lower alkoxy, lower alkylsulfanyl, lower alkylsulfenyl, lower alkylsulfonyl, oxo, hydroxy, mercapto, amino optionally substituted by alkyl, carboxy, carbamoyl optionally substituted by alkyl, aminosulfonyl optionally substituted by alkyl, nitro, cyano, halogen, or lower perfluoroalkyl, multiple degrees of substitution being allowed. Such a ring may be optionally fused to one or more of another "heterocyclic" ring(s) or cycloalkyl ring(s). Examples of "heterocyclic" include, but are not limited to, tetrahydrofuran, pyran, 1 ,4- dioxane, 1 ,3-dioxane, piperidine, pyrrolidine, morpholine, tetrahγdrothiopyran, tetrahydrothiophene, and the like.
As used herein, the term "aryl" refers to an optionally substituted benzene ring or to an optionally substituted benzene ring system fused to one or more optionally substituted benzene rings to form, for example, anthracene, phenanthrene, or napthalene ring systems. Exemplary optional substituents include lower alkyl, lower alkoxy, lower alkylsulfanyl, lower alkylsulfenyl, lower alkylsulfonyl, oxo, hydroxy, mercapto, amino optionally substituted by alkyl, carboxy, tetrazolyl, carbamoyl optionally substituted by alkyl, aminosulfonyl optionally substituted by alkyl, acyl, aroyl, heteroaroyl, acyloxy, aroyloxy, heteroaroyloxy, alkoxycarbonyl, nitro, cyano, halogen, lower perfluoroalkyl, heteroaryl, or aryl, multiple degrees of substitution being allowed. Examples of "aryl" groups include, but are not limited to, phenyl, 2-naphthyl, 1-naphthyl, biphenyl, as well as substituted derivatives thereof.
As used herein, the term "aralkyl" refers to an aryl or heteroaryl group, as defined herein including both unsubstituted and substituted versions thereof, attached through a lower alkylene linker, wherein lower alkylene is as defined herein. As used herein, the term "heteroaralkyl" is included within the scope of the term "aralkyl". The term heteroaralkyl is defined as a heteroaryl group, as defined herein, attached through a lower alkylene linker, lower alkylene is as defined herein. Examples of "aralkyl", including "heteroaralkyl", include, but are not limited to, benzyl, phenylpropyl, 2-pyridinylmethyl, 4-pyridinylmethyl, 3-isoxazolylmethyl, 5-methyl-3-isoxazolylmethyl, and 2-imidazoyly ethyl.
As used herein, the term "arylamino" refers to an aryl or heteroaryl group, as defined herein, attached through an amino group -NR2-, wherein R2 is as defined herein.
As used herein, the term "heteroaryl" refers to a monocyclic five to seven membered aromatic ring, or to a fused bicyclic aromatic ring system comprising two of such monocyclic five to seven membered aromatic rings. These heteroaryl rings contain one or more nitrogen, sulfur, and/or oxygen heteroatoms, where N-oxides and sulfur oxides and dioxides are permissible heteroatom substitutions and may be optionally substituted with up to three members selected from a group consisting of lower alkyl, lower alkoxy, lower alkylsulfanyl, lower alkylsulfenyl, lower alkylsulfonyl, oxo, hydroxy, mercapto, amino optionally substituted by alkyl, carboxy, tetrazolyl, carbamoyl optionally substituted by alkyl, aminosulfonyl optionally substituted by alkyl, acyl, aroyl, heteroaroyl, acyloxy, aroyloxy, heteroaroyloxy, alkoxycarbonyl, nitro, cyano, halogen, lower perfluoroalkyl, heteroaryl, or aryl, multiple degrees of substitution being allowed. Examples of "heteroaryl" groups used herein include furan, thiophene, pyrrole, imidazole, pyrazole, triazole, tetrazole, thiazole, oxazole, isoxazole, oxadiazole, thiadiazole, isothiazole, pyridine, pyridazine, pyrazine, pyrimidine, quinoline, isoquinoline, benzofuran, benzothiophene, indole, indazole, and substituted versions thereof.
As used herein, the term "alkoxy" refers to the group RaO-, where Ra is alkyl as defined above and the term "C1-C2 alkoxy" refers to the group RaO-, where Ra is C1-C2 alkyl as defined above.
As used herein, the term "haloalkoxy" refers to the group RaO-, where Ra is haloalkyl as defined above and the term "C1-C2 haloalkoxy" refers to the group RaO-, where Ra is C1-C2 halolkyl as defined above.
As used herein the term "aralkoxy" refers to the group R-RaO-, where Ra is alkylene and Rb is aryl, both as defined above. As used herein, the term "alkylsulfanyl" refers to the group RaS-, where Ra is alkyl as defined above.
As used herein, the term "alkylsulfenyl" refers to the group RaS(O)-, where Ra is alkyl as defined above.
As used herein, the term "alkylsulfonyl" refers to the group RaSθ2-, where Ra is alkyl as defined above.
As used herein, the term "oxo" refers to the group =0
As used herein, the term "mercapto" refers to the group -SH.
As used herein, the term "carboxy" refers to the group -C00H.
As used herein, the term "cyano" refers to the group -CN.
As used herein the term "cyanoalkyl" refers to the group -RaCN wherein Ra is C1-C3 alkylene as defined above. Exemplary "cyanoalkyl" groups useful in the present invention include, but are not limited to, cyanomethyl, cyanoethyl, and cyanopropyl.
As used herein, the term "aminosulfonyl" refers to the group
As used herein, the term "carbamoyl" refers to the group -C(0)NH2.
As used herein, the term "sulfanyl" shall refer to the group -S-.
As used herein, the term "sulfenyl" shall refer to the group -S(0)-. As used herein, the term "sulfonyl" shall refer to the group -S(0)2- or -SO2- or - S(02).
As used herein, the term "acyl" refers to the group RaC(O)-, where Ra is alkyl, cycloalkyl, or heterocyclyl as defined herein.
As used herein, the term "aroyl" refers to the group RaC(O)- , where Ra is aryl as defined herein.
As used herein, the term "heteroaroyl" refers to the group RaC(O)- , where Ra is heteroaryl as defined herein.
As used herein, the term "alkoxycarbonyl" refers to the group RaOC(O)-, where Ra is alkyl as defined herein.
As used herein, the term "acyloxy" refers to the group RaC(0)0- , where Ra is alkyl, cycloalkyl, or heterocyclyl as defined herein.
As used herein, the term "aroyloxy" refers to the group RaC(0)0- , where Ra is aryl as defined herein.
As used herein, the term "heteroaroyloxy" refers to the group RaC(0)0- , where Ra is heteroaryl as defined herein.
As used herein, the term "optionally" means that the subsequently described event(s) may or may not occur, and includes both event(s), which occur, and events that do not occur.
As used herein, the term "physiologically functional derivative" refers to any pharmaceutically acceptable derivative of a compound of the present invention, for example, an ester or an amide, which upon administration to a mammal is capable of providing (directly or indirectly) a compound of the present invention or an active metabolite thereof. Such derivatives are clear to those skilled in the art, without undue experimentation, and with reference to the teaching of Burger's Medicinal Chemistry And Drug Discovery, 5th Edition, Vol 1 : Principles and Practice, which is incorporated herein by reference to the extent that it teaches physiologically functional derivatives.
As used herein, the term "solvate" refers to a complex of variable stoichiometry formed by a solute (in this invention, a compound of formula (I), (II), (III), or (IV) or a salt or physiologically functional derivative thereof) and a solvent. Such solvents for the purpose of the invention may not interfere with the biological activity of the solute. Examples of suitable solvents include, but are not limited to, water, methanol, ethanol and acetic acid. Preferably the solvent used is a pharmaceutically acceptable solvent. Examples of suitable pharmaceutically acceptable solvents include water, ethanol and acetic acid. Most preferably the solvent used is water.
The compounds of formulae (I), (II), (III), or (IV) may have the ability to crystallize in more than one form, a characteristic, which is known as polymorphism, and it is understood that such polymorphic forms ("polymorphs") are within the scope of formulae (I), (II), (III), and (IV). Polymorphism generally can occur as a response to changes in temperature or pressure or both and can also result from variations in the crystallization process. Polymorphs can be distinguished by various physical characteristics known in the art such as x-ray diffraction patterns, solubility, and melting point.
As used herein, the term "substituted" refers to substitution with the named substituent or substituents, multiple degrees of substitution being allowed unless otherwise stated.
Certain of the compounds described herein may contain one or more chiral atoms, or may otherwise be capable of existing as two enantiomers. Accordingly, the compounds of this invention include mixtures of enantiomers as well as purified enantiomers or enantiomerically enriched mixtures. Also included within the scope of the invention are the individual isomers of the compounds represented by formula (I), (II), (III), and (IV) above as well as any wholly or partially equilibrated mixtures thereof. The present invention also covers the individual isomers of the compounds represented by the formulas above as mixtures with isomers thereof in which one or more chiral centers are inverted.
It is also noted that the compounds of Formula (I), (II), (III), or (IV) may form tautomers. It is understood that all tautomers and mixtures of tautomers of the compounds of the present invention, more specifically, the compounds of formula (III) are included within the scope of the compounds of the present invention, including the compounds of formula (III).
It is to be understood that the following embodiments refer to compounds within the scope of all of formula (I), formula (II), formula (III), and formula (IV) as defined above except as specifically limited by the definition of each formula or specifically limited otherwise. It is also understood that the embodiments of the present invention described herein, including uses and compositions, are applicable to all of formula (I), (II), (III), and (IV).
In one embodiment D is:
Figure imgf000019_0001
In another embodiment, D is:
Figure imgf000020_0001
In a further embodiment, D is
Figure imgf000020_0002
It is understood that D is attached to the indicated nitrogen of Formula (I) through the bond of D having an unfilled valence and being indicated by " '. The appropriate attachment is further illustrated in Formulae (II), (III), or (IV) and in the working examples recited below.
In one embodiment, Xi is hydrogen or G-4 alkyl. In a preferred embodiment, Xi is methyl or ethyl. In a more preferred embodiment, Xi is methyl.
In one embodiment, X2 is hydrogen or G-4 alkyl. In a preferred embodiment, X2 is hydrogen or methyl. In a more preferred embodiment, X2 is hydrogen. In another preferred embodiment, X2 is methyl.
In one embodiment, X3 is halogen. In a preferred embodiment, X3 is hydrogen.
In one embodiment, X4 is hydrogen, G-G- alkyl, cyanoalkyl, or '-(CH2)PC≡C(CH2)tH.
In a preferred embodiment, X4 is hydrogen, methyl, ethyl, isopropyl, cyanomethyl, or - (CH2)PC≡C(CH2)tH, wherein p is 1 and t is 0. In a more preferred embodiment, X4 is methyl. In one embodiment, Xi is methyl or ethyl, X2 is hydrogen or methyl, X3 is hydrogen or halogen, and X4 is hydrogen, methyl, ethyl, isopropyl, cyanomethyl, or - (CH2)PC≡C(CH2)tH, wherein p is 1 and t is 0. In a preferred embodiment, Xi is methyl, X2 is hydrogen, X3 is hydrogen, and X4 is methyl. In another preferred embodiment, Xi is methyl, X2 is methyl, X3 is hydrogen, and X is methyl.
In a preferred embodiment, D is:
Figure imgf000021_0001
and Xi is methyl, X2 is hydrogen, X3 is hydrogen, and X4 is methyl.
In another preferred embodiment, D is
Figure imgf000021_0002
and Xi is methyl, X2 is methyl, X3 is hydrogen, and X is methyl.
In one embodiment, W is N. In another embodiment W is C-R wherein R is H, F, or
Cl. In a preferred embodiment, W is N, C-H, C-F, or C-CN. In a more preferred embodiment, W is C-F or C-H. In a most preferred embodiment, W is C-H.
In another embodiment, Qi is hydrogen, halogen, C1-C2 alkyl or C1-C2 alkoxy. In a preferred embodiment, Qi is hydrogen, chlorine, methyl, or methoxy.
In one embodiment, Q2 is A1 and Q3 is A2. In an alternative embodiment, Q2 is A2 and Qs is A1. In one embodiment, Q2 is A2 and Q3 is A1, wherein A1 is hydrogen, halogen, or C1-C3 haloalkyl and A2 is the group defined by -(Z)m-(Z1)-(Z2), wherein Z is CH2 and m is 0, 1 , 2, or 3, or Z is NR2 and m is 0 or 1 , or Z is CH2NR2 and m is 0 or 1 ; Z1 is S(0)2, S(0), or C(0); and Z2 is G-C4alkyl or NR3R4 and wherein R2, R3, and R4 are each independently selected from H or G-C4alkyl. In a preferred embodiment, Q2 is A2and Q3 is A1, wherein A1 is hydrogen or chlorine and A2 is the group defined by -(Z)m-(Z1)-(Z2), wherein Z is CH2 and m is 0, 1 , 2, or 3; Z1 is S(0)2; and Z2 is G-C4alkyl.
In one embodiment, Q2 is A1 and Q3 is A2, wherein A1 is hydrogen, halogen, or C1-C3 alkyl and A2 is the group defined by -{l)m-[Z])-{Z2), wherein Z is CH2 and m is 0, 1 , 2, or 3, or Z is NR2 and m is 0 or 1 , or Z is CH2NR2 and m is 0 or 1 ; Z1 is S(0)2, S(0), or C(0); and Z2 is C1-C4 alkyl or NR3R4, and wherein R2, R3, and R4 are each independently selected from H or C1-C4 alkyl. In a preferred embodiment, Q2 is A1 and Q3 is A2, wherein A1 is hydrogen, methyl, or chlorine and A2 is the group defined by -(Z)m-(Z1)-(Z2), wherein Z is CH2 and m is 0, 1 , 2, or 3; Z1 is S(0)2; and Z2 is G-G alkyl or NR3R4, wherein R3 and R4 are each independently selected from hydrogen or G-G alkyl.
In one embodiment, Xi is hydrogen or C1-4 alkyl; X2 is hydrogen or G-4 alkyl; X3 is hydrogen or halogen; and X is hydrogen, G-C4 alkyl, cyanoalkyl, or -(CH2)PC≡C(CH2)tH; W is N; Qi is hydrogen, halogen, C1-C2 alkyl or C1-C2 alkoxy; and Q2 is A2 and Q3 is A1, wherein A1 is hydrogen, halogen, or C1-C3 haloalkyl and A2 is the group defined by -(Z)m-(Z1)-(Z2), wherein Z is CH2 and m is 0, 1 , 2, or 3, or Z is NR2 and m is 0 or 1 , or Z is CH2NR2 and m is 0 or 1 ; Z1 is S(0)2 or C(0); and Z2 is G-G alkyl or NR3R4 and wherein R2, R3, and R4 are each independently selected from hydrogen or G-Galkyl.
In one embodiment, Xi is hydrogen or C1-4 alkyl; X2 is hydrogen or C1-4 alkyl; X3 is hydrogen or halogen; and X4 is hydrogen, G-G alkyl, cyanoalkyl, or -(CH2)PC≡€(CH2)tH; W is C-R wherein R is H, F, Cl, or CN; Qi is hydrogen, halogen, G-G alkyl or C1-C2 alkoxy; and Q2 is A2 and Q3 is A1 , wherein A1 is hydrogen, halogen, or G-G haloalkyl and A2 is the group defined by -(Z)m-(Z1)-(Z2), wherein Z is CH2 and m is 0, 1, 2, or 3, or Z is NR2 and m is 0 or 1 , or Z is CH2NR2 and m is 0 or 1 ; Z1 is S(0)2 or C(0); and Z2 is G-G alkyl or NR3R4 and wherein R2, R3, and R are each independently selected from hydrogen or G-Galkyl. In one embodiment, Xi is hydrogen or G-4 alkyl; X2 is hydrogen or G-4 alkyl; X3 is hydrogen or halogen; and X4 is hydrogen, G-G alkyl, cyanoalkyl, or -(CH2)PC≡C(CH2)tH; W is N; Qi is hydrogen, halogen, C1-C2 alkyl or G-G alkoxy; Q2 is A1 and Q3 is A2 , wherein A1 is hydrogen, halogen, or G-G alkyl and A2 is the group defined by -(Z)m-(Z1)-(Z2), wherein Z is CH2 and m is 0, 1 , 2, or 3, or Z is NR2 and m is 0 or 1 , or Z is CH2NR2 and m is 0 or 1 ; Z1 is S(0)2, S(0), or C(O); and Z2 is G-G alkyl or NR3R4, and- wherein R2, R3, and R4 are each independently selected from hydrogen or G-Galkyl.
In one embodiment, Xi is hydrogen or G-4 alkyl; X2 is hydrogen or C1-4 alkyl; X3 is hydrogen or halogen; and X4 is hydrogen, G-G alkyl, cyanoalkyl, or -(CH2)PC≡C(CH2)tH; W is C-R wherein R is H, F, Cl, or CN; Qi is hydrogen, halogen, G-G alkyl or G-G alkoxy; Q2 is A1 and Q3 is A2 , wherein A1 is hydrogen, halogen, or G-G alkyl' and A2 is the group defined by -(Z)m-(Z1)-(Z2), wherein Z is CH2 and m is 0, 1 , 2, or 3, or Z is NR2 and m is 0 or 1 , or Z is CH2NR2 and m is 0 or 1(; Z1 is S(0)2, S(0), or C(0); and Z2 is G-G alkyl or NR3R\ and wherein R2, R3, and R4 are each independently selected from hydrogen or G-G alkyl.
In one embodiment, Xi is methyl or ethyl; X2 is hydrogen or methyl; X3 is hydrogen; and X4 is hydrogen, methyl, ethyl, isopropyl, cyanomethyl, or -(CH2)PC≡C(CH2)tH, wherein p is 1 and t is 0.; W is N, C-H, C-F, C-CN; Qi is hydrogen, chlorine, or methoxy; Q2 is A1 and Q3 is A2 , wherein A1 is hydrogen, methyl, or chlorine and A2 is the group defined by -(Z)m-(Z1)-(Z2), wherein Z is CH2 and m is 0, 1 , 2, or 3, or Z is NR2 and m is 0 or 1 , or Z is CH2NR2 and m is 0 or 1 ; Z1 is S(0)2, S(0), or C(0); and Z2 is G-G alkyl or NR3R\ and wherein R2, R3, and R4 are each independently selected from hydrogen or G- alkyl.
In one embodiment, Xi is methyl or ethyl; X2 is hydrogen or methyl; X3 is hydrogen; and X4 'ιs hydrogen, methyl, ethyl, isopropyl, cyanomethyl, or -(CH2) C≡C(CH2)tH, wherein p is 1 and t is 0.; W is C-H or C-F; Qi is hydrogen, chlorine, methyl, or methoxy; Q2 is A1 and Q3 is A2 , wherein A1 is hydrogen, methyl, or chlorine and A2 is the group defined by -(Z)m- (Z1)-(Z2), wherein Z is CH2 and m is 0, 1 , 2, or 3, or Z is NR2 and m is 0 or 1 , or Z is CH2NR2 and m is 0 or 1 ; Z1 is S(0)2, S(0), or C(0); and Z2 is G-C4 alkyl or NR3R\ and wherein R2, R3, and R4 are each independently selected from hydrogen or G-G alkyl.
In one embodiment, Xi is methyl; X2 is hydrogen; X3 is hydrogen; and X4 is methyl; W is C-H; Qi is hydrogen, methyl, chlorine, or methoxy; Q2 is A1 and Q3 is A2 , wherein A1 is hydrogen, methyl, or chlorine and A2 is the group defined by -(Z)m-(Z1)-(Z2), wherein Z is CH2 and m is 0, 1 , 2, or 3, or Z is NR2 and m is 0 or 1 , or Z is CH2NR2 and m is 0 or 1 ; Z1 is S(0)2, S(0), or C(O); and Z2 is G-G alkyl or NR3R4, and wherein R2, R3, and R4 are each independently selected from hydrogen or G-Galkyl.
In a preferred embodiment, D is:
Figure imgf000024_0001
and Xi is methyl; X2 is hydrogen; X3 is hydrogen; and X4 is methyl; W is C-H; Qi is hydrogen, methyl, chlorine, or methoxy; Q2 is A1 and Q3 is A2 , wherein A1 is hydrogen, methyl, or chlorine and A2 is the group defined by -(Z)m-(Z1)-(Z2), wherein Z is CH2 and m is 0, 1 , 2, or 3, or Z is NR2 and m is 0 or 1 , or Z is CH2NR2 and m is 0 or 1 ; Z1 is S(0)2, S(0), or C(0); and Z2 is G-G alkyl or NR3R4, and wherein R2, R3, and R4 are each independently selected from hydrogen or G-Galkyl.
In one embodiment, Xi is methyl; X2 is methyl; X3 is hydrogen; and X4 is methyl; W is C-H; Qi is hydrogen, chlorine, methyl, or methoxy; Q2 is A1 and Q3 is A2 , wherein A1 is hydrogen, methyl, or chlorine and A2 is the group defined by -(Z)m-(Z1)-(Z2), wherein Z is CH2 and m is 0, 1 , 2, or 3, or Z is NR2 and m is 0 or 1 , or Z is CH2NR2 and m is 0 or 1 ; Z1 is S(0)2, S(0), or C(0); and Z2 is G-G alkyl or NR3R\ and wherein R2, R3, and R4 are each independently selected from hydrogen or G-Galkyl.
In another preferred embodiment, D is
Figure imgf000025_0001
and Xi is methyl; X2 is methyl; X3 is hydrogen; and X4 is methyl; W is C-H; Qi is hydrogen, chlorine, methyl, or methoxy; Q2 is A1 and Q3 is A2 , wherein A1 is hydrogen, methyl, or chlorine and A2 is the group defined by -(Z)m-(Z1)-(Z2), wherein Z is CH2 and m is 0, 1 , 2, or 3, or Z is NR2 and m is 0 or 1 , or Z is CH2NR2 and m is 0 or 1 ; Z1 is S(0)2, S(0), or C(0); and Z2 is G-G alkyl or NR3R4, and wherein R2, R3, and R are each independently selected from hydrogen or G-Galkyl.
In one embodiment, Xi is methyl; X2 is hydrogen; X3 is hydrogen; and X4 is methyl; W is C-F; Qi is hydrogen, chlorine, or methoxy; Q2 is A1 and Q3 is A2 , wherein A1 is hydrogen, methyl, or chlorine and A2 is the group defined by -(Z)m-(Z1)-(Z2), wherein Z is CH2 and m is 0, 1 , 2, or 3, or Z is NR2 and m is 0 or 1 , or Z is CH2NR2 and m is 0 or 1 ; Z1 is S(0)2, S(0), or C(0); and Z2 is G-G alkyl or NR3R\ and wherein R2, R3, and R4 are each independently selected from hydrogen or G-G alkyl.
Specific examples of compounds of the present invention include the following:
Λ/ -[5-(ethylsulfonyl)-2-methoxyphenyl]-5-fluoro-Λ/4-methyl-Λ/4-(3-methyl-1 V-indazol-6- yl)-2,4-pyrimidinediamine;
3-({5-fluoro-4-[methyl(3-methyl-1 r/-indazol-6-yl)amino]-2-pyrimidinyl}amino)-4- methoxy-Λ/-methylbenzenesulfonamide;
5-fluoro-/ 4-methyl-Λ/4-(3-methyl-1 f/-indazol-6-yl)-Λ/2-{3- [(methylsulfonyl)methyl]phenyl}-2,4-pyrimidinediamine;
3-({5-fluoro-4-[methyl(3-methyl-1 f/-indazol-6-yl)amino]-2-pyrimidinyl}amino)-/V- isopropylbenzenesulfonamide;
5-fluoro-Λ/2-[5-(isopropyIsulfonyl)-2-methoxyphenyl]-Λ/4-methyl-/V4-(3-methyl-1 r/- indazol-6-yl)-2,4-pyrimidinediamine;
N-[5-({5-fluoro-4-[methyl(3-methyl-1 r/-indazol-6-yl)amino]-2-pyrimidinyl}amino)-2- methylphenyl]methanesulfonamide; 5-fluoro-Λ/4-methyl-Λ/4-(3-methyl-1 r/-indazol-6-yl)-Λ/2-[4-(methylsulfonyl)phenyl]-2,4- pyrimidinediamine;
Λ/*-(3-ethyl-1 r/-indazol-6-yl)-5-fluoro-/V4-methyl-Λ/2-{3- [(methylsulfonyl)methyl]phenyl}-2,4-pyrimidinediamine;
4-({5-fluoro~4-[methyl(3-methyl-1 /7-indazol-6-yl)amino]-2- pyrimidinyl}amino)benzenesulfonamide;
N4-ethyl-5-fluoro-N2-[2-methoxy-5-(methylsulfonyl)phenyl]-N4-(3-methyl-l H-indazol-6- yl)-2,4-pyrimidinediamine;
[4-({5-fluoro-4-[methyl(3-methyl-1 f/-indazol-6-yl)amino]-2-pyrimidinyl}amino)phenyl]- Λ/-methylmethanesulfonamide;
5-fluoro-Λ/2-{3-[(isopropylsulfonyl)methyl]phenyl}-Λ/4-methyl-/V*-(3-methyl-1 r/-indazol- 6-yl)-2,4~pyrimidinediamine;
3-({5-fluoro-4-[methyl(3-methyl-1 r/-indazol-6-yI)amino]-2-pyrimidinyl}amino)-4- methoxybenzamide;
4-({5-fluoro-4-[methyl(3-methyl-1 f/-indazol-6-yl)amino]-2-pyrimidinyl}amino)-3- methoxybenzenesulfonamide;
N2-(3-methyl-l H-indazol-6-yl)-N4-{3-[(methylsulfonyl)methyl]phenyI}-1 ,3,5-triazine- 2,4-diamine trifluoroacetate;
N2-methyl-N2-(3-methyl-l H-indazol-6-yl)-N4-{3-[(methylsulfonyl)methyl]phenyl}-1 ,3,5- triazine-2,4-diamine;
Λ/2-[5-(ethylsulfonyl)-2-methoxyphenyl]-/V4-methyl-/V4-(3-methyl-1 r/-indazol-6-yl)-1 ,3,5- triazine-2,4-diamine;
Λ/-[2-methyl-5-({4-[methyl(3-methyl-1 /-indazol-6-yl)amino]-1 ,3,5-triazin-2- yl}amino)phenyl]methanesulfonamide;
/\^-methyl-λV2-(3-methyl-1 /-indazol-6-yl)-/\/4-[3-(methylsulfonyl)phenyl]-1 ,3,5-triazine- 2,4-diamine; Λ/-[4-({4-[methyl(3-methyl-1 r/-indazol-6-yl)amino]-1 ,3,5-triazin-2- yl}amino)phenyl]acetamide;
3-({4-[methyl(3-methyl-1 r/-indazoI-6-yl)amino]-2- pyrimidinyl}amino)benzenesulfonamide;
Λr2-[5-(ethyIsulfonyl)-2-methoxyphenyl]-Λ/4-methyl-/\/4-(3-methyl-1 /-indazol-6-yl)-2,4- pyrimidinediamine;
Λ/4-methyl-Λ/4-(3-methyl-1 r/-indazol-6-yl)-Λ/2-{3-[(methylsuIfonyl)methyl]phenyl}-2,4- pyrimidinediamine;
Λ/-isopropyl-3-({4-[methyl(3-methyl-1 r/-indazol-6-yl)amino]-2- pyrimidinyl}amino)benzenesulfonamide;
Λ/-cyclopropyl-3-({4-[methyl(3-methyl-1 r/-indazol-6-yl)amino]-2- pyrimidinyI}amino)benzenesulfonamide;
Λ/4-ethyl-Λr-[5-(ethylsulfonyl)-2-methoxyphenyl]-/V -(3-methyl-1 /-indazol-6-yl)-2,4- pyrimidinediamine;
Λ/-[3-({4-[methyl(3-methyl-1 r/-indazol-6-yi)amino]-2- pyrimidinyl}amino)phenyl]methanesulfonamide; Λr2-{3-[(isopropylsulfonyl)methyl]phenyl}-/V4-methyl-Λ/4-(3-methyl-1 f/-indazol-6-yl)-2,4- pyrimidinediamine;
Λ/2-{4-[(isopropylsulfonyl)methyl]phenyl}-Λ/ -methyl-Λ/4-(3-methyl-1 f/-indazol-6-yl)-2,4- pyrimidinediamine;
Λ/2-[5-(isobutylsulfonyl)-2-methoxyphenyl]-/V4-(3-methyl-1 r/-indazol-6-yl)-2,4- pyrimidinediamine;
Λ/-[3-({4-[methyl(3-methyl-l W-indazol-6-yl)amino]-2- pyrimidinyl}amino)phenyl]acetamide;
/V-[3-({4-[ethyl(3-methyl-1 r/-indazol-6-yl)amino]-2- pyrimidinyl}amino)phenyI]acetamide;
Λ/2-(2-methoxy-5-{[(5-methyl-3-isoxazolyI)methyl]sulfonyl}phenyl)-/V4-(3-methyl-1 r/- indazol-6-yl)-2,4-pyrimidinediamine; 4-methoxy-3-({4-[(3-methyl-1 f/-indazol-6-yl)amino]-2- pyrimidinyl}amino)benzenesulfonamide;
Λ/2-[5-(isopropylsulfonyl)-2-methoxyphenyl]-Λ/4-methyl-Λ/4-(3-methyl-1 r/-indazol-6-yl)- 2,4-pyrimidinediamine;
Λ/2-[5-(ethylsulfonyl)-2-methoxyphenyl]-Λ/*-isopropyl-Λ/ -(3-methyl-1 r/-indazol-6-yl)-2,4- pyrimidinediamine;
Λ/ -(l r/-indazol-6-yl)-ΛT1-methyl-Λ/2-{3-[(methylsulfonyl)methyl]phenyl}-2,4- pyrimidinediamine;
Λ/4-(l ,3-dimethyl-1 /-indazol-6-yl)-Λ/4-methyl-Λ/2-{3-[(methylsulfonyl)methyl]phenyl}- 2,4-pyrimidinediamine;
Λ/4-(2,3-dimethyl-2f/-indazol-6-yl)-Λ/4-methyl-Λ/2-{3-[(methylsulfonyl)methyl]phenyl}- 2,4-pyrimidinediamine;
Λ/ -(2,3-dimethyl-2/V-indazol-6-yl)-Λ/2-[5-(ethylsulfonyl)-2-methoxyphenyl]-Λ/4-methyl- 2,4-pyrimidinediamine;
1-[4-methoxy-3-({4-[(3-methyl-1 /7-indazol-6-yl)amino]-2-pyrimidinyl}amino)phenyl]-1- propanone;
4-methoxy- Λ/-[3-({4-[methyl(3-methyl-l H-indazol-6-yl)amino]-2- pyrimidinyl}amino)phenyl]benzenesulfonamide;
4-methoxy-Λ/-methyl-3-({4-[(3-methyl-l W-indazol-6-yl)amino]-2- pyrimidinyl}amino)benzenesulfonamide;
[(3-methyl-1 r/-indazol-6-yl)(2-{4-[(methylsulfonyl)methyl]anilino}-4- pyrimidinyl)amino]acetonitriIe;
[{2-[5-(ethylsulfonyl)-2-methoxyanilino]-4-pyrimidinyl}(3-methyl-1 /V-indazol-6- yl)amino]acetonitrile;
[(3-methyl-l H-indazol-6-yl)(2-{3-[(methylsulfonyl)methyl]anilino}-4- pyrimidinyl)amino]acetonitrile;
4-methoxy-Λ/-methyl-3-({4-[methyl(3-methyI-1 /-indazol-6-yl)amino]-2- pyrimidinyl}amino)benzenesulfonamide; 4-({4-[methyl(3-methyl-1 r/-indazol-6-yl)amino]-2-pyrimidinyl}amino)benzamide;
3-methoxy-4-({4-[methyl(3-methyl-1 r/-indazol-6-yl)amino]-2- pyrimidinyl}amino)benzenesulfonamide;
Λ/*-ethynyl-Λ/4-(3-methyl-1 f/-indazol-6-yl)-/\/2-{3-[(methylsulfonyl)methγl]phenyl}-2,4- pyrimidinediamine;
3-({4-[(3-methyl-1 r/-indazoI-6-yl)(2-propynyl)amino]-2-pyrimidinyI}amino) benzenesulfonamide;
4-({4-[methyl(3-methyl-1 r/-indazol-6-yl)amino]-2-pyrimidinyl}amino) benzenesulfonamide;
/V -methyl-/V4-(3-methyl-1 r/-indazol-6-yl)-Λ/2-[3-(methylsulfonyl)phenyl]-2,4- pyrimidinediamine;
4-methoxy-3-({4-[methyl(3-methyl-1 f/-indazol-6-yl)amino]-2- pyrimidinyl}amino)benzenesulfonamide;
Λ/2-[5-(ethylsulfonyl)-2-methoxyphenyl]-Λ/ -(3-methyl-1 f/-indazol-6-yl)-2,4- pyrimidinediamine;
3-({4-[methyl(3-methyl-1 r/-indazol-6-yl)amino]-2-pyrimidinyI}amino)benzamide;
Λ/2-[4-(ethylsulfonyl)phenyl]-Λ/4-methyl-/V4-(3-methyl-1 f/-indazol-6-yl)-2,4- pyrimidinediamine;
Λ/-[4-({4-[methyl(3-methyl-1 r/-indazol-6-yl)amino]-2-pyrimidinyl}amino) benzyl]ethanesulfonamide;
N-[3-({4-[methyl(3-methyl-l H-indazol-6-yl)amino]-2-pyrimidinly}amino)benzyI] methanesulfonamide;
2-chloro-5-({4-[methyl(3-methyl-1 H-indazol-6-yl)amino]-2- pyrimidinyl}amino)benzenesulfonamide; 2-chloro-4-({4-[methyl(3-methyl-1 f/-indazol-6-yl)amino]-2- pyrimidinyl}amino)benzenesulfonamide;
4-chloro-3-({4-[methyl(3-methyl-1 /-indazol-6-yl)amino]-2- pyrimidinyl}amino)benzenesulfonamide;
3-methyl-4-({4-[methyl(3-methyl-1 f/-indazol-6-yl)amino]-2-pyrimidinyl}amino) benzenesulfonamide;
2-methyl-5-({4-[methyl(3-methyl-1 r/-indazol-6-yl)amino]-2- pyrimidinyl}amino)benzenesulfonamide;
4-methyl-3-({4-[methyl(3-methyl-l H-indazol-6-yl)amino]-2- pyrimidinyl}amino)benzenesulfonamide;
Λ/4-methyl-Λ/4-(3-methyl-1 r/-indazol-6-yl)-Λ/2-[3-(methylsulfinyl)phenyl]-2,4- pyrimidinediamine;
Λ/2-[2-fluoro-5-(methylsulfonyl)phenyl]-tV -methyl-/V4-(3-methyl-1 r-indazol-6-yl)-2,4- pyrimidinediamine;
Λ/2-[2-methoxy-5-(methylsulfonyl)phenyl]-/V4-methyl-/V4-(3-methyl-1 r/-indazol-6-yl)-2,4- pyrimidinediamine;
5-({4-[(2,3-dimethyl-2 /-indazol-6-yl)(methyl)amino]pyrimidin-2-yl}amino)-2- methylbenzenesulfonamide;
3-({4-[(2,3-dimethyl-2r/-indazol-6-yl)(methyl)amino]pyrimidin-2- yl}amino)benzenesulfonamide;
2-[4-({4-[(2,3-dimethyl-2r/-indazol-6-yl)(methyl)amino]pyrimidin-2- yl}amino)phenyl]ethanesulfonamide;
/V*-(2,3-dimethyl-2f -indazol-6-yl)-/V4-methyl-Λ/2-{4-[(methylsulfonyl) methyljphenyl}pyrimidine-2,4-diamine;
3-({4-[[3-(hydroxymethyl)-2-methyl-2f/-indazol-6-yl](methyl)amino]pyrimidin-2- yl}amino)benzenesulfonamide;
3-({4-[(1 ,2-dimethyl-1 f/-benzimidazol-5-yl)(methyl)amino]pyrimidin-2- yl}amino)benzenesulfonamide; 3-({4-[(2-benzyl-1-methyl-1 /-benzimidazol-5-yl)(methyl)amino]pyrimidin-2- yl}amino)benzenesulfonamide;
3-({4-[(2-ethyl-3-methyl-2r/-indazol-6-yl)(methyl)amino]pyrimidin-2- yl}amino)benzenesulfonamide;
3-({4-[[2-(3-chlorobenzyl)-3-methyl-2/V-indazol-6-yl](methyl)amino]pyrimidin-2- yl}amino)benzenesuIfonamide;
3-({4-[(2,3-dimethyl-2r/-indazol-6-yl)(methyl)amino]-1,3,5-triazin-2- yl}aminό)benzenesulfonamide; and
5-({4-[(2,3-dimethyl-2 V-indazoI-6-yl)(methyl)amino]-1 ,3,5-triazin-2-yl}amino)-2- methylbenzenesulfonamide;
or a salt, solvate, or physiologically functional derivative thereof.
Typically, the salts of the present invention are pharmaceutically acceptable salts. Salts encompassed within the term "pharmaceutically acceptable salts" refer to non-toxic salts of the compounds of this invention. Salts of the compounds of the present invention may comprise acid addition salts derived from a nitrogen on a substituent in the compound of formula (I). Representative salts include the following salts: acetate, benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, bromide, calcium edetate, camsylate, carbonate, chloride, clavulanate, citrate, dihydrochloride, edetate, edisylate, estolate, esylate, fumarate, gluceptate, gluconate, glutamate, glycollylarsanilate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, hydroxynaphthoate, iodide, isethionate, lactate, lactobionate, laurate, malate, maleate, mandelate, mesylate, methylbromide, methylnitrate, methylsulfate, monopotassium maleate, mucate, napsylate, nitrate, N-methylglucamine, oxalate, pamoate (embonate), palmitate, pantothenate, phosphate/diphosphate, polygalacturonate, potassium, salicylate, sodium, stearate, subacetate, succinate, tannate, tartrate, teoclate, tosylate, triethiodide, trimethylammonium and valerate. Other salts, which are not pharmaceutically acceptable, may be useful in the preparation of compounds of this invention and these form a further aspect of the invention. While it is possible that, for use in therapy, therapeutically effective amounts of a compound of formula (I), as well as salts, solvates and physiological functional derivatives thereof, may be administered as the raw chemical, it is possible to present the active ingredient as a pharmaceutical composition. Accordingly, the invention further provides pharmaceutical compositions, which include therapeutically effective amounts of compounds of the formula (I) and salts, solvates and physiological functional derivatives thereof, and one or more pharmaceutically acceptable carriers, diluents, or excipients. The compounds of the formula (I) and salts, solvates and physiological functional derivatives thereof, are as described above. The carrier(s), diluent(s) or excipient(s) must be acceptable in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof. In accordance with another aspect of the invention there is also provided a process for the preparation of a pharmaceutical formulation including admixing a compound of the formula (I), or salts, solvates and physiological functional derivatives thereof, with one or more pharmaceutically acceptable carriers, diluents or excipients.
Pharmaceutical formulations may be presented in unit dose forms containing a predetermined amount of active ingredient per unit dose. Such a unit may contain, for example, 0.5mg to 1g, preferably 1 mg to 700mg, of a compound of the formula (I) depending on the condition being treated, the route of administration and the age, weight and condition of the patient. Preferred unit dosage formulations are those containing a daily dose or sub-dose, as herein above recited, or an appropriate fraction thereof, of an active ingredient. Furthermore, such pharmaceutical formulations may be prepared by any of the methods well known in the pharmacy art.
Pharmaceutical formulations may be adapted for administration by any appropriate route, for example by the oral (including buccal or sublingual), rectal, nasal, topical (including buccal, sublingual or transdermal), vaginal or parenteral (including subcutaneous, intramuscular, intravenous or intradermal) route. Such formulations may be prepared by any method known in the art of pharmacy, for example by bringing into association the active ingredient with the carrier(s) or excipient(s). Pharmaceutical formulations adapted for oral administration may be presented as discrete units such as capsules or tablets; powders or granules; solutions or suspensions in aqueous or non-aqueous liquids; edible foams or whips; or oil-in-water liquid emulsions or water-in-oil liquid emulsions.
For instance, for oral administration in the form of a tablet or capsule, the active drug component can be combined with an oral, non-toxic pharmaceutically acceptable inert carrier such as ethanol, glycerol, water and the like. Powders are prepared by comminuting the compound to a suitable fine size and mixing with a similarly comminuted pharmaceutical carrier such as an edible carbohydrate, as, for example, starch or mannitol. Flavoring, preservative, dispersing and coloring agent can also be present
Capsules are made by preparing a powder mixture as described above, and filling formed gelatin sheaths. Glidants and lubricants such as colloidal silica, talc, magnesium stearate, calcium stearate or solid polyethylene glycol can be added to the powder mixture before the filling operation. A disintegrating or solubilizing agent such as agar-agar, calcium carbonate or sodium carbonate can also be added to improve the availability of the medicament when the capsule is ingested.
Moreover, when desired or necessary, suitable binders, lubricants, disintegrating agents and coloring agents can also be incorporated into the mixture. Suitable binders include starch, gelatin, natural sugars such as glucose or beta-lactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth or sodium alginate, carboxymethylcellulose, polyethylene glycol, waxes and the like. Lubricants used in these dosage forms include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and the like. Disintegrators include, without limitation, starch, methyl cellulose, agar, bentonite, xanthan gum and the like. Tablets are formulated, for example, by preparing a powder mixture, granulating or slugging, adding a lubricant and disintegrant and pressing into tablets. A powder mixture is prepared by mixing the compound, suitably comminuted, with a diluent or base as described above, and optionally, with a binder such as carboxymethylcellulose, an aliginate, gelatin, or polyvinyl pyrrolidone, a solution retardant such as paraffin, a resorption accelerator such as a quaternary salt and/or an absorption agent such as bentonite, kaolin or dicalcium phosphate. The powder mixture can be granulated by wetting with a binder such as syrup, starch paste, acadia mucilage or solutions of cellulosic or polymeric materials and forcing through a screen. As an alternative to granulating, the powder mixture can be run through the tablet machine and the result is imperfectly formed slugs broken into granules. The granules can be lubricated to prevent sticking to the tablet forming dies by means of the addition of stearic acid, a stearate salt, talc or mineral oil. The lubricated mixture is then compressed into tablets. The compounds of the present invention can also be combined with a free flowing inert carrier and compressed into tablets directly without going through the granulating or slugging steps. A clear or opaque protective coating consisting of a sealing coat of shellac, a coating of sugar or polymeric material and a polish coating of wax can be provided. Dyestuffs can be added to these coatings to distinguish different unit dosages.
Oral fluids such as solution, syrups and elixirs can be prepared in dosage unit form so that a given quantity contains a predetermined amount of the compound. Syrups can be prepared by dissolving the compound in a suitably flavored aqueous solution, while elixirs are prepared through the use of a non-toxic alcoholic vehicle. Suspensions can be formulated by dispersing the compound in a non-toxic vehicle. Solubilizers and emulsifiers such as ethoxylated isostearyl alcohols and polyoxy ethylene sorbitol ethers, preservatives, flavor additives such as peppermint oil or natural sweeteners or saccharin or other artificial sweeteners, and the like can also be added.
Where appropriate, dosage unit formulations for oral administration can be microencapsulated. The formulation can also be prepared to prolong or sustain the release as for example by coating or embedding particulate material in polymers, wax or the like.
The compounds of formula (I) and salts, solvates and physiological functional derivatives thereof, can also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles. Liposomes can be formed from a variety of phosphohpids, such as cholesterol, stearylamine or phosphatidylcholines.
The compounds of formula (I) and salts, solvates and physiological functional derivatives thereof may also be delivered by the use of monoclonal antibodies as individual carriers to which the compound molecules are coupled. The compounds may also be coupled with soluble polymers as targetable drug carriers. Such polymers can include polyvinylpyrrolidone, pyran copolymer, polyhydroxypropylmethacrylamide-phenol, polyhydroxyethylaspartamidephenol, or polyethyleneoxidepolylysine substituted with palmitoyl residues. Furthermore, the compounds may be coupled to a class of biodegradable polymers useful in achieving controlled release of a drug, for example, polylactic acid, polepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates and cross-linked or amphipathic block copolymers of hydrogels.
Pharmaceutical formulations adapted for transdermal administration may be presented as discrete patches intended to remain in intimate contact with the epidermis of the recipient for a prolonged period of time. For example, the active ingredient may be delivered from the patch by iontophoresis as generally described in Pharmaceutical Research, 3(6), 318 (1986).
Pharmaceutical formulations adapted for topical administration may be formulated as ointments, creams, suspensions, lotions, powders, solutions, pastes, gels, sprays, aerosols or oils.
For treatments of the eye or other external tissues, for example mouth and skin, the formulations are preferably applied as a topical ointment or cream. When formulated in an ointment, the active ingredient may be employed with either a paraffinic or a water-miscible ointment base. Alternatively, the active ingredient may be formulated in a cream with an oil-in-water cream base or a water-in-oil base. Pharmaceutical formulations adapted for topical administrations to the eye include eye drops wherein the active ingredient is dissolved or suspended in a suitable carrier, especially an aqueous solvent.
Pharmaceutical formulations adapted for topical administration in the mouth include lozenges, pastilles and mouth washes.
Pharmaceutical formulations adapted for rectal administration may be presented as suppositories or as enemas.
Pharmaceutical formulations adapted for nasal administration wherein the carrier is a solid include a coarse powder having a particle size for example in the range 20 to 500 microns which is administered in the manner in which snuff is taken, i.e., by rapid inhalation through the nasal passage from a container of the powder held close up to the nose. Suitable formulations wherein the carrier is a liquid, for administration as a nasal spray or as nasal drops, include aqueous or oil solutions of the active ingredient.
Pharmaceutical formulations adapted for administration by inhalation include fine particle dusts or mists, which may be generated by means of various types of metered, dose pressurised aerosols, nebulizers or insufflators.
Pharmaceutical formulations adapted for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or spray formulations.
Pharmaceutical formulations adapted for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents. The formulations may be presented in unit-dose or multi-dose containers, for example sealed ampules and vials, and may be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example water for injections, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets.
It should be understood that in addition to the ingredients particularly mentioned above, the formulations may include other agents conventional in the art having regard to the type of formulation in question, for example those suitable for oral administration may include flavouring agents.
A therapeutically effective amount of a compound of the present invention will depend upon a number of factors including, for example, the age and weight of the animal, the precise condition requiring treatment and its severity, the nature of the formulation, and the route of administration, and will ultimately be at the discretion of the attendant physician or veterinarian. However, an effective amount of a compound of formula (I) for the treatment of neoplastic growth, for example colon or breast carcinoma, will generally be in the range of 0.1 to 100 mg/kg body weight of recipient (mammal) per day and more usually in the range of 1 to 10 mg/kg body weight per day. Thus, for a
70kg adult mammal, the actual amount per day would usually be from 70 to 700 mg and this amount may be given in a single dose per day or more usually in a number (such as two, three, four, five or six) of sub-doses per day such that the total daily dose is the same. An effective amount of a salt or solvate, or physiologically functional derivative thereof, may be determined as a proportion of the effective amount of the compound of formula (I) per se. It is envisaged that similar dosages would be appropriate for treatment of the other conditions referred to above.
The compounds of the present invention and their salts and solvates, and physiologically functional derivatives thereof, may be employed alone or in combination with other therapeutic agents for the treatment of the above-mentioned conditions. In particular, in anti-cancer therapy, combination with other chemotherapeutic, hormonal or antibody agents is envisaged as well as combination with surgical therapy and radiotherapy. Combination therapies according to the present invention thus comprise the administration of at least one compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, or a physiologically functional derivative thereof, and the use of at least one other cancer treatment method. Preferably, combination therapies according to the present invention comprise the administration of at least one compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, or a physiologically functional derivative thereof, and at least one other pharmaceutically active agent, preferably an anti-neoplastic agent. The compound(s) of formula (I) and the other pharmaceutically active agent(s) may be administered together or separately and, when administered separately this may occur simultaneously or sequentially in any order. The amounts of the compound(s) of formula (I) and the other pharmaceutically active agent(s) and the relative timings of administration will be selected in order to achieve the desired combined therapeutic effect.
The compounds of the Formula (I) or salts, solvates, or physiologically functional derivatives thereof and at least one additional cancer treatment therapy may be employed in combination concomitantly or sequentially in any therapeutically appropriate combination with such other anti-cancer therapies. In one embodiment, the other anticancer therapy is at least one additional chemotherapeutic therapy including administration of at least one anti-neoplastic agent. The administration in combination of a compound of formula (I) or salts, solvates, or physiologically functional derivatives thereof with other anti-neoplastic agents may be in combination in accordance with the invention by administration concomitantly in (1) a unitary pharmaceutical composition including both compounds or (2) separate pharmaceutical compositions each including one of the compounds. Alternatively, the combination may be administered separately in a sequential manner wherein one anti-neoplastic agent is administered first and the other second or vice versa. Such sequential administration may be close in time or remote in time.
Anti-neoplastic agents may induce anti-neoplastic effects in a cell-cycle specific manner, i.e., are phase specific and act at a specific phase of the cell cycle, or bind DNA and act in a non cell-cycle specific manner, i.e., are non-cell cycle specific and operate by other mechanisms. Anti-neoplastic agents useful in combination with the compounds and salts, solvates or physiologically functional derivatives thereof of formula 1 include the following:
(1) cell cycle specific anti-neoplastic agents including, but not limited to, diterpenoids such as paclitaxel and its analog docetaxel; vinca alkaloids such as vinblastine, vincristine, vindesine, and vinorelbine; epipodophyllotoxins such as etoposide and teniposide; fluoropyrimidines such as 5-fluorouracil and fluorodeoxyuridine ; antimetabolites such as allopurinol, fludurabine, methotrexate, cladrabine, cytarabine, mercaptopurine and thioguanine; and camptothecins such as 9-amino camptothecin, irinotecan, CPT-11 and the various optical forms of 7-(4-methylpiperazino-methylene)- 10,1 1 -ethylenedioxy-20-camptothecin;
(2) cytotoxic chemotherapeutic agents including, but not limited to, alkylating agents such as melphalan, chlorambucil, cyclophosphamide, mechlorethamine, hexamethylmelamine, busulfan, carmustine, lomustine, and dacarbazine; anti-tumour antibiotics such as doxorubicin, daunomycin, epirubicin, idarubicin, mitomycin-C, dacttinomycin and mithramycin; and platinum coordination complexes such as cisplatin, carboplatin, and oxaliplatin; and
(3) other chemotherapeutic agents including, but not limited to, anti-estrogens such as tamoxifen, toremifene, raloxifene, droloxifene and iodoxyfene; progestrogens such as megestrol acetate; aromatase inhibitors such as anastrozole, letrazole, vorazole, and exemestane; antiandrogens such as flutamide, nilutamide, bicalutamide, and cyproterone acetate; LHRH agonists and antagagonists such as goserelin acetate and luprolide, testosterone 5α-dihydroreductase inhibitors such as finasteride; metalloproteinase inhibitors such as marimastat; antiprogestogens; urokinase plasminogen activator receptor function inhibitors; cyclooxygenase type 2 (COX-2) inhibitors such as celecoxib; other angiogenic inhibiting agents such as VEGFR inhibitors other than those described herein and TIE-2 inhibitors; growth factor function inhibitors such as inhibitors of the functions of hepatocyte growth factor; erb-B2, erb-B4, epidermal growth factor receptor (EGFr), platelet derived growth factor receptor (PDGFr), vascular endothelial growth factor receptor (VEGFR) other than those described in the present invention, and TIE-2; and other tyrosine kinase inhibitors such as cyclin dependent inhibitors such as CDK2 and CDK4 inhibitors.
The compounds of formula (I) and salts, solvates and physiological functional derivatives thereof, are believed to have anticancer activity as a result of inhibition of the protein kinase VEGFR2 and its effect on selected cell lines whose growth is dependent on VEGFR2 protein kinase activity.
The present invention thus also provides compounds of formula (I) and pharmaceutically acceptable salts or solvates thereof, or physiologically functional derivatives thereof, for use in medical therapy, and particularly in the treatment of disorders mediated by inappropriate VEGFR2 activity.
The inappropriate VEGFR2 activity referred to herein is any VEGFR2 activity that deviates from the normal VEGFR2 activity expected in a particular mammalian subject. Inappropriate VEGFR2 activity may take the form of, for instance, an abnormal increase in activity, or an aberration in the timing and or control of VEGFR2 activity. Such inappropriate activity may result then, for example, from overexpression or mutation of the protein kinase or ligand leading to inappropriate or uncontrolled activation of the receptor. Furthermore, it is also understood that unwanted VEGFR2 activity may reside in an abnormal source, such as a malignancy. That is, the level of VEGFR2 activity does not have to be abnormal to be considered inappropriate, rather the activity derives from an abnormal source. In a like manner, the inappropriate angiogenesis referred to herein is any angiogenic activity that deviates from the normal angiogenic activity expected in a particular mammalian subject. Inappropriate angiogenesis may take the form of, for instance, an abnormal increase in activity, or an aberration in the timing and or control of angiogenic activity. Such inappropriate activity may result then, for example, from overexpression or mutation of a protein kinase or ligand leading to inappropriate or uncontrolled activation of angiogenesis. Furthermore, it is also understood that unwanted angiogenic activity may reside in an abnormal source, such as a malignancy. That is, the level of angiogenic activity does not have to be abnormal to be considered inappropriate, rather the activity derives from an abnormal source.
The present invention is directed to methods of regulating, modulating, or inhibiting VEGFR2 for the prevention and/or treatment of disorders related to unregulated VEGFR2 activity. In particular, the compounds of the present invention can also be used in the treatment of certain forms of cancer. Furthermore, the compounds of the present invention can be used to provide additive or synergistic effects with certain existing cancer chemotherapies and radiation, and/or be used to restore effectiveness of certain existing cancer chemotherapies and radiation.
The compounds of the present invention are also useful in the treatment of one or more diseases afflicting mammals which are characterized by cellular proliferation in the area of disorders associated with neo-vascularization and/or vascular permeability including blood vessel proliferative disorders including arthritis and restenosis; fibrotic disorders including hepatic cirrhosis and atherosclerosis; mesangial cell proliferative disorders include glomerulonephritis, diabetic nephropathy, malignant nephrosclerosis, thrombotic microangiopathy syndromes, proliferative retinopathies, organ transplant rejection and glomerulopathies; and metabolic disorders include psoriasis, diabetes mellitus, chronic wound healing, inflammation and neurodegenerative diseases.
A further aspect of the invention provides a method of treatment of a mammal suffering from a disorder mediated by inappropriate VEGFR2 activity, including susceptible malignancies, which includes administering to said subject an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt, solvate, or a physiologically functional derivative thereof. In a preferred embodiment, the disorder is cancer.
A further aspect of the invention provides a method of treatment of a mammal suffering from cancer, which includes administering to said subject an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, or a physiologically functional derivative thereof. A further aspect of the present invention provides the use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, or a physiologically functional derivative thereof, in the preparation of a medicament for the treatment of a disorder characterized by inappropriate VEGFR2 activity. In a preferred embodiment, the disorder is cancer.
A further aspect of the present invention provides the use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, or a physiologically functional derivative thereof, in the preparation of a medicament for the treatment of cancer and malignant tumours.
The mammal requiring treatment with a compound of the present invention is typically a human being.
In another embodiment, therapeutically effective amounts of the compounds of formula (I) or salts, solvates or physiologically derived derivatives thereof and agents which inhibit growth factor receptor function may be administered in combination to a mammal for treatment of a disorder mediated by inappropriate VEGFR2 activity, for instance in the treatment of cancer. Such growth factor receptors include, for example, EGFR, PDGFR, erbB2, erbB4, VEGFR, and/or TIE-2. Growth factor receptors and agents that inhibit growth factor receptor function are described, for instance, in Kath, John C, Exp. Opin. Ther. Patents (2000) 10(6):803-818 and in Shawver et al DDT Vol 2, No. 2 February 1997.
The compounds of the Formula (I) or salts, solvates, or physiologically functional derivatives thereof and the agent for inhibiting growth factor receptor function may be employed in combination concomitantly or sequentially in any therapeutically appropriate combination. The combination may be employed in combination in accordance with the invention by administration concomitantly in (1) a unitary pharmaceutical composition including both compounds or (2) separate pharmaceutical compositions each including one of the compounds. Alternatively, the combination may be administered separately in a sequential manner wherein one is administered first and the other second or vice versa. Such sequential administration may be close in time or remote in time.
In another aspect of the present invention, there is provided a method of treating a disorder in a mammal, said disorder being mediated by inappropriate angiogenesis, including: administering to said mammal a therapeutically effective amount of a compound of formula (I), or a salt, solvate or physiologically functional derivative thereof. In one embodiment, the inappropriate angiogenic activity is due to at least one of inappropriate VEGFR1 , VEGFR2, VEGFR3, or TIE-2 activity. In another embodiment, the inappropriate angiogenesis is due to inappropriate VEGFR2 and TIE-2 activity. In a further embodiment, the method further includes administering a therapeutically effective amount of a TIE-2 inhibitor along with the compounds of formula (I) or salts, solvates or physiologically functional derivatives thereof. Preferably the disorder is cancer.
In another aspect of the present invention, there is provided the use of a compound of formula (I), or a salt, solvate or physiologically functional derivative thereof in the preparation of a medicament for use in treating a disorder in a mammal, said disorder being characterized by inappropriate angiogenesis. In one embodiment, the inappropriate angiogenic activity is due to at least one of inappropriate VEGFR1 , VEGFR2, VEGFR3 or TIE-2 activity. In another embodiment, the inappropriate angiogenic activity is due to inappropriate VEGFR2 and TIE-2 activity. In a further embodiment, the use further includes use of a TIE-2 inhibitor to prepare said medicament.
The combination of a compound of formula (I) or salts, solvates, or physiologically functional derivatives with a TIE-2 inhibitor may be employed in combination in accordance with the invention by administration concomitantly in (1) a unitary pharmaceutical composition including both compounds or (2) separate pharmaceutical compositions each including one of the compounds. Alternatively, the combination may be administered separately in a sequential manner wherein one is administered first and the other second or vice versa. Such sequential administration may be close in time or remote in time. The compounds of this invention may be made by a variety of methods, including standard chemistry. Any previously defined variable will continue to have the previously defined meaning unless otherwise indicated. Illustrative general synthetic methods are set out below and then specific compounds of the invention are prepared in the working Examples.
Compounds of general formula (I), (II), (III), and (IV) may be prepared by methods known in the art of organic synthesis as set forth in part by the following synthesis schemes. Generally, the following schemes are illustrated using compounds of formula (II), but it is recognized that such schemes are easily adaptable by the skilled artisan to prepare compounds of formula (I), including compounds of formula (III) and (IV). It is also recognized that in all of the schemes described below, it is well understood that protecting groups for sensitive or reactive groups are employed where necessary in accordance with general principles of chemistry. Protecting groups are manipulated according to standard methods of organic synthesis (T. W. Green and P. G. M. Wuts (1991) Protecting Groups in Organic Synthesis, John Wiley £t Sons). These groups are removed at a convenient stage of the compound synthesis using methods that are readily apparent to those skilled in the art. The selection of processes as well as the reaction conditions and order of their execution shall be consistent with the preparation of compounds of formula (I). Those skilled in the art will recognize if a stereocenter exists in compounds of formula (I). Accordingly, the present invention includes both possible stereoisomers and includes not only racemic compounds but the individual enantiomers as well. When a compound is desired as a single enantiomer, it may be obtained by stereospecific synthesis or by resolution of the final product or any convenient intermediate. Resolution of the final product, an intermediate, or a starting material may be effected by any suitable method known in the art. See, for example, Stereochemistry of Organic Compounds by E. L Eliel, S. H. Wilen, and L N. Mander (Wiley-lnterscience, 1994).
Compounds of formula (II), wherein W is C-H, can be prepared according to the synthetic sequence shown in Scheme 1 and further detailed in the Examples section following. Typically 2,4-Dichloropyrimidine (1) undergoes a displacement reaction at C4 with an appropriate aminoindazole (A) to provide the 2-chloro-4-arylaminopyrimidine derivative (B). For compounds of formula (II), wherein X4 is hydrogen, a further displacement at C2 is carried out with an appropriate arylamine (C) to provide the compound of Formula (II), wherein X4 is hydrogen. Alternatively, for compounds of Formula (II), wherein X4 is not hydrogen, chloropyrimidine B is treated with di-t-butyl- dicarbonate to affect BOC protection at N1 of the indazole (Scheme 2). Subsequent N- alkylation under standard conditions affords the N4-alkyl-2-chloropyrimidine D, which is treated with an arylamine C in a similar fashion as above to provide the compound of Formula (II), wherein X4 is not hydrogen. In exceptional cases, BOC deprotection is not fully facilitated in the displacement reaction and the initial reaction product is further exposed to TFA or HCI to afford the desired product.
SCHEME 1
Figure imgf000045_0001
Formula II (X4 = H)
SCHEME2
nt (X4)
Figure imgf000046_0001
(X4 = H)
Figure imgf000046_0002
D (X4 is not H) Formula II (X4 is not H)
Compounds of Formula (II), wherein W is C-F, can be prepared according to the synthetic sequence shown in Scheme 3 and further detailed in the Examples section following. 5-Fluorouracil (2) is converted to 5-fluoro-2,4-dichloropyrimidine (3) by treatment with POCta. The remaining steps in the synthesis of compounds of Formula (II), wherein W is C-F, are parallel to those described above in Scheme 1 and/or Scheme 2. Compounds of formula (III), wherein W is C-F, can be prepared by using 5-fluoro-2,4- dichloropyrimidine (3) with appropriate adaptation of Scheme 10 following, such adaptation being within the purview of those skilled in the art.
SCHEME 3
Figure imgf000047_0001
see Scheme 1
Figure imgf000047_0002
Figure imgf000047_0003
Formula II
Compounds of Formula (II), wherein W is N, can be prepared according to the synthetic sequence shown in Scheme 4 and further detailed in the Examples section following. 2,4-Dichloro-1 , 3, 5-triazine (4) is treated with an arylamine C in a suitable solvent (e.g., CH3CN) to afford the a chlorotriazine E. Compound E is further treated with arylamine A (X4 is H or alkyl) to provide the compound of Formula (II). Compounds of formula (III), wherein W is N, can be prepared by using 2,4-Dichloro-1 ,3,5-triazine (4) with appropriate adaptation of Scheme 10 following, such adaptation being within the purview of those skilled in the art.
SCHEME 4
Figure imgf000048_0001
The aniline moieties of Formula (I), depicted as structure C in Schemes 1 , 2 and 4 above, are available through multi-step organic synthesis familiar to one who is skilled in the art. The following schemes illustrate the methods that can be used to derive the anilines of structure C, which are incorporated into compounds of Formula (I) of the present invention. ''
As shown in Scheme 5, the appropriately substituted meta- or para-NO∑
; benzylamine can be condensed with an alkyl- or arylsulfonyl chloride under suitable conditions (e.g., triethylamine, CH2CI2) to provide a sulfonamide F. The NO2 moiety of F can be reduced using SnCI∑/conc. HCI or by hydrogenation (e.g., 10°/o Pd/C in methanol) to provide the desired aniline. Other embodiments of the present invention can be derived from anilines that are prepared as shown in Scheme 6. A nitro-substituted benzyl chloride G is converted to a sodium benzylsulfonate salt H by reaction at elevated temperature with Na2Sθ3 in a H2θ/dioxane mixture. Treatment of H with SOCI2 (cat. DMF/CH2CI2) provides the corresponding sulfonylchloride I, which can be treated with an amine to provide a sulfonamide J. Reduction of the nitro group in J can be accomplished in similar fashion as described above in Scheme 5. SCHEME 5
Figure imgf000049_0001
SCHEME 6
Figure imgf000049_0002
see Scheme 5
Figure imgf000049_0004
Figure imgf000049_0003
Scheme 7 depicts the synthesis of other anilines of structure C that are useful in the preparation of compounds of Formula (I). An appropriate thiolate anion undergoes a displacement reaction with a nitro-substituted benzyl chloride G to provide a benzylic sulfide K. Oxidation of the sulfide, for example with mCPBA, provides the corresponding sulfone, which is then reduced by standard methods to the desired aniline C.
SCHEME 7
Figure imgf000049_0005
Scheme 8 depicts the synthesis of other anilines of structure C that are useful in the preparation of compounds of Formula (I). The 2-methoxyacetanilide undergoes chlorosulfonylation under standard conditions to provide the expected arylsulfonyl chloride L Animation of L with an amine affords a sulfonamide, which is hydrolyzed under appropriate conditions to provide the desired aniline C for use in the synthesis of compounds of Formula (I).
SCHEME 8
Figure imgf000050_0001
Scheme 9 depicts the synthesis of other anilines of structure C that are useful in the preparation of compounds of Formula (I). The para-methoxy sulfenimide M can be prepared as described in the prior art. Mitsunobu-type substitution with an alcohol provides the phenyl sulfide N. (In certain cases, one who is skilled in the art will recognize that the same phenylsulfide N can be derived by alkylation of the para-methoxy thiophenoxide anion with an alkyl halide.) Oxidation of sulfide N affords a sulfone 0, which undergoes nitration to provide the methoxynitrosulfone P. Methoxynitrosulfone P is reduced as already described by the earlier scheme to the aniline C.
SCHEME 9
Figure imgf000050_0002
Scheme 10 depicts the synthesis of compounds of Formula (III). A substituted 6- nitroindazole Q undergoes alkylation by an appropriate alkylating agent (e.g., trimethyloxonium tetraflouroborate, triethyloxonium tetrafluoroborate, benzyl halide) to provide the N2-alkylated nitroindazole R. Reduction of the nitro group using standard conditions (e.g., SnC , aqueous acid or 10°/o Pd/C, methanol, ammonium formate) followed by condensation with 2,4-dichloropyrimidine provides the chloropyrimidine S. Alkylation of the bisaryl amine nitrogen under appropriate alkylation conditions (e.g., Mel, CS2CO3, DMF) affords intermediate T, which undergoes subsequent condensation with an appropriately substituted aniline to provide the compound of Formula (III).
SCHEME 10
1. NOj group reduction
Figure imgf000051_0001
Certain embodiments of the present invention will now be illustrated by way of example only. The physical data given for the compounds exemplified is consistent with the assigned structure of those compounds. EXAMPLES
As used herein the symbols and conventions used in these processes, schemes and examples are consistent with those used in the contemporary scientific literature, for example, the Journal of the American Chemical Society or the Journal of Biological Chemistry. Standard single-letter or three-letter abbreviations are generally used to designate amino acid residues, which are assumed to be in the L-configuration unless otherwise noted. Unless otherwise noted, all starting materials were obtained from commercial suppliers and used without further purification. Specifically, the following abbreviations may be used in the examples and throughout the specification: g (grams); mg (milligrams);
L (liters); mL (milliliters); μL (microliters); psi (pounds per square inch);
M (molar); mM (millimolar); i. v. (intravenous); Hz (Hertz);
MHz (megahertz); mol (moles); mmol (millimoles); RT (room temperature); min (minutes); h (hours); mp (melting point); TLC (thin layer chromatography);
Tr (retention time); RP (reverse phase);
MeOH (methanol); /-PrOH (isopropanol);
TEA (triethylamine); TFA (trifluoroacetic acid);
TFAA (trifluoroacetic anhydride); THF (tetrahydrofuran);
DMSO (dimethylsulfoxide); EtOAc (ethyl acetate);
DME (1 ,2-dimethoxyethane); DCM (dichloromethane);
DCE (dichloroethane); DMF (Λ/,Λ/-dimethylformamide); DMPU (Λ/,Λ/'-dimethylpropyleneurea); (CDI (1,1-carbonyldiimidazole); IBCF (isobutyl chloroformate); HOAc (acetic acid);
HOSu (JV-hydroxysuccinimide); HOBT (1 -hydroxybenzotriazole); tnCPBA (meta-chloroperbenzoic acid; EDC (ethylcarbodii ide hydrochloride); BOC (ter -butyloxycarbonyl); FMOC (9-fluorenylmethoxycarbonyl); DCC
(dicyclohexylcarbodiimide); CBZ (benzyloxycarbonyl); Ac (acetyl); atm (atmosphere); TMSE (2-(trimethylsilyl)ethyl); TMS (trimethylsilyl);
TIPS (triisopropylsilyl); TBS (f-butyldimethylsilyl);
DMAP (4-dimethylaminopyridine); Me (methyl);
OMe (methoxy); Et (ethyl); HPLC (high pressure liquid chromatography);
BOP (bis(2-oxo-3-oxazolidinyl)phosphinic chloride);
TBAF (tetra-/7-butylamιnonium fluoride);
Et (ethyl); tBu (tert-butyl).
All references to ether are to diethyl ether; brine refers to a saturated aqueous solution of NaCl. Unless otherwise indicated, all temperatures are expressed in °C (degrees Centigrade). All reactions conducted under an inert atmosphere at room temperature unless otherwise noted.
NMR spectra were recorded on a Varian VXR-300, a Varian Unity-300, a Varian Unity-400 instrument, or a General Electric QE-300. Chemical shifts are expressed in parts per million (ppm, δ units). Coupling constants are in units of hertz (Hz). Splitting patterns describe apparent multiplicities and are designated as s (singlet), d (doublet), t (triplet), q
(quartet), m (multiplet), br (broad).
Low-resolution mass spectra (MS) were recorded on a JOEL JMS-AX505HA, JOEL
SX-102, or a SCIEX-APIiii spectrometer; high resolution MS were obtained using a JOEL SX-102A spectrometer. All mass spectra were taken under electrospray ionization (ESI), chemical ionization (Cl), electron impact (El) or by fast atom bombardment (FAB) methods. Infrared (IR) spectra were obtained on a Nicolet 510 FT-IR spectrometer using a 1-mm NaCl cell. All reactions were monitored by thin-layer chromatography on 0.25 mm E. Merck silica gel plates (60F-254), visualized with UV light, 5% ethanolic phosphomolybdic acid or p-anisaldehyde solution. Flash column chromatography was performed on silica gel (230-400 mesh, Merck). Optical rotations were obtained using a Perkin Elmer Model 241 Polarimeter. Melting points were determined using a Mel-Temp II apparatus and are uncorrected. The following examples describe the syntheses of intermediates particularly useful in the synthesis of compounds of Formula (l),(ll), (III), and (IV):
Intermediate Example 1
Preparation of 3-methyl-1 H-indazol-6-amine
Figure imgf000054_0001
To a solution of 10 g (.06 mol) of 2-ethyl-5-nitroaniline (prepared by nitration of 2-ethylaniline: Bergman and Sand, Tetrahedron 1990, 46, 6085-61 12) in 300 ml of glacial acetic acid, at room temperature, was added a solution of 8.98 ml (.06 mol) of -"erf-butyl nitrite in 40 ml of acetic acid dropwise over 15 min. After the addition was complete the solution was allowed to stir for 30 min. The acetic acid was removed in vacuo to afford an orange solid. The solid was dissolved in approximately 120 ml of ethyl acetate and washed with 3 x 100 ml sat. aqueous NaHCU3. The organic layer was dried over MgSU4 and the solvent was removed in vacuo to afford 3-methyl-6-nitroindazole as a yellow solid (10.4 g, 98%).
To a stirred solution of 10 g (.06 mol) of 3-ιnethyl-6-nitroindazole in 100 ml of 2- methoxyethyl ether, at 0 °C, was added a solution of 45 g (.24 mol) of tin(ll) chloride in 86 ml of concentrated HCI dropwise over 15 min, in order to keep the reaction temperature below 100 °C. After the addition was complete, the ice bath was removed and the solution was allowed to stir for an additional 20 min. Approximately 70 ml of diethyl ether was added to reaction, resulting in precipitate formation. The resulting precipitate was isolated by filtration and washed with diethyl ether, and afforded a yellow solid (10 g, 92 %), the HCI salt of 3-methyl-1 r7-indazol-6-amine.
Intermediate Example 2
Preparation of N, 3-dimethyl-l H-indazol-6-amine
Figure imgf000054_0002
To a 100-ιnL flask containing 1.88 g (34.8mmol) sodium methoxide and 60 mL of dry methanol was added 1.27 g (6.96 mmol) of 3-methyl-l W-indazol-6-amine hydrochloride. After stirring the mixture at room temperature for 15 minutes, 0.38 g (12.6 mmol) of paraformaldehyde was added and the flask placed into a 60 °C oil bath for 10 minutes. The flask was then removed from the oil bath and allowed to stir at room temperature for 4.5 hours. To the reaction mixture was added 0.26 g (6.96 mmol) of sodium borohydride and the mixture heated to reflux for 2 hours then allowed to cool to room temperature and stir overnight. To the reaction mixture was added 1 M sodium hydroxide (13 mL). After 10 minutes the reaction mixture was concentrated in vacuo to an aqueous suspension. The suspension was diluted with 40 mL of water and pH adjusted to pH 8 with aq. hydrochloric acid. The aqueous suspension was extracted three times with ethyl acetate, and the organic extracts combined and washed with brine, dried with sodium sulfate, and filtered. To the filtrate was added 5 g of silica gel and the resultant suspension concentrated to dryness in vacuo. The solid was loaded on top of a column of 90 g of silica gel and eluted with chloroform/ethyl acetate/methanol (9:0.5:0.5). The proper fractions were combined and concentrated to give 0.43 g (39%) of N, 3-diιnethyl- l H-indazol-6-amine as a white solid. HNMR: δ 1 1.88 (s, I H). 7.29 (d, 1 H), 6.44 (d, I H), 6.20 (s, 1 H), 5.80 (brs, I H), 2.67 (s, 3H) 2.32 (s, 3H); MS (ES+, m/z) 162 (M+H).
Intermediate Example 3
Preparation of 2, 4-Dichloro-5-fluoropyrimidine.
Figure imgf000055_0001
To 5-fluorouracil (5.0 g, 0.04 mol) was added phosphorus oxychloride (25 mL, 0.27 mol) and Λ/,Λ/-diethylaniline (6 mL, 0.06 mol) while stirring at room temperature. After being heated under reflux for 100 min, the mixture was concentrated under reduced pressure. The residue was poured into ice water (100 mL) and extracted with ether. The organic layer was dried with sodium sulfate and evaporated at 0 °C under reduced pressure to give 5.35 g of the desired product (85%). Mp 37-38 °C. HNMR: δ 8.95 (s, 1 H). Intermediate Example 4
Preparation of Λ/-(2-chloro-5- fluoro-4-pyrimidinyl) -Λ/-(3-methyl- l H-indazol-6- yOamine.
Figure imgf000056_0001
To a stirred solution of 3-methyl-6-aminoindazole (2J1 g, 0.015 mol) and NaHCOs
(1.26 g, 0.045 mol) in THF (15 mL) and EtOH (60 mL) was added 5-fluoro-2,4- dichloropyrimidine (3.2 g, 0.019 mol) at room temperature. After the reaction was stirred overnight, the brown suspension was filtered and washed thoroughly with EtOH. The filtrate was concentrated under reduced pressure, and the resulting solid was washed with ether to remove excess pyrimidine to yield 3.7 g of the desired product (89 %). HNMR: δ 12.57 (s, 1 H), 10.01 (s, 1 H), 8.28 (d, 1 H), 7.93 (s, 1 H), 7.60 (d, 1 H), 7.27 (dd, 1 H) 3.1 1 (s, 3H).
Intermediate Example 5
Preparation of Λ/-(2-chloro-5-4-pyrimidinyl)-Λ/-(3-methyl-1 H-indazol-6-yl)amine. ,
Figure imgf000056_0002
To a stirred solution of 3-ιnethyl-6-aminoindazole (271 g, .015 mol) and NaHCU3 (1.26 g,
.045 mol) in THF (15 mL) and ethanol (60 mL) was added 2,4-dichloropyrimidine (6.66 g,
.045 mol) at room temperature. After the reaction was stirred for four hours, the suspension was filtered and washed thoroughly with ethanol. The filtrate was concentrated under reduced pressure, and the resulting solid was washed with ether to remove excess pyrimidine to yield 3.5 g (89 % yield) of Λ/-(2-chloro-4-pyrimidinyl)-/V-(3- methyl-1 r/-indazol-6-yl)amine.
Intermediate Example 6 Preparation of rert-butyl 6-[(2-chloro-5-fluoro-4-pyrimidinyl)amino]-3-methyl-l H- indazole-1-carboxylate.
Figure imgf000057_0001
To a stirred suspension of the product of intermediate example 4 (3.0 g, 0.01 1 mol), triethylamine (1.5 mL, 0.01 1 mol), 4-dimethylaminopyridine (.13 g, 0.1 1 mmol), and acetonitrile (14 mL) was added DMF (50 mL) at room temperature. Once the mixture was in solution, di-tert-buty I dicarbonate (2.36 g, 0.01 1 mol) was added portion wise over three minutes. After being stirred for 1 hour, the solution was diluted with water and extracted with ether (3 X 40 mL). The combined extracts were dried over sodium sulfate, filtered, and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (9:1 , CH2Cl2:EtOAc), giving 3.3 grams of the desired product (85%).
Intermediate Example 7
Preparation of tert-butyl 6-[(2-chloro-4-pyrimidinyl)amino]-3-methyl-l H-indazole-1- carboxylate.
Figure imgf000057_0002
To a stirred suspension of Λ/-(2-chloro-4-pyrimidinyl)-Λ/-(3-methyl-1 r/-indazol-6- γl)amine (2.8 g, .01 1 mol), triethylamine (1.5 mL, .01 1 mol), 4-dimethylaminopyridine (.13 g, .1 1 mmol), and acetonitrile (14 mL) was added DMF (50 mL) at room temperature. Once the mixture is in solution, di-tert-butyl dicarbonate (2.36 g, .011 mol) was added portion wise over three minutes. After being stirred for 1 hour, the solution was diluted with water and extracted with ether (3X 40 mL). The combined extracts were dried over sodium sulfate, filtered, and concentrated under reduced pressure. The resulting residue was purified by column chromatography (silica gel, 9:1 CH2CI2- EtOAc), giving 3.3 grams (85% yield) of fetf-butyl 6-[(2-chloro-4-pyrimidinyl)amino]-3-methyl-1 r/-indazole-1 - carboxylate. Intermediate Example 8
Preparation of tert-butyl 6-[(2-chloro-5-fluoro-4-pyrimidinyl)(methyl)amino]-3-methyl- 1 W-indazole-1 -carboxylate.
Figure imgf000058_0001
To a stirred solution of the product of Intermediate Example 6 (3.3 g, 8.8 mmol) in 44 mL of DMF was added NaH (0.23 g, 9.6 mmol) portion wise over 3 min at room temperature. After being stirred for 15 min, iodomethane (1.37 g, 9.6 mmol) was added dropwise. After being stirred for 30 min, the reaction was- quenched with water and extracted with ether (3 X 30 mL). The combined extracts were dried over sodium sulfate, filtered, and concentrated under reduced pressure to yield a yellow solid. The resulting solid was purified by silica gel column chromatography (CH2CI2), giving 3.26 g of the desired product (95%). HNMR: δ 8.18 (d, 1 H), 7.90 (s, 1 H), 7.82 (d, 1 H), 7.35 (d, 1 H), 3.45 (s, 3H), 2.48 (s, 3H) 1.54 (s, 9H). MS (ES+, m/z) 292 (M+H).
Intermediate Example 9
Preparation of fert-butyl 6-[(2-chloro-4-pyrimidinyl)(methyl)amino]-3-methyl-l H- indazole-1-carboxylate.
Figure imgf000058_0002
This intermediate wherein W = H was prepared in similar fashion to Intermediate Example 8 described above.
Intermediate Example 10
Preparation of 4-Chloro-/V-{3-[(methylsulfonyl)methyl]phenyl}-1 ,3,5-triazin-2-amine.
Figure imgf000059_0001
To a dry flask containing a magnetic stir bar and a nitrogen atmosphere was added 0.247 g (1.33 mmol) of 3-[(methylsulfonyl)methyl]aniline, 2 mL dry acetonitrile and 0.23mL (1.3 mmol) of diisopropylethyl amine and resultant mixture cooled in an ice bath. To the cold solution was added a solution of 0.2 g (1.33 mmol) of 2,4-dichloro-1 ,3,5- triazine in 2.4 mL of dry acetonitrile over 1 min. The reaction mixture was stirred for ca. 16 hrs and 1 gram of silica gel was added. The mixture was concentrated in vacuo to dryness and applied to the top of column of silica gel and eluted with a 15-50% ethyl acetate/ dichloromethane gradient. The proper fractions were combined and concentrated in vacuo to give 0.28 g (70%) of 4-chloro-/V-{3- [(methylsulfonyl)methyl]phenyl}-1 ,3,5-triazin-2-amine as a white solid. HNMR: δ 10.83 (s, 1 H), 8.64 (s, 1 H), 7.63 (m, 2H), 7.4 (t, 1 H), 7.25 (d, 1 H), 4.48 (s, 2H), 2.94 (s, 3H); MS (ES+, m/z) 299, 301 (M+H).
Intermediate Example 11
Preparation of 2,3-dimethyl-2r/-indazol-6-amine
Figure imgf000059_0002
To a stirred solution of 18.5 g (0.11 mol) of 3-methyl-6-nitro- 7W-indazole in 350 ml acetone, at room temperature, was added 20 g (0.14 mol) of trimethyloxonium tetraflouroborate. After the solution was allowed to stir under argon for 3 hours, the solvent was removed under reduced pressure. To the resulting solid was added saturated aqueous NaHC03 (600 ml) and a 4:1 mixture of chloroform-isopropanol (200 ml), and the mixture was agitated and the layers were separated. The aqueous phase was washed with additional chloroform: isopropanol (4 x 200 ml) and the combined organic phase was dried (Na2S04). Filtration and removal of solvent gave a tan solid. The solid was washed with ether (200 ml) to afford 2,3-dimethyl-6-nitro-2r/-indazole as a yellow solid (15.85 g, 73 o/o). 1H NMR (300 MHz, dβDMSO) δ 8.51 (s, I H), 7.94 (d, J = 9.1 Hz, 1 H), 7.73 (d, J = 8.9 Hz, 1 H), 4.14 (s, 3H), 2.67 (s, 3H). MS (ES+, m/z) 192 (M+H).
To a stirred solution of 2,3-dimethyl-6-nitro-2V-indazole (1.13 g) in 2- methoxyethyl ether (12 ml), at 0 °C, was added a solution of 4.48 g of tin(ll) chloride in 8.9 ml of concentrated HCI dropwise over 5 min. After the addition was complete, the ice bath was removed and the solution was allowed to stir for an additional 30 min. Approximately 40 ml of diethyl ether was added to reaction, resulting in precipitate formation. The resulting precipitate was isolated by filtration and washed with diethyl ether, and afforded a yellow solid (1.1 g, 95 %), the HCI salt 2,3-dimethyl-2/7-indazol-6- amine. 1H NMR (300 MHz, deDMSO) δ 7.77 (d, J = 8.9 Hz, 1 H), 7.18 (s, 1 H), 7.88 (m, 1 H), 4.04 (s, 3H), 2.61 (s, 3H). MS (ES+, m/z) 162 (M+H).
Intermediate Example 12 Preparation of Λ/-(2-chloropyrimidin-4-yl)-2,3-dimethyl-2H-indazol-6-amine
Figure imgf000060_0001
to a stirred solution of Intermediate Example 11 (2.97 g, .015 mol) and NaHCOs (5.05 g, .06 mol) in THF (15 mL) and ethanol (60 mL) was added 2,4-dichloropyrimidine (6.70 g, .045 mol) at room temperature. After the reaction was stirred for four hours at 85 °C, the suspension was cooled to rt, filtered and washed thoroughly with ethyl acetate. The filtrate was concentrated under reduced pressure, and the resulting solid was triturated with ethyl acetate to yield 3.84 g (89 % yield) of Λ/-(2-chloropyrimidin-4-yl)- 2,3-dimethyl-2tf-indazol-6-amine. 1H NMR (400 MHz, deDMSO) δ 7.28 (d, J = 9.0 Hz, 1 H), 6.42 (d, J = 8.8 Hz, 1 H), 6.37 (s, 1 H), 5.18 (br s, 1 H), 3.84 (s, 3H), 2.43 (s, 3H). MS (ES+, m/z) 274 (M+H). Intermediate Example 13
Preparation of Λ/-(2-chloropyrimidin-4-yl)-Λ/,2,3-trimethyl-2r/-indazol-6-amine
Figure imgf000061_0001
To a stirred solution of the Intermediate 12 (7.37 g) in DMF (50 ml) was added CS2CO3 (7.44 g, 2 eqv.) and Mel (1.84 ml, 1.1 eqv.) at room temperature. Mixture was stirred at rt for overnight The reaction mixture was poured into ice-water bath, and the precipitate was collected via filtration and washed with water. The precipitate was air- dried to afford Λ/-(2-chloropyrimidin-4-yl)-Λ/,2,3-trimethyl-2r/-indazol-6-amine as an off-white solid (6.43 g, 83%). 'H NMR (400 MHz, dsDMSO) δ 7.94 (d, J = 6.0 Hz, 1 H), 7.80 (d, J = 7.0 Hz, 1 H), 7.50 (d, J = 1.0 Hz, 1 H), 6.88 (m, 1 H), 6.24 (d, J = 6.2 Hz, 1 H), 4.06 (s, 3H), 3.42 (s, 3H), 2.62 (s, 3H). MS (ES+, m/z) 288 (M+H).
Intermediate Example 14
Preparation of 2-Chloro-5-({4-[(2,3-dimethyl-2 /-indazol-6-yl)amino]-1 ,3,5-triazine
Figure imgf000061_0002
Intermediate Example 1 1 (free base) (0.080g, 0.5 mmol), and 2,4-dichloro-1 ,3,5- triazine (Harris, R.L.N.; Amide-acid chloride adducts in organic synthesis. Part 12. The synthesis of triazines form N-cyanocarbamimidates. SYNTHESIS (1981), 11 , 907-8)
(0.075 g, 0.5 mmol), were combined in acetonitrile. DIEA was added and the solution was stirred at RT for 18 h. The resulting precipitate was filtered off and washed with acetonitrile to give analytically pure product as a light yellow solid (0.10 g, 0.36 mmol). 1H NMR (300 MHz, deDMSO) δ 10.73 (s, 1 H), 8.63 {d, J = 15.3 Hz, 1 H), 7.94 (d, J = 7.7 Hz, 1 H), 7.62 (d, J = 8.9 Hz, 1 H), 7.13 (d, J = 7.9 Hz, 1 H), 4.01 (s, 3H), 2.57 (s, 3H). MS (ES+, m/z) 275 (M+H).
Intermediate Example 15
Preparation of 2-Chloro-5-({4-[(2,3-dimethyl-2r/-indazol-6-yl)(methyl)amino]-1 ,3,5- triazine
Figure imgf000062_0001
Intermediate Example 14 (0.05 g, 0.18 mmol) was combined with cesium carbonate (0.088 g, 0.27 mmol), and DMF (1 mL). Methyl iodide (0.033 mL, 0.54 mmol) was added and the solution was stirred at RT for 18 h. Water was added and the solution was washed with diethyl ether. The organic layer was dried with magnesium sulfate, filtered, and concentrated, to give a light yellow glass (0.035 g, 0.12 mmol) which was >90 pure by HPLC. This material was used directly in the next step. 1H NMR (300 MHz, deDMSO) δ 8.6 (br s, 1 H), 7.70 (d, J = 8.2 Hz, 1 H), 7.48 (s, 1 H), 6.90 (d, J = 8.0 Hz, 1 H), 4.04 (s, 3H), 3.48 (s, 3H), 2.60 (s, 3H). MS (ES+, m/z) 289 (M+H).
Intermediate Example 16 Preparation of Nl-methyl-4-nitrobenzene-1 ,2-diamine
Figure imgf000062_0002
In a 350 mL pressure flask, 2-fluoro-5-nitroaniline (10 g, .064 mol), methylamine as a 2M solution in THF (65 mL, .13 mol) and potassium carbonate (18 g, .13 mol) in 1-
Methyl-2-pyrrolidinone (80 mL) were combined. The flask was sealed and heated to 120 degrees C overnight. The reaction was monitored by TLC. When reaction was judged to be complete based upon consumption of 2-fluoro-5-nitroaniline, it was cooled to room temperature and poured into 2-3 times the total reaction volume of water. When a precipitate was formed, it was filtered and dried. The product was carried on without purification. 1 H NMR (300 MHz, deDMSO) δ 7.54 (dd, J = 8.79, 2.64 Hz, I H), 7.39 (d, J = 2.64 Hz, 1 H), 6.41 (d, J = 8.79 Hz, 1 H), 6.1 1 (d, J = 4.39 Hz, 1 H), 5.07 (s, 2H), 2.83 (d, J = 4.83 Hz, 3H).
Intermediate Example 17
Preparation of 1 ,2-dimethyl-5-nitro-l W-benzimidazole
Figure imgf000063_0001
Intermediate Example 16 (7 g, .042 mol) and trimethoxy orthoacetate (5.86 mL,
.046 mol) were combined in 4N HCI (70 mL). The reaction was heated to reflux and followed by TLC. When reaction was judged to be complete based upon consumption of diamine, it was slowly poured into 6N NaOH (65 mL) and ice and allowed to stir until the pH was greater than 7.0. The product was extracted with EtOAc, dried over sodium sulfate, filtered and concentrated. The resulting material was carried on without purification. I H NMR (300 MHz, deDMSO) δ 8.39 (d, J = 2.20 Hz, I H), 8.12 (dd, J = 8.94, 2.20 Hz, 1 H), 7.71 (d, J = 8.94 Hz, 1 H), 2.58 (s, 3H), 3.80 (s, 3H).
Intermediate Example 18 Preparation of Preparation of 2-benzyl-1 -methyl-5-nitro-1 H-benzimidazole
Figure imgf000063_0002
Intermediate Example 16 (2.3 g, .014 mol) and phenylacetic acid (2.8 g, .021 mol) were combined in 4N HCI (30 mL). The reaction was heated to reflux and followed by TLC.
When reaction was judged to be complete based upon consumption of diamine, it was slowly poured into 6N NaOH (27 mL) and ice and allowed to stir until the pH was greater than 7.0. The product was extracted with EtOAc, dried over sodium sulfate, filtered and concentrated. The resulting material was generally carried on without purification. 1 H NMR (300 MHz, deDMSO) δ8.46 (d, J = 2.20 Hz, I H), 8.14 (dd, J = 8.94, 2.20 Hz, I H.) 7.72 (d, J = 8.94 Hz, 1 H) 7.30 (m, 5H), 4.37 (s, 2H), 3.79 (s, 3H).
Intermediate Example 19
Preparation of 1 ,2-dimethyl-1 r/-benzimidazol-5-amine
Figure imgf000064_0001
Intermediate Example 17 (7 g, .037 mol) and 10% Pd/C (7g) in a concentrated methanol solution were shaken under approximately 40 psi of H2 in appropriate pressure vessel using a Parr Hydrogenator. When the reaction was judged to be complete based upon the consumption of the nitrobenzimidazole, it was diluted with EtOAc and filtered through Celite and silica gel, which was washed with a mixture of EtOAc and MeOH and concentrated. The product was carried on without purification. 1 H NMR (300 MHz, deDMSO) δ 7.1 1 (d, J = 8.38 Hz, 1 H), 6.69 (d, J = 1.51 Hz, 1 H), 6.53 (dd, J = 8.38, 1.51 Hz, 1 H), 4.65 (s, 2H), 3.62 (s, 3H), 2.43 (s, 3H).
Intermediate Example 20
Preparation of N-(2-chloropyrimidin-4-yl)-1,2-dimethyl-1 H-benzimidazol-5-amine
Figure imgf000064_0002
Intermediate Example 19 (4.5g, .028 mol) and sodium bicarbonate (4.69 g, .056 mol) were combined in a 2:1 mixture of EtOH:THF (180 mL). 2,4-dichloropyrimidine (8.32 g, .056 mol) was added and the reaction was heat to 80 degrees C. The reaction was monitored by TLC. When reaction was judged to be complete based upon the consumption of aminobenzimidazole, the reaction was filtered while hot and the filtrate was concentrated. The resulting solid was washed with ether and EtOAc to remove excess 2,4-dichloropyrimidine and the resulting solid was carried on without purification. 1 H NMR (300 MHz, deDMSO) δ 9.97 (s, I H) 8.1 1 (d, J = 5.91 Hz, 1 H) 7.80 (s, I H) 7.48 (d, J = 8.52 Hz, 1 H) 7.27 (d, J = 7.83 Hz, 1 H) 6.68 (d, J = 5.91 Hz, 1 H) 3.74 (s, 3H) 2.54 (s, 3H).
Intermediate Example 21
Preparation of N-(2-chloropyrimidin-4-yl)-N,1 ,2-trimethyl-1 H-benzimidazol-5-amine
Figure imgf000065_0001
Intermediate Example 20 (6.5 g, .024 mol) was dissolved in DMF (70 mL). Sodium hydride (1.06 g of 60% dispersion in mineral oil, .026 mol) was slowly added in portions and the reaction was allowed to stir for 20 minutes under nitrogen. Methyl iodide (1.65 mL, .026 mol) was added and the reaction stirred for an additional 30 minutes. The reaction was monitored by TLC. When the reaction was judged to be complete based upon consumption of the anilinopyrimidine, water was slowly added to quench excess sodium hydride and product was extracted with EtOAc. The combined organic layers were washed with water to remove DMF, dried over sodium sulfate, filtered and concentrated. The reaction was chromatographed on silica gel using CH2CI2 and MeOH as eluent to purify. 1 H NMR (300 MHz, deDMSO) δ 7.89 (d, J = 6.15 Hz, 1 H) 7.59 (d, J = 8.50 Hz, 1 H) 7.50 (d, J = 1.76 Hz, 1 H) 7.13 (dd, J = 8.50, 1.90 Hz, 1 H) 6.10 (d, J = 5.27 Hz, I H) 3.75 (s, 3H) 3.41 (s, 3H) 2.53 (s, 3H).
Example 1 recites the general procedure for the synthesis of compounds of formula (I) and (II) wherein W = C-F: Example 1
/Vz-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-fluoro-Λ/l-methyl-Λ/4-(3-methyl-1 r/-indazol-6- yl)-2,4-pyrimidinediamine
Figure imgf000066_0001
To a stirred suspension of the product of Intermediate Example 8 (2.0 g, 5.1 mmol) and 3-amino-4-methoxyphenyl ethyl sulfone (1.2 g, 5.6 mmol), in 10 mL of isopropanol, was added a drop of concentrated HCI at 80 °C. After being stirred for 15 hr, the suspension was concentrated under reduced pressure. The resulting residue was diluted with 5 mL CH2CI2 and 5 mL trifluoroacetic acid and stirred for 30 min at room temperature, then was diluted with CH2CI2 (3 X 40 mL), and washed with saturated NaHCOs. The extracts were dried over sodium sulfate, filtered, and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (4:1 , CH2CI2:EtOAc), giving 1.0 g (42%) of /V2-[5-(ethylsulfonyl)-2-methoxyphenyl]-5- fluoro-Λ/*-methyl-Λ/*-(3-methyl-1 r/-indazol-6-yl)-2,4-pyrimidinediamine as a white solid. HNMR (400 MHz, de-DMSO): δ 12.60 (bs,l H), 8.91 (bs, 1 H), 7.96 (d,l H, J = 5.5), 7.92 (s, 1 H), 7.64 (d, 1 H, J = 8.6), 7.42 (d, 1 H, J = 8.4), 7.31 (s, 1 H), 7.22 (d,l H, J = 8.6), 6.99 (d, 1 H, J = 8.4), 3.94 (s, 3H), 3.48 (s, 3H), 3.14 (q, 2H, J = 7.3), 2.44 (s, 3 H), 1.04 (t, 3H, J = 7.4).
The compounds of Examples 2-15 were prepared according to the general procedure set forth in Example 1.
Example 2
3-({5-fluoro-4-[methyl(3-methyl-l W-indazol-6-yl)amino]-2-pyrimidinyl}amino)-4- methoxy~Λ/-methylbenzenesulfonamide
Figure imgf000066_0002
HNMR (400 MHz, de-DMSO): δ 12.60 (S,1H), 8.89 (s, 1H), 7.95 (d,lH), 7.91 (s, 1H), 7.64 (d, 1H), 7.31 (3H, ), 7.00 (d, 1H), 4.04 (m, 1H), 3.94 (s, 3H), 3.48 (s, 3H), 3.11 (s, 3H), 1.10 (d, 6H); MS (ES+, m/z) = 442 (M+H).
Example 3
5-fluoro-Λ/-methyl-Λ/-(3- [(methylsulfonyl)methyl]ph
Figure imgf000067_0001
HNMR (400 MHz, de-DMSO): δ 12.65 (br s, 1H), 10.05 (s, 1H), 8.06 (d, 1H), 7.70 (d, 1H), 7.64 (s, 1 H), 7.54 (d, 1 H), 7.40 (m, 1 H), 7.22 (m, 1 H), 7.02 (m, 2H), 4.52 (s, 2H), 4.36 (s, 3H), 3.43 (s, 3H), 2.87 (s, 3H); MS (ES+, m/z) = 441 (M+H).
Example 4 3-({5-fluoro-4-[methyl(3-methyl-1 /-indazol-6-yl)amino]-2-pyrimidinyl}amino)-Λ/- isopropyl-4-methoxybenzenesulfonamide
Figure imgf000067_0002
HNMR (400 MHz, de-DMSO): δ 12.59 (s, 1H), 8.83 (s, 1H), 7.93 (d, 1H), 7.85 (s, 1H), 7.65 (d, 1H), 7.43 (s, 1H), 7.36 (d, 1H), 7.30 (s, 1H), 7.28 (d, 1H), 7.16 (d, IH), 6.99 (d, 1H), 3.91 (s, 3H), 3.47 (s, 3H), 3.16 (m, 1H), .89 (d, 6H); MS (ES+, m/z) = 470 (M+H).
Example 5
5-fluoro-V2-[5-(isopropylsulfonyl)-2-methoxyphenyl]-Λ/4-methyl-Λ/4-(3-methyl-1V- indazol-6-yl)-2,4-pyrimidinediamine
Figure imgf000068_0001
HNMR (400 MHz, de-DMSO): δ 12.60 (s, IH), 8.89 (s, 1H), 7.98 (d, IH).7.91 (s, 1H), 7.64 (d, 1H), 7.31 (m, 3H), 7.00 (d, 1H), 4.04 (m, IH), 3.94 (s, 3H), 3.48 (s, 1H), 3.11 (s, 3H).1.10 (d, 6H);MS(ES+, m/z) = 485 (M+H).
Example 6
Λ/-[5-({5-fluoro-4-[methyl(3-methyl-1f/-indazoI-6-yl)amino]-2-pyrimidinyl}amino)-2- methylphenyljmethanesulfonamide
Figure imgf000068_0002
HNMR (400 MHz, de-DMSO): δ 12.66 (br s, 1H), 9.56 (s, 1H), 8.98 (s, 1H), 7.95 (d, 1H), 7.66 (d, 1H), 7.57 (s, IH), 7.41 (d, 1H), 7.33 (s, IH), 7.03 (d, 1H), 7.00 (d, IH), 3.48 (s, 3H), 2.93 (s, 3H), 2.44 (s, 3H), 2.18 (s, 3H); MS (ES+, m/z) = 456 (M+H).
Example 7 5-fluoro-/\T-methyl-Λ/4-(3-methyl-1 /-indazol-6-yl)-Λ/2-[4-(methylsulfonyl)phenyl]-2,4- pyrimidinediamine
Figure imgf000068_0003
HNMR (400 MHz, de-DMSO): δ 12.68 (s, 1H), 9.80 (s, IH), 8.01 (d, IH), 776 (d, IH), 7.66 (d, 1H), 7.58 (d, 1H), 7.36 (s, 1H), 7.01 (d, 1H), 3.48 (s, 3H), 3.05 (s, 3H), 2.38 (s, 3H); MS (ES+, m/z) = 427 (M+H). Example 8
/V4-(3-ethyl-1r/-indazol [(methylsulfonyl)methy
Figure imgf000069_0001
HNMR (400 MHz, de-DMSO): δ 12.57 (br s, 1H), 9.35 (s, 1H), 7.92 (d, 1H, J = 5.7), 7.75 (br s, 1H), 7.67 (d, 1H, J = 8.6), 7.60 (d, 1H, J = 8.5), 7.28 (s, 1H), 7.14 (dd, 1H, J = 7.8, 7.9), 6.97 (d, 1H, J = 8.4), 6.87 (d, 1H, J = 7.5), 4.31 (s, 2H), 3.47 (s, 3H), 2.88 (m, 2H), 2.85 (s, 3H), 1.26 (t, 3H, J = 7.6); MS (AP+, m/z) = 455 (M+H).
Example 9
4-({5-fluoro-4-[methyl(3-methyl-1V-indazol-6-yl)amino]-2- pyrimidinyl}amino)benzenesulfonamide
Figure imgf000069_0002
HNMR (400 MHz, de-DMSO): δ 12.65 (br s, 1H), 9.81 (s, 1H), 8.01 (d, 1H), 7.75 (d, 1H), 7.67 (d, 1H), 7.59 (d, 2H), 7.33 (s, 1H), 7.10 (br s, 1H), 7.00 (d, 1H), 3.80 (s, 1H), 3.49 (s, 3H), 2.40 (s, 3H); MS (ES+, m/z) = 428 (M+H).
Example 10 /V4-ethyI-5-fluoro-Λ/2-[2-methoxy-5-(methylsulfonyl)phenyl]-/V4-(3-methyl-1r/-indazol-6- yl)-2,4-pyrimidinediamine
Figure imgf000070_0001
HNMR (400 MHz, de-DMSO): δ 12.57 (s, 1 H).9.32 (s, IH), 7.89 (s, IH), 7.72 (s, 1H), 7.64 (d, 1H), 7.59 (d, 1H), 7.25 (s, IH), 6.95 (d, IH), 6.87 (d, 1H), 4.29 (s, 3H), 3.98 (q, 2H), 2.86(s, 3H), 2.43 (s, 3H), 1.15 (t, 3H); MS (ES+, m/z) = 471 (M+H).
Example 11
[4-({5-fluoro-4-[methyl(3-methyl-1r/-indazol-6-yl)amino]-2-pyrimidinyl}amino)phenyl]- N-methylmethanesulfonamide
Figure imgf000070_0002
HNMR (400 MHz, de-DMSO): δ 12.57 (s, 1H), 9.35 (s, 1H), 7.92 (d, 1H), 7.66 (d, 1 H), 7.64 (s, 1H), 7.63 (d, 1H), 7.28 (s, 1H), 7.16 (d, 1H), 7.13 (d, 1 H).6.87 (d, 1H), 4.29 (s, 2H), 3.47 (s, 3H), 4.1 (s, 1H), 2.80 (s, 3H), 2.48 (s, 3H); MS (ES+, m/z) = 456 (M+H).
Example 12 5-fluoro-Λ/2-{3-[(isopropylsulfonyl)methyl]phenyl}-Λ/4-methyl-ΛT-(3-methyl-1r/-indazol- 6-yl)-2,4-pγrimidinediamine
Figure imgf000070_0003
HNMR (400 MHz, de-DMSO): δ 12.70 (br s, 1H), 973 (s, 1H), 7.99 (d, 1H), 7.72 (s, 1H), 7.67 (d, 1H), 7.56 (d, 1H), 7.35 (s, 1H), 7.18 (dd, 1H), 7.01 (d, 1H), 6.95 (d, 1H), 4.32 (s, 2H), 3.50 (s, 3H), 3.13 (m, 1H), 2.43 (s, 3H), 1.21 (d, 6H); MS (ES+, m/z) = 469 (M+H). Example 13
3-({5-fluoro-4-[methyl(3-methyl-1 f/-indazol-6-yl)amino]-2-pyrimidinyl}amino)-4- methoxybenzamide
Figure imgf000071_0001
HNMR (400 MHz, de-DMSO): δ 12.62 (s, 1 H), 8.80 (d, 1 H), 7.95 (d, 1 H), 7.79 (s, 1 H), 7.78 (brs, 1 H), 7.68 (d, 1 H), 7.53 (dd, 1 H), 7.32 (s, 1 H), 7.1 1 (brs, 1 H), 7.05 (d, 1 H), 7.02 (d, 1 H), 3.92 (s, 3H), 3.49 (s, 3H), 2.47 (s, 3H); MS (ES+, m/z) = 422 (M+H).
Example 14
4-({5-fluoro-4-[methyl(3-methyl-1 r/-indazol-6-yl)amino]-2-pyrimidinyl}amino)-3- methoxybenzenesulfonamide
Figure imgf000071_0002
HNMR (400 MHz, de-DMSO): δ 12.30 (br s, 1 H), 8.77 (s, 1 H), 8.10 (d, 1 H), 7.73 (d, 1 H), 7.54 (d, 1 H), 7.44 (s, 1 H), 7.24 (d, 1 H), 7.22 (s, 1 H), 7.20 (brs, 2H), 7.08 (d, 1 H), 3.96 (s, 3H), 3.55 (s, 3H), 2.47 (s, 3H); MS (ES+, m/z) = 457 (M+H).
Examples 15 and 16 recite the general procedure for the synthesis of compounds of formula (I) and (II) wherein W = N:
Example 15
^-(S-methyl-I H-indazol-θ-yO-Ar-IS-^methylsulfonyOmethyllphenylJ-I.S.δ-triazine- 2,4-diamine trifluoroacetate
Figure imgf000072_0001
To a flask containing a magnetic stir bar was added 0.03 g (0.20 mmol) of 3- methyl-1 r/-indazol-6-amine and 0.060 g ( 0.20 mmol) of 4-chloro-Λ/-{3- [(methylsulfonyl)methyl]phenyl}-1,3,5-triazin-2-amine and 2 mL of isopropanol and the resultant mixture was heated at reflux for ca. 16 hours. Upon cooling the reaction mixture a solid precipitated. The solid was filtered and washed with ethyl acetate (2 x 4 mL), acetonitrile (4 mL), and ethyl ether (4 mL) and dried under vacuum to give N2-(3-methyl- l H-indazol-6-yl)-N4-{3-[(methylsulfonyl)methyl]phenyl}-1 ,3,5-triazine-2,4-diamine hydrochloride as a solid. The solid was purified by C-18 RP-HPLC using an acetonitrile/water gradient containing 0.5% trifluoroacetic acid buffer. Concentrating the proper fractions gave 0.015 g (10 %) of N2-(3-methyl-l H-indazol-6-yl)-N4-{3- [(methylsulfonyl)methyl]phenyl}-1,3,5-triazine-2,4-diamine trifluoroacetate as a white solid. HNMR: δ12.4 (br s, 1 H), 9.9 (br s, 1 H), 8.34 (S, 1 H), 7.8 (br s, 1 H), 7.67 (br s, 1 H), 7.56 (d, 1 H), 7.29(m, 2H), 7.02 (d, 1 H), 4.34 (br s, 2H), 2.83 (br s, 3H), 2.40 (s, 3H). MS (ES+, m/z) = 409 (M+H).
Example 16
Λ/2-methyl-Λ/2-(3-methyl-l H-indazol-6-yl)-Λ/4-{3-[(methylsulfonyl)methyl]phenyl}-1 ,3,5- triazine-2,4-diamine hydrochloride
Figure imgf000072_0002
To a flask containing a magnetic stir bar was added 0.027 g (0.17mmol) of N,3- dimethyl-l H-indazol-6-amine and 0.058 g (0.19 mmol) of 4-chloro-/V-{3- [(methylsulfonyl)methyI]phenyl}-1 ,3,5-triazin-2-amine and 2 mL of isopropanol and the resultant mixture heated at reflux for ca. 16 hours. Upon cooling the reaction mixture a solid precipitated. The solid was filtered and washed with ethyl acetate (2 x 4 mL), acetonitrile (4 mL), and ethyl ether (4 mL) and dried under vacuum to give 0.03 g (42%) of Λ/2- m ethyl -A/2- (3 -m ethyl -1 H-indazol-6-yl)-Λ/*-{3-[(methylsulfonyl) methyl]phenyl}-1 ,3,5- triazine-2,4-diamine hydrochloride as a light pink solid. Some of the peaks in the NMR spectrum are broad at room temperature. Heating to 90 °C produces peaks that are well resolved. HNMR: δ12.5 (br s, 1 H), 9.9 (br s, 1 H), 8.24 (m, 1 H) 7.72 (d, 1 H) 7.5 (m), 7.38 (s, 1 H), 7.01 (d, 1 H) 6.9 (br s, 1 H) 3.47 (s, 3H), 2.75 (br s, 3H), 2.47 (S, 3H). HNMR (at 90 °C): δ 9.62 (s, 1 H), 8.29 (s, 1 H), 7.76 (d, 1 H), 7.66 (s, 1 H), 7.54 (d, 1 H), 7.43 (s, 1 H) 7.1 (m, 3H), 4.13 (s, 2H), 3.56 (s, 3H), 2.93 (s, 3H), 2.55 (s, 3H); MS (ES+, m/z) = 424 (M+H).
In most cases the hydrochloride salts are obtained in sufficient purity. When this is not the case, the amine hydrochloride salts are purified either by Reverse Phase High Pressure Liquid Chromatography (RPHPLC), or by normal phase chromatography by loading the solids on 1 gram of silica gel. The silica gel mixture is then loaded on top of a column of silica gel and eluted with a chloroform/ethyl acetate to methanol/ethyl acetate gradient. As stated above, some of the peaks in the NMR spectrum are broad at room temperature. Heating to 90 °C produces peaks that are well resolved.
The compounds of Examples 17-20 were prepared according to the general procedures set forth above in Examples 15 and 16.
Example 17
Λ/z-[5-(ethylsulfonyl)-2-methoxyphenyl]-/\ft-methyl-r -(3-methyl-l H-indazol-6-yl)-1 ,3,5- triazine-2,4-diamine hydrochloride
Figure imgf000073_0001
HNMR (deDMSO, 300 MHz): δ 8.89 (br s, 1 H), 8.56 (br s, 1 H), 8.26 (s, 1 H), 772 (d, 1 H), 7.62 (d, 1 H), 7.41 (s, 1 H), 7.31 (d, 1 H), 7.04 (d, 1 H), 3.95 (s, 3H), 3.50 (s, 3H), 3.13 (br s, 2H), 1.08 (t, 3H). At 90 degrees, peaks sharpen and peak at 3.13 resonates as a quartet. MS (AP+, m/z) = 454 (M+1).
Example 18
Λ/-[2-methyl-5-({4-[methyl(3-methyl-1f-indazol-6-yl)amino]-1,3,5-triazin-2- yl}amino)phenyl]methanesulfonamide
Figure imgf000074_0001
HNMR (deDMSO, 300 MHz): δ 12.60 (br s, IH), 9.6 (br s, IH), 8.92 (br s, 1H), 8.15 (br s, 1H) 7.67 (d, 1H), 7.52 (br s, IH), 7.39 (br s, 1 H), 7.34 (s, 1H), 6.99 (d, IH), 3.46 (s, 3H), 2.89 (s, 3H), 2.14 (s, 3H). HNMR (deDMSO @ 90°C, 300 MHz): δ 12.46 (br s, 1H), 9.39 (s, 1H), 8.73 (s, 1H), 8.23 (s, 1H), 7.73 (d, IH).7.59 (s, 1 H), 7.47 (d, 1H), 7.40 (s, IH), 7.06 (d, IH), 6.93 (d, 1 H), 3.55 (s, 3H), 2.99, (s, 3 H), 2.24 (s, 3H). MS (AP+, m/z) = 439 (M+1).
Example 19
/V2-methyl-Λ/2-(3-methyl-1r/-indazol-6-yl)-Λ/4-[3-(methylsulfonyl)phenyl]-1,3,5-triazine- 2,4-diamine
Figure imgf000074_0002
HNMR (deDMSO @ 90°C, 300 MHz): δ 12.48 (br s, 1H), 9.82 (s, 1H), 8.36 (s, 1H), 8.30 (s, 1H), 7.91 (d, 1H), 7.75 (d, 1H), 7.50 (d, 1H), 7.43 (s, IH).7.33 (t, 1H), 7.07 (d, IH), 3.57 (s, 3H), 2.54 (s, 3H). Note: at room temperature, the S02CH3 group resonates at 3.05 as a broad singlet, whereas at 90°C, the S02CH3 group resonates under the H20 peak. MS (ES+, m/z) = 410 (M+1). Example 20
A/-[4-({4-[methyl(3-methyl-1 r/-indazol-6-yl)amino]-1 ,3,5-triazin-2- yl}amino)phenyl]acetamide hydrochloride
Figure imgf000075_0001
HNMR (deDMSO @ 90°C, 300 MHz): δ 9.58 (s. 1 H), 9.54 (s, I H), 8.27 (S,1 H), 7.75 (d, 1 H), 7.50 (s, 1 H), 7.45 (d, 2H), 7.33 (d, 2H), 7.08 (d, 1 H), 3.56 (s, 3H), 2.56 (s, 3H), 2.03 (s, 3H). MS (ES+, m/z) = 389 (m+1).
Example 21 recites the general procedure for the synthesis of compounds of formula (I) and (II) wherein W = C-H:
Example 21 3-({4-[methyl(3-methyl-1 /-indazol-6-yl)amino]-2- pyrimidinyl}amino)benzenesulfonamide hydrochloride
Figure imgf000075_0002
To a solution of Intermediate Example 9 (200 mg, 0.535 mmol) and 3- aminobenzenesulfonamide (92.1 mg, 0.535 mmol). in isopropanol (6 ml) was added 4 drops of cone. HCI. The mixture was heated to reflux overnight. The mixture was cooled to rt and diluted with ether (6 ml). Precipitate was collected via filtration and washed with ether. 3-({4-[methyl(3-methyl-1 fV-indazol-6-yl)amino]-2-pyrimidinyl}amino)- benzenesulfonamide was isolated as off-white solid (214 mg).
'H NMR (300 MHz, deDMSO) δ 12.73 (br s, 1 H), 9.54 (s, 1 H), 8.55 (s, 1 H), 7.86 (d, J ■= 6.0 Hz, 1 H), 778-7.81 (m, 2H), 7.40 (s, 1 H), 7.33-7.34 (m, 2H), 7.25 (br s, 2H), 7.02 (d, J = 8.4 Hz, 1 H), 5.82 [d, J = 6.0 Hz, 1 H), 3.51 (s, 3H), 2.50 (s, 3H). MS (ES+, m/z) 410 (M+H).
Unless otherwise indicated, the compounds of Examples 22-37 and 41-68 were prepared according to the general procedures set forth above in Example 21. In most cases the hydrochloride salts of these examples were readily obtained as described in the experimental above. In certain cases it was more convenient to isolate the final compound as its free base by partitioning with an organic solvent (e.g., ethyl acetate) and an aqueous base (e.g. aqueous sodium bicarbonate). It will be readily apparent to those skilled in the art that the syntheses of these examples will use either of Scheme 1 or Scheme 2 described above, depending on group X4, the nature of which defines the alkylating agent whose use is described in Scheme 2. The NMR data characterizing these examples describe either the salt form or the free base form.
Example 22
/V2-[5-(ethylsulfonyl)-2-methoxyphenyl]-/V4-methyl-/V -(3-methyl-1 r/-indazol-6-yl)-2,4- pyrimidinediamine
Figure imgf000076_0001
HNMR: δ 12.74 (s, 1 H), 9.10 (s, 1 H), 7.85 (d, J =6.0 Hz, 1 H), 7.81 (s, 1 H), 779 (d, J =8.2 Hz, 1 H), 7.46 (d, J =8.6 Hz, 1 H), 7.41 (s, 1 H), 7.25 (d, J =8.2 Hz, 1 H), 7.05 (d, J =8.6 Hz, 1 H), 5.78 (d, J =6.0 Hz, 1 H), 3.99 (s, 3H), 3.51 (s, 3H), 3.18 (q, J =7.4 Hz, 2H), 2.50 (s, 3H), 1.09 (t, J =7.4 Hz, 3H); MS (ES+, m/z) = 451, 452 (M+H). Example 23
/v4-methyl-Λ/4-(3-methyl-1 /-indazol-6-yl)-/\/2-{3-[(methylsulfonyl)methyl]phenyl}-2,4- pyrimidinediamine
Figure imgf000077_0001
HNMR: δ 12.70 (s, 1 H), 9.24 (s, 1 H), 7.85 (d, J =6.1 Hz, 1 H), 7.81 (s, 1 H), 7.78 (d, J =8.5 Hz, 1 H), 7.65 (d, J =8.1 Hz, 1 H), 7.37 (s, 1 H), 7.15 (t, J =7.9 Hz, 1 H), 7.00 (d, J =8.5 Hz, 1 H), 6.89 (d, J =7.5 Hz, 1 H), 5.81 (d, J =6.1 Hz, 1 H), 4.27 (s, 1 H), 3.49 (s, 3H), 2.86 (s, 3H), 2.51 (s, 3H); MS (ES+, m/z) = 423, 424 (M+H).
Example 24
/V-isopropyl-3-({4-[methyl(3-methyl-1 f/-indazol-6-yl)amino]-2- pγrimidinyl}amino)benzenesulfonamide
Figure imgf000077_0002
HNMR: δ 12.84 (s, 1 H), 10.26 (s, 1 H), 8.39 (s, 1 H), 7.85 (d, J =6.5 Hz, 1 H), 7.83 (d, J =5.0 Hz, 1 H), 7.72 (s, I H), 7.57 (d, J =7.4 Hz, 1 H), 7.48 (s, 1 H), 7.47 (s,l H), 7.05 (d, J =8.4 Hz, 1 H), 5.90 (d, J =6.5 Hz, 1 H), (s, 1 H), 3.54 (s, 3H), 3.25 (septet, J =6.8 Hz, 1 H), 2.51 (s, 3H), 0.95 (d, J =6.8 Hz, 6H).
Example 25 Λ/-cyclopropyl-3-({4-[methyl(3-methyl-1 r/-indazol-6-yl)amino]-2- pyrimidinyl}amino)benzenesulfonamide
Figure imgf000078_0001
HNMR: δ 12.72 (s, 1H), 9.57 (s, 1H), 8.57 (s, 1H), 7.85 (d, J=6.1 Hz, 1H), 7.80 (s, 1H), 7.78 (d, J =5.2 Hz, 1 H), 7.39 (s, 1 H), 7.37 (t, J =8.1 Hz, 1 H), 7.29 (d, J =7.7 Hz, 1 H), 7.00 (d, J =8.5 Hz, 1H), 5.79 (d,J=6.1 Hz, 1H), 3.51 (s, 3H), 2.51 (s, 3H), 2.18-2.10 (m, 1H), 0.51-0.30 (m, 4H).
Example 26
Λ/-ethyl-Λ/2-[5-(ethylsulfonyl)-2-methoxyphenyl]-Λ/4-(3-methyl-1r/-indazol-6-yl)-2,4- pyrimidinediamine
Figure imgf000078_0002
HNMR: δ 12.70 (s, 1 H), 9.00 (s, 1 H), 7.78 (s, 1 H), 7.76 (d, 1 H), 7.74 (d, 1 H), 7.42 (d, 1 H), 7.33 (s, 1H), 7.22 (d, 1H), 6.92 (d, 1H), 5.57 (d, 1H), 4.05 (q, 2H), 3.95 (s, 3H), 3.43 (s, 3H), 3.12 (q, 2H), 1.14 (t, 3H), 1.06 (t, 3H); MS (ES+, m/z) = 485 (M+H).
Example 27
Λ/-[3-({4-[methyl(3-methyl-1r/-indazol-6-yl)amino]-2- pyrimidinyl}amino)phenyl]methanesulfonamide
Figure imgf000078_0003
HNMR:δ 12.66 (s, 1H), 9.24 (s, 1H), 9.16 (s, 1H), 7.78 (d, J =5.9Hz, 1H), 7.74 (d, J =8.3 Hz, 1 H), 7.65 (s, 1 H), 7.42 (d, J =8.3 Hz, 1 H), 7.33 (s, 1 H), 7.04 (t, J =8.0 Hz, 1 H), 6.95 (d, J =8.3 Hz, 1 H), 6.67 (d, J =7.9 Hz, 1 H), 5.71 (d, J =5.9 Hz, 1 H), 3.44 (s, 3H). 2.92 (s, 3H), 2.46 (s, 3H); MS (ES+, m/z) = 424, 426 (M+H).
Example 28
Λ/2-{3-[(isopropylsulfonyl)methyI]phenyl}-Λ/4-methyl-Λ/4-(3-methyl-1 r/-indazol-6-yl)-2,4- pyrimidinediamine
Figure imgf000079_0001
HNMR: δ 12.88 (s, 1 H), 10.37 (s, 1 H), 7.86 (d, .7 =6.5 Hz, 1 H), 7.82 (d, J =8.6 Hz, 1 H), 7.67 (s, 1 H), 7.56 (d, J =7.9 Hz, 1 H), 7.29 (s, 1 H), 7.12 (d, J =7.3 Hz, 1 H), 7.05 (d, J =8.6 Hz, 1 H), 5.95 (d, J =6.5 Hz, 1 H), 4.38 (s, 2H), 3.55 (s, 3H), 3.16 (septet, J =6.8 Hz, 1 H), 2.51 (s, 3H). 1.26 (d, J =6.8 Hz, 6H); MS (ES+, m/z) = 451 , 452 (M+H).
Example 29
Λ/2-{4-[(isopropylsulfonyl)methyl]phenyl}-Λ/4-methyl-/v4-(3-methyl-1 r-indazol-6-yl)-2,4- D pvyrriimmiiddiinneeddiiaammiinnee
Figure imgf000079_0002
HNMR: δ 12.87 (s, 1 H), 10.21 (s, 1 H), 7.85 (d, J =6.2 Hz, 1 H), 7.83 (d, J =8.5 Hz, 1 H), 7.57 (d, J =8.1 Hz, 2H), 7.49 (s, 1 H), 7.30 (d, J =8.5 Hz, 1 H), 7.05 (d, J =8.1 Hz, 2H), 5.98 (d, J =6.2 Hz, 1 H), 4.39 (s, 2H), 3.54 (s, 3H), 3.14 (septet, J =6.3 Hz, 1 H), 2.51 (s, 3H), 1.26 (d, J =6.3 Hz, 6H), MS (ES+, m/z) = 451 , 452 (M+H).
Example 30
Λ/2-[5-(isobutylsulfonyl)-2-methoxyphenyl]-Λ/*-(3-methyl-1 r/-indazol-6-yl)-2,4- pyrimidinediamine
Figure imgf000080_0001
HNMR (400 MHz, de-DMSO) δ 12.29 (S,1H), 9.57 (s.lH), 8.75 (dd,lH,J=2.14 Hz and J=6.42Hz), 8.05 (d, 1H, J=5.89, 1H), 7.87 (br s, 1H), 7.77 (d,1H,J=2.85Hz), 7.54 (d, 1H, J=874Hz), 7.47 (dd, 1H, J=2.14Hz and J=8.56 Hz), 7.23 (d, 1H, J=8.65 Hz), 7.16 (d,lH, J=8.56Hz), 6.33 (d,lH, J=57lHz), 3.94 (S,1H, 3H), 3.00 (d,lH, J= 6.42Hz), 2.39 (s,3H), 1.97 - 1.90 (m, 1H), 0.87 (d, 6H, J=678Hz), MS (ES+.M/Z) 467 (M+H),(ES-,m/z) 465 (M-H).
Example 31
Λ/-[3-({4-[methyl(3-methyl-1 /-indazol-6-yl)amino]-2- pyrimidinyl}amino)phenyl]acetamide
Figure imgf000080_0002
HNMR: δ 1270 (s, 1H), 9.79 (s, 1H), 9.15 (s, 1H), 7.99 (s, 3H), 7.95 (s, 1H), 7.82 (d, IH), 7.78 (d, IH), 7.41 (s, 1H), 7.40 (s, 1H), 7.04 (dd, 1H), 7.01 (dd, 1H), 5.76 (d, 1H), 3.48 (s, 3H), 3.33 (s, 3H), 2.01 (s, 3H); MS (ES+, m/z) = 388 (M+H).
Example 32
Λ/-[3-({4-[ethyl(3-methyl-1ry-indazol-6-yl)amino]-2-pyrimidinyl}amino)phenyl]acetamide
Figure imgf000080_0003
HNMR: δ 12.67 (s, 1H), 9.73 (s, 1H), 9.09 (s, 1H), 7.76 (s, 1H), 7.83 (d, 1H), 7.74 (d, 1H), 7.34 (s, 1H), 7.32 (d, 1H), 6.45 (dd, 1H), 6.41 (dd, 2H), 5.76 (d, 1H), 3.97 (q, 1H), 3.47 (s, 3H), 3.33 (s, 3H), 2.13 (s, 3H); MS (ES+, m/z) = 402 (M+H).
Example 33
Λ/2-(2-methoxy-5-{[(5-methyl-3-isoxazolyl)methyl]sulfonyl}phenyl)-Λ/4-(3-methyl-1f/- indazol-6-yl)-2,4-pyrimidinediamine
Figure imgf000081_0001
HNMR (400 MHz, de-DMSO) δ 12.34 (br s, 1 H), 9.63 (br s,1 H), 8.77 - 8.75 (m,1 H),8.08 (d,1 H, J=579Hz), 7.90 (br s, 1 H), 7.78 (brs,1 H), 7.41 (dd,1 H, J=2.12Hz and J=8.61 Hz), 7.24 (d, 1 H, J=875Hz), 7.19 (br s, 1H), 6.38 (d, 1H, J=5.93Hz), 6.14 (s, IH), 4.64 (s, 2H), 3.98 (s, 3H), 2.42 (s,3H), 2.34 (s,3H), MS (ES+, m/z) 506 (M+H).
Example 34
4-methoxy-3-({4-[(3-methyl-1r7-indazol-6-yl)amino]-2- pyrimidinyl}amino)benzenesulfonamide
Figure imgf000081_0002
HNMR (400 MHz, de-DMSO) δ 12.28 (br s, 1H), 9.56 (br s, 1H), 8.72 (br s, 1H), 8.02 (d,JH, J=571HZ), 7.87 (br s, 1H), 7.74 (br s, 1H), 7.55 (d, 1H, J=874Hz), 7.43 (d, 1H, J=8.03Hz), 7.17 - 7.13 (m, 4H), 6.32 (d, 1H, J=5.89Hz), 3.91 (s, 3H), 2.39 (s, 3H), MS (ES, m/z) 424 (M- H). Example 35
Λ/2-[5-(isopropylsulfonyl)-2-methoxyphenyl]-/\ -methyl-/\f-(3-methyl-1/V-indazol-6-yl)- 2,4-pyrimidinediamine
Figure imgf000082_0001
1H NMR (400 MHz, de-DMSO) δ 12.71 (brs, lH),9.03(s, 1H), 7.83-779 (m, 2H), 7.78 (d, -/ = 8.4 Hz, 1 H), 7.40-7.38 (m, 2H), 7.22 (d, J = 8.6 Hz, 1 H), 6.97 (d, J = 8.4 Hz, 1 H), 5.74 (d, J = 6.1 Hz, 1H), 3.95 (s,3H), 3.47 (s,3H), 3.24 (m,lH), 2.45 (s,3H), 1.11 (d,_/=67 Hz, 6H). MS (ES+, m/z) 467 (M+H).
Example 36
Λ/2-[5-(ethylsulfonyl)-2-methoxyphenyl]-Λ/4-isopropyl-Λ/4-(3-methyl-1r/-indazol-6-yl)-2,4- pyrimidinediamine
Figure imgf000082_0002
HNMR: δ 12.69 (s, 1 H), 9.18 (s, 1 H), 7.78 (s, 1 H), 7.76 (d, 1 H), 7.69 (d, 1 H), 7.57 (d, 1 H), 7.22 (s, 1H), 6.86 (d, 1H), 6.82 (d, 1H), 5.26 (d, 1H), 5.24 (m, 1H), 4.28 (q, 2H), 2.8J (s, 3H), 2.44 (s, 3H), 1.31 (t, 3H), 1.08 (d, 6H); MS (ES+, m/z) = 481 (M+H).
Example 37 /\r-(1f-indazol-6-yl)-/V4-methyl-/V2-{3-[(methylsulfonyl)methyl]phenyl}-2,4- pyrimidinediamine
Figure imgf000083_0001
HNMR (400 MHz, de-DMSO) δ 13.15 (br s, 1 H), 9.25 (br s, 1 H), 8.10 (br s, 1 H), 7.87 - 7.80 (m, 3H), 7.66 (d. 1 H, J=974Hz), 7.47 (s, 1 H), 7.13 (t, 1 H, J=7.90Hz), 7.04 (d, 1 H, J=8.33Hz), 6.89 (d, 1 H, J=7.34Hz), 5.82 (d, 1 H, J=5.93Hz), 4.29 (s, 2H), 3.49 (s, 3H), 2.88 (s, 3H), MS (AP+, m/z) 409 (M+H).
Example 38
/V4-(l ,3-dimethyl-1 r/-indazol-6-yl)-Λ/4-methyl-Λ/2-{3-[(methylsulfonyl)methyl]phenyl}- 2,4-pyrimidinediamine
Figure imgf000083_0002
To a solution of /V*-methyl-Λrl-(3-methyl-1 f/-indazol-6-yl)-Λ/2-{3- [(methylsulfonyl)methyl]phenyl}-2,4-pyrimidinediamine (Example 23) (389 mg, 0.92 mmol) in DMF (4 ml) was added CS2CO3 (600 mg, 1.84 mmol) followed by iodomethane (64 ul, 1.02 mmol). The mixture was stirred at rt overnight. The mixture was diluted with water and extracted with EtOAc. The organic layer was washed with brine, dried over MgS04, filtered and evaporated. Purification of crude product by prep TLC provided 260 mg of /^-(l .S-dimethyl-l /V-indazol-e-yO-Λ^-methyl-Λ^-IS-^methylsulfony methyl]- phenyl}-2,4-pyrimidinediamine. 1H NMR (300 MHz, deDMSO) δ 9.25 (s, 1 H), 7.86 (d, J = 6.0 Hz, 1 H), 7.82 (s, 1 H), 7.77 (d, J = 8.5 Hz, 1 H), 7.65 (d, J = 7.8 Hz, 1 H), 7.58 (s, 1 H), 7.15 (t, J = 7.8 Hz, 1 H), 7.02 (d, J = 8.5 Hz, 1 H), 6.89 (d, J = 7.8 Hz, 1 H), 5.83 (d, J = 6.0 Hz, 1 H), 4.28 (s, 2H), 3.92 (s, 3H), 3.49(s, 3H), 2.87 (s, 3H), 2.48 (s, 3H). MS (ES+, m/z) 437 (M+H).
Example 39
A/4-(2,3-dimethyl-2f/-indazol-6-yl)-Λ/4-methyl-Λ/2-{3-[(methylsulfonyl)methyl]phenyl}- 2,4-pyrimidinediamine
Figure imgf000084_0001
o a solution of /v4-methyl-/V*-(3-methyl-1 /-indazol-6-yl)-/\/2-{3-
[(methylsulfonyl)methyl]phenyl}-2,4-pyrimidinediamine (Example 23) (389 mg, 0.92 mmol) in DMF (4 ml) was added CS2CO3 {600 mg, 1.84 mmol) followed by iodomethane (64 ul, 1.02 mmol). The mixture was stirred at rt overnight. The mixture was diluted with water and extracted with EtOAc. The organic layer was washed with brine, dried over MgS0 , filtered and evaporated. Purification of crude product by prep TLC provided 120 mg Λ/4-(2,3-dimethyl-2f/-indazol-6-yl)-Λ/4-methyl-Λr-{3-[(methylsulfonyl)methyl]- phenyl}~2,4-pyrimidinediamine. H NMR (300 MHz, deDMSO) δ 9.23 (s, 1H), 7.84-7.86 (m, 2H), 7.74 (d, J = 8.8 Hz, 1 H), 7.64 (d, J = 7.9 Hz, 1 H), 7.42 (s, 1 H), 7.18 (t, J = 7.8 Hz, 1 H), 6.85-6.90 (m, 2H), 5.81 (d, J = 5.8 Hz, I H), 4.23 (s, 2H), 4.04 (s, 3H), 3.45 (s, 3H), 2.83 (s, 3H), 2.61 (s, 3H). MS (ES+, m/z) 437 (M+H).
Example 40 Λ 1-(2,3-dimethyl-2r/-indazol-6-yl)-Λ/2-[5-(ethylsulfonyl)-2-methoxyphenyl]-/\/4-methyl- 2,4-pyrimidinediamine
Figure imgf000084_0002
This example was prepared using procedures similar to those of Example 39. 1H NMR (300 MHz, deDMSO) δ 9.15 (d, 7 = 1.9 Hz, 1 H), 7.88 (d, J = 6.1 Hz, 1 H), 779-7.81 (m, 2H), 7.47- 7.50 (m, 2H), 7.28 (d, J = 8.6 Hz, 1 H), 6.95 (d, J = 87 Hz, 1 H), 5.81 (d,' J = 6.1 Hz, 1 H), 4.08 (s, 3H), 4.03 (s, 3H), 3.53 (s, 3H), 3.22 (q, J = 7.4 Hz, 2H), 2.65 (s, 3H), 1.13 (t, J = 7.4 Hz, 3H). MS (ES+, m/z) 467 (M+H). Example 41
1-[4-methoxy-3-({4-[(3-methyl-1 r/-indazol-6-yl)amino]-2-pyrimidinyl}amino)phenyl]-1- propanone
Figure imgf000085_0001
HNMR (400 MHz, de-DMSO) δ 12.45 (br s, 1 H), 1 1.01 (br s, 1 H), 9.90 (br s, 1 H), 8.23 (s, 1 H), 7.99 (d, 1 H, J=678Hz), 7.89 (d, 1 H, J=7.33Hz), 7.59 (br s, 1 H), 7.51 (d, 1 H, J=678Hz), 7.30 - 7.27 (m, 2H), 6.52 (s, I H), 3.93 (s, 3H), 2.66 (br s, 2H), 2.43 (s, 3H), 0.85 (brs, 3H), MS (ES+, m/z) 403 (M+H).
Example 42
4-methoxy- /V-[3-({4-[methyl(3-methyl-1 /-indazol-6-yl)amino]-2- pyrimidinyl}amino)phenyl]benzenesulfonamide
Figure imgf000085_0002
HNMR: δ 12.87 (s, 1 H), 10.22 (s, 1 H), 7.85 (d, J =8.5 Hz, 1 H), 7.78 (d, J =7.2 Hz, 1 H), 7.69 (d, J =8.8 Hz, 2H), 7.48 (s, 1 H), 7.42 (s, 1 H), 7.25 (d, J =7.7 Hz, 1 H), 7.04 (d, J =8.8 Hz, 2H), 7.02 (d, J =8.5 Hz, 1 H), 6.80 (d, J =8.1 Hz, 1 H), 5.89 (d, J =7.2 Hz, 1 H), 3.77 (s, 3H), 3.50 (s, 3H), 2.51 (s, 3H); MS (ES+, m/z) = 516, 517 (M+H).
Example 43 4-methoxy-Λ/-methyl-3-({4-[(3-methyl-1 f/-indazol-6-yl)amino]-2- pyrimidinyl}amino)benzenesulfonamide
Figure imgf000086_0001
HNMR (400 MHz, de-DMSO) δ 12.31 (s, 1H), 9.59 (s, 1H), 8.72 (s, 1H), 8.03 (d,lH, J=571HZ), 7.89 (br s, 1H), 7.72 (s, 1H), 7.54 (d, 1H, J=8.56Hz), 7.36 (d, 1H, J=8.38Hz), 7.28 - 7.22 (m, 1H), 7.19 - 7.15 (m, 2H), 6.33 (d, 1H, J=5.89Hz), 3.92 (s, 3H), 2.39 (s, 3H), 2.34 (d, 3H, J=4.99Hz), MS (AP+, m/z) 440 (M+H).
Example 44
[(3-methyl-lW-indazol-6-yl)(2-{4-[(methylsulfonyl)methyl]anilino}-4- pyrimidinyl)amino]acetonitrile
Figure imgf000086_0002
'H NMR (300 MHz, de-DMSO) δ 12.83 (br s, 1H), 9.52 (s, 1H), 7.97 (d, J = 5.9 Hz, 1H), 7.86 (d, J = 8.3 Hz, 1 H), 7.78 (d, J = 8.5 Hz, 2H), 7.47 (s, 1 H), 7.27 (d, J = 8.5 Hz, 2H), 7.03 (dd, J = 8.5 Et 1.5 Hz, 1H), 5.78 (d, J = 5.9 Hz, 1H), 5.02 (s, 2H), 4.37 (s, 2H), 2.86 (s, 3H), 2.51 (s, 3H). MS (ES+, m/z) 448 (M+H).
Example 45
[{2-[5-(ethylsulfonyl)-2-methoxyanilino]-4-pyrimidinyl}(3-methyl-1r/-indazol-6- yl)amino]acetonitrile
Figure imgf000086_0003
Η NMR (300 MHz, de-DMSO) δ 12.85 (br s, 1 H), 8.98 (d, J = 2.2 Hz, 1 H), 8.08 (s, I H), 8.00 (d, J = 5.9 Hz, 1 H), 7.87 (d, J = 8.5 Hz, 1 H), 7.52-7.49 (m, 2H), 7.29 (d, J = 8.8 Hz, 1 H), 7.03 (dd, J = 8.5 ft 1.4 Hz, 1 H), 5.80 (d, J = 5.9 Hz, 1 H), 5.08 (s, 2H), 4.00 (s, 3H), 3.22 (q, J = 7.3 Hz, 2H), 2.51 (s, 3H), 1.12 (t, J = 7.4 Hz, 3H). MS (ES+, m/z) 478 (M+H).
Example 46
[(3-methyl-1 r/-indazol-6-yl)(2-{3-[(methylsulfonyl)methyl]anilino}-4- pyrimidinyl)amino]acetonitrile
Figure imgf000087_0001
1H NMR (300 MHz, de-DMSO) δ 12.83 (br s, 1 H), 9.53 (s, 1 H), 7.96 (m, 2H), 7.86 (d, J = 8.4 Hz, 1 H), 7.62 (d, J = 8.4 Hz, 1 H), 7.47 (s, 1 H), 7.26 (t, J = 7.8 Hz, 1 H), 7.04-6.96 (m, 2H), 5.76 (d, J = 5.8 Hz, I H), 5.02 (s, 2H), 4.39 (s, 2H), 2.90 (s, 3H), 2.51 (s, 3H). MS (ES+, m/z) 448 (M+H).
Example 47
4-methoxy-Λ/-methyl-3-({4-[methyl(3-methyl-1 r/-indazol-6-yl)amino]-2- pyrimidinyl}amino)benzenesulfonamide
Figure imgf000087_0002
1H NMR (400 MHz, deDMSO) δ 12.70 (br s, 1 H), 8.99 (d, J = 2.2 Hz, 1 H), 774-7.80 (m, 3H), 7.32-7.36 (m, 2H), 7.15-7.18 (m, 2H), 6.97 (d, J = 8.4 Hz, 1 H), 5.73 (d, J = 6.0 Hz, 1 H), 3.92 (s, 3H), 3.47 (s, 3H), 2.45 (s, 3H), 2.36 (d, J = 5.0 Hz, 3H). MS (ES+, m/z) 454 (M+H). Example 48
4-({4-[methyl(3-methyl-1 r/-indazol-6-yl)amino]-2-pyrimidinyl}amino)benzamide
Figure imgf000088_0001
1H NMR (300 MHz, de-DMSO) δ 12.72 (br s, 1 H), 9.45 (s, 1 H), 7.89 (d, J = 6.0 Hz, 1 H), 7.78- 7.81 (m, 2H), 7.69-772 (m, 2H), 7.41 (s, 1 H), 7.09 (br s, 1 H), 7.03 (d, J = 8.5 Hz, 1 H), 5.85 (d, J = 6.0 Hz, 1 H), 3.50 (s, 3H), 2.50 (s, 3H). MS (ES+, m/z) 374 (M+H).
Example 49
3-methoxy-4-({4-[methyl(3-methyl-1 -indazol-6-yl)amino]-2- pyrimidinyl}amino)benzenesulfonamide
Figure imgf000088_0002
1H NMR (300 MHz, deDMSO) δ 12.92 (br s, 1 H), 9.53 (d, J = 2.2 Hz, 1 H), 7.97-8.04 (m, 2H), 7.91 (s, 1 H), 7.59-7.64 (m, 2H), 7.34-7.38 (m, 3H), 7.20 (dd, J = 8.6 8t 1.5 Hz, 1 H), 5.96 (d, J = 6.0 Hz, 1 H), 4.14 (s, 3H), 3.69 (s, 3H), 2.68 (s, 3H). MS (ES+, m/z) 440 (M+H).
Example 50
/v4-ethynyl-Λ/4-(3-methyl-l H-indazoI-6-yl)-Λ/2-{3-[(methylsulfonyl)methyl]phenyl}-2,4- pyrimidinediamine
Figure imgf000088_0003
'H NMR (300 MHz, de-DMSO) δ 12.99 (br s, 1 H), 9.57 (s, 1 H), 8.08-8.10 (m, 2H), 7.99 (d, J = 8.4 Hz, 1 H), 7.86 (d, J = 8.4 Hz, 1 H), 7.63 (s, 1 H), 7.38 (t, J = 7.8 Hz, 1 H), 7.19-7.23 (m, 1 H), 7.12 (d, J= 7.5 Hz, 1H), 5.94 (d, J= 4.7 Hz, 1H), 5.94 (s, 2H), 4.95 (s, 2H), 3.08 (s, 3H), 2.68 (s, 3H). MS (ES+, m/z) 447 (M+H).
Example 51
3-({4~[(3-methyl-1r/-indazol-6-yl)(2-propynyl)amino]-2- pyrimidinyl}amino)benzenesulfonamide
Figure imgf000089_0001
HNMR (400 MHz, de-DMSO): δ 12.76 (br s, 1H), 9.62 (s, 1H), 8.29 (br s, 1H), 7.97 (br s, 1H), 7.92 (d, 1 H, J = 5.8), 7.81 (d, 1 H, J = 8.6), 7.45 (s, 1 H), 7.34 (d, 1 H, J = 4.2), 7.26 (s, 2H), 7.03 (d, 1H, J = 8.4), 5.76 (d, 1H, J = 5.9), 4.80 (s, 2H), 3.18 (s, 1H), 2.88 (m, 2H), 2.49 (s, 3H); MS (ES+, m/z) = 455 (M+H).
Example 52
4-({4-[methyl(3-methyl-1f/-indazol-6-yl)amino]-2- pyrimidinyl}amino)benzenesulfonamide
Figure imgf000089_0002
1H NMR (300 MHz, deDMSO) δ 12.91 (brs, 1H), 9.77 (s, 1H), 8.10 (d, J= 6.1 Hz, 1H), 8.04 (d, J = 8.8 Hz, 2H), 7.98 (d, J = 8.5 Hz, 1 H), 7.78 (d, J = 8.8 Hz, 2H), 7.59 (s, 1 H), 7.29 (br s, 2H), 7.20 (dd, J= 8.5 Et 1.5 Hz, 1H), 6.08 (d, J= 6.1 Hz, 1H), 3.68 (s, 3H), 2.69 (s, 3H). MS (ES+, m/z) 410 (M+H).
Example 53
Λ/4-methyl-Λ/4-(3-methyl-1r/-indazol-6-yl)-/V2-[3-(methylsuIfonyl)phenyl]-2,4- pyrimidinediamine
Figure imgf000090_0001
1H NMR (300 MHz, deDMSO) δ 12.75 (br s, 1 H), 9.65 (s, 1 H), 8.69 (s, 1 H), 7.87-7.89 (m, 2H), 7.80 (d, J = 8.4 Hz, 1 H), 7.41 (m, 3H), 7.03 (d, J = 8.2 Hz, 1 H), 5.82 (d, J = 5.8 Hz, 1 H), 3.52 (s, 3H), 3.16 (s, 3H). 2.51 (s, 3H). MS (ES+, m/z) 409 (M+H).
Example 54
4-methoxy-3-({4-[methyl(3-methyl-1 r7-indazol-6-yl)amino]-2- pyrimidinyl}amino)benzenesulfonamide
Figure imgf000090_0002
1H NMR (300 MHz, deDMSO) δ 9.95 (br s, 1 H), 8.73 (br s, 1 H), 7.86-7.91 (m, 2H), 7.68 (d, J = 8.8 Hz, 1 H), 7.55 (s, 1 H), 7.30-7.34 (m, 3H). 7.08 (d, J = 8.5 Hz, 1 H), 5.88 (d, J = 7.4 Hz, 1 H), 3.97 (s, 3H), 3.58 (s, 3H), 2.52 (s, 3H). MS (ES+, m/z) 440 (M+H).
Example 55 Λr?-[5-(ethylsuifonyl)-2-methoxyphenyl]-/V*-(3-methyl-l H-indazol-6-yl)-2,4- pyrimidinediamine
Figure imgf000090_0003
HNMR (400 MHz, de-DMSO) δ 1 1.42 (br s, 1 H), 10.19 (br s 1 H), 7.96 (d, 2H, J=7.14 Hz), 7.74 (dd, 1 H, J=1.92 Hz andJ=87 Hz), 7.53 (br s, 1 H), 7.39 (d, 1 H, J=879 Hz), 7.32 (br s, 1 H), 6.64 (br s, I H). 3.88 (s, 3H), 2.96 (br s, 2H), 2.39 (s. 3H), 0.90 (br s, 3H), MS (ES-, m/z) 437 (M-H).
Example 56
3-({4-[methyl(3-methyl-1 /V-indazol-6-yl)amino]-2-pyrimidinyl}amino)benzamide
Figure imgf000091_0001
Η NMR (300 MHz, deDMSO) δ 12.83 (s, 1 H), 9.84 (br s, 1 H). 8.29 (s, 1 H), 7.92-7.84 (m, 3H), 7.78 (d, J = 7.7 Hz, 1 H), 7.51-7.48 (m, 2H), 7.34-7.26 (m. 2H), 7.07 (d, J = 8.5 Hz, 1 H), 5.89 (d, J = 6.4 Hz, 1 H), 3.55 (s, 3H), 2.54 (s, 3H). MS (ES+, m/z) 374 (M+H).
Example 57
Λ/2-[4-(ethylsulfonyl)phenyl]-Λ/4-methyl-ΛT-(3-methyl-1 r/-indazol-6-yl)-2,4- pyrimidinediamine
Figure imgf000091_0002
1H NMR (300 MHz, de-DMSO) δ 12.73 (s, 1 H), 9.75 (s, 1 H), 7.89-7.95 (m, 3H), 7.81 (d, J = 8.5 Hz, 1 H), 7.58 (d, J = 8.8 Hz, 2H), 7.41 (s, 1 H). 7.03 (dd, J = 8.5 Et 1.5 Hz, 1 H), 5.96 (d, J = 6.0 Hz, 1 H), 3.50 (s, 3H), 3.16 (q, J = 7.3 Hz, 2H), 2.52 (s, 3H), 1.07 (t, J = 7.3 Hz, 3H). MS (ES+, m/z) 423 (M+H).
Example 58
Λ/-[4-({4-[methyl(3-methyl-1 H-indazol-6-yl)amino]-2- pyrimidinyl}amino)benzyl]ethanesulfonamide
Figure imgf000092_0001
1H NMR (400 MHz, de-DMSO) δ 12.7 (s, 1 H), 9.17 (s, 1 H), 7.85 (d, J=6.0 Hz, 1 H), 7.78 (d, J=8.4 Hz, 1 H), 7.67 (d, J=8.6 Hz, 2H), 7.47 (t, J=6.4 Hz, 1 H), 7.38 (s, 1 H), 7.12 (d, J=8.4 Hz, 2H), 7.0 (dd, J=1.6 Hz, J=8.4 Hz, 1 H), 5.79 (d, J=6.0 Hz, 1 H), 4.02 (d, J=6.2 Hz, 2H), 3.47 (s, 3H), 2.87 (q, J=7.3 Hz, 2H), 2.51 (s, 3H), 1.13 (t, J=7.3 Hz, 3H).
Example 59
N-[3-({4-[methyl(3-methyl-l H-indazol-6-yl)amino]-2-pyrimidinly}amino)benzyl] methanesulfonamide
Figure imgf000092_0002
'H NMR (400 MHz, de-DMSO) δ 127 (s, 1 H), 9.21 (s, 1 H), 7.84 (d, J=5.8 Hz, 1 H), 7.78 (d, J=8.4 Hz, 1 H), 7.78 (d, J=8.4 Hz, 1 H), 7.57 (d, J=7.8 Hz, 1 H), 7.48 (t, J=6.3 Hz, 1 H), 7.38 (s, 1 H), 7.12 (t, J=7.8 Hz, 1 H), 7.0 (dd, J=1.6 Hz, J=8.4 Hz, 1 H), 6.85 (d, J=7.5Hz, 1 H), 5.79 (d, J=5.8 Hz, 1 H), 4.02 (d, J=6.2 Hz, 2H), 3.49 (s, 3H), 2.84 (2, 3H), 2.51 (s, 3H).
Example 60
2-chloro-5-({4-[methyl(3-methyl-1 /-indazol-6-yl)amino]-2- pyrimidinyl}amino)benzenesulfonamide
Figure imgf000092_0003
'H NMR (300 MHz, de-DMSO) δ 1273 (s, 1 H), 9.65 (s, I H), 8.73 (d, J = 2.1 Hz, 1 H), 779- 7.87 (m, 2H), 7.34-7.46 (m, 3H). 7.02 (d, J = 8.2 Hz, 1 H). 5.81 (d, J = 6.0 Hz, 1 H), 3.51 (s, 3H), 2.51 (s, 3H). MS (ES+, m/z) 444 (M+H).
Example 61
2-chloro-4-({4-[methyl(3-methyl-1 r -indazol-6-yl)amino]-2- pyrimidinyl}amino)benzenesulfonamide
Figure imgf000093_0001
1H NMR (300 MHz, de-DMSO) δ 12.73 (s, 1 H), 9.76 (s, 1 H), 8.1 1 (s, I H), 7.95 (d, J = 6.0 Hz, 1 H), 7.80 (d, J = 8.6 Hz, 1 H), 7.64-773 (m, 2H), 7.41 (s, 1 H), 7.33 (s, 2H), 7.03 (d, J = 8.3 Hz, 1 H), 5.95 (d, J = 6.0 Hz, 1 H), 3.49 (s, 3H), 2.51 (s, 3H). MS (ES+, m/z) 444 (M+H).
Example 62
4-chloro-3-({4-[methyi(3-methyl-1 /7-indazol-6-yl)amino]-2- pyrimidinyl}amino)benzenesulfonamide
Figure imgf000093_0002
'H NMR (300 MHz, de-DMSO) δ 12.73 (s, I H), 8.85 (d, J = 2.1 Hz, 1 H), 8.28 (s, 1 H), 778- 7.85 (m, 2H), 7.69 (d, J = 8.4 Hz, 1 H), 7.40-7.48 (m, 4H), 7.01 (d, J = 8.5 Hz, 1 H), 5.80 (d, J = 7.4 Hz, 1 H), 3.46 (s, 3H), 2.50 (s, 3H). MS (ES+, m/z) 444 (M+H).
Example 63
3-methyl-4-({4-[methyl(3-methyl-l H-indazol-6-yl)amino]-2- pyrimidinyl}amino)benzenesulfonamide
Figure imgf000094_0001
1H NMR (300 MHz, de-DMSO) δ 12.84 (br s, 1 H), 9.33 (br s, I H), 7.82-7.92 (m, 3H), 7.69 (s, 1 H), 7.59 (m, 1 H), 7.46 (s, 1 H), 7.27 (s, 2H). 7.04 (dd, J = 8.5 Et 1.3 Hz, 1 H), 5.90 (d, J = 5.1 Hz, 1 H), 3.46 (s, 3H), 2.51 (s, 3H), 2.36 (s, 3H). MS (ES+, m/z) 424 (M+H).
Example 64
2-methyl-5-({4-[methyl(3-methyl-1 /-indazol-6-yl)amino]-2- pyrimidinyl}amino)benzenesu!fonamide
Figure imgf000094_0002
Η NMR (300 MHz, de-DMSO) δ 12.71 (br s, 1 H), 9.38 (s, 1 H), 8.55 (s, 1 H), 7.67-7.87 (m, 3H), 7.37 (s, 1 H), 7.21 (s, 1 H), 7.1 1 (d, J = 8.4 Hz, 1 H), 6.99 (d, J = 8.5 Hz, 1 H), 574 (d, J = 5.8 Hz, 1 H), 3.48 (s, 3H), 2.49 (s, 3H), 2.47 (s, 3H). MS (ES+, m/z) 424 (M+H).
Example 65
4-methyl-3-({4-[methyl(3-methyl-1 r/-indazol-6-yl)amino]-2- pyrimidinyl}amino)benzenesulfonamide
Figure imgf000094_0003
1H NMR (300 MHz, de-DMSO) δ 12.71 (br s, 1H), 10.25 (s, 1H), 8.30 (s, 1H), 7.82-7.89 (m, 2H), 7.62 (d, J = 7.9 Hz, 1H), 7.50 -7.52 (m, 2H), 7.38 (s, 2H), 7..05 (d, J = 9.5 Hz, 1H), 5.84 (d, J = 7.2 Hz, 1 H), 3.46 (s, 3H), 2.51 (s, 3H), 2.39 (s, 3H). MS (ES+, m/z) 424 (M+H).
Example 66
/V4-methyl-/V-(3-methyl-1r-indazol-6-yl)-/\/2-[3-(methylsulfinyl)phenyi]-2,4- pyrimidinediamine
Figure imgf000095_0001
1H NMR (300 MHz, de-DMSO) δ 12.72 (s, 1H), 9.50 (s, 1H), 8.29 (s, 1H), 7.89 (d, J= 5.9 Hz, 1H), 7.79 (d, J = 8.5 Hz, 1H), 7.70 (d, J = 7.9 Hz, 1H), 7.40 (s, 1H), 7.33 ( , 1H), 7.12 (d, J = 7.7 Hz, 1 H), 7.07 (d, J = 8.5 Hz, 1 H), 5.84 (d, J = 6.0 Hz, 1 H), 3.50 (s, 3H), 2.63 (s, 3H), 2.51 (s, 3H). MS (ES+, m/z) 393 (M+H).
Example 67 /V2-[2-fluoro-5-(methylsulfonyl)phenyl]-/V-methyI-/v4-(3-methyl-1r/-indazol-6-yl)-2,4- pyrimidinediamine
Figure imgf000095_0002
Η NMR (300 MHz, de-DMSO) δ 12.76 (br s, 1H), 9.07 (s, 1H), 8.89 (s, 1H), 779-7.85 (m, 2H), 7.42-7.59 (m, 3H), 7.02 (m, 1H), 5.82 (m, 1H), 3.48 (s, 3H), 3.20 (s, 3H), 2.50 (s, 3H). MS (ES+, m/z) 427 (M+H).
Example 68
Λ/2-[2-methoxy-5-(methylsulfonyl)phenyl]-Λ/-methyl-Λ/4-(3-methyl-1r/-indazol-6-yl)-2,4- pyrimidinediamine
Figure imgf000096_0001
HNMR: δ 12.74 (s, 1 H), 9.13 (s, 1 H), 7.85 (d, J =6.0 Hz, 1 H), 7.80 (s, 1 H), 7.79 (d, J =10.3 Hz, 1 H), 7.46 (dd, J =2.2, 8.6 Hz, 1 H),7.40 (s, 1 H), 7.24 (d, J =8.6 Hz, 1 H), 7.00 (d, J =8.4 Hz, 1 H), 5.78 (d, J =6.1 Hz, 1 H), 3.97 (s, 3H). 3.50 (s, 3H), 3.1 1 (s, 3H). 2.48 (s, 3H); MS (ES+, m/z) = 439 (M+H).
Example 69
5-({4-[(2,3-dimethyl-2r/-indazol-6-yl)(methyl)amino]pyrimidin-2-yl}amino)-2- methylbenzenesulfonamide
Figure imgf000096_0002
To a solution of Intermediate Example 13 (200 mg, 0.695 mmol) and 5-amino-2- ethylbenzenesulfonamide (129.4 mg, 0.695 mmol) in isopropanol (6 ml) was added 4 drops of cone. HCI. The mixture was heated to reflux overnight. The mixture was cooled to rt and diluted with ether (6 ml). Precipitate was collected via filtration and washed with ether. HCI salt of 5-({4-[(2,3-dimethyl-2H-indazol-6-yl)(methyl)amino]-pyrimidin-2- yl}amino)-2-methylbenzenesulfonamide was isolated as an off-white solid. Y\ NMR (400 MHz, deDMSO+NaHCOa) δ 9.50 (br s, 1 H), 8.55 (br s, 1 H), 7.81 (d, J = 6.2 Hz, 1 H), 7.75 (d, J = 8.7 Hz, 1 H), 7.69 (m, 1 H), 7.43 (s, 1 H), 7.23 (s, 2H), 7.15 (d, J = 8.4 Hz, 1 H), 6.86 (m, 1 H), 5.74 (d, J = 6.1 Hz, 1 H), 4.04 (s, 3H), 3.48 (s, 3H), 2.61 (s, 3H), 2.48 (s, 3H). MS (ES+, m/z) 438 (M+H). Examples 70-72 were prepared according to the general procedures set forth above in Example 69.
Example 70
3-({4-[(2,3-dimethyl-2r/-indazol-6-yl)(methyl)amino]pyrimidin-2- yl}amino)benzenesulfonamide
Figure imgf000097_0001
1H NMR (400 MHz, deDMSO+NaHCOa) δ 9.58 (br s, 1 H), 8.55 (br s, 1 H), 7.83 (d, J = 6.2 Hz, 1 H), 774-779 (m, 2H), 7.43 (s, 1 H), 7.34-7.37 (m, 2H), 7.24 (s, 2H), 6.86 (m, 1 H), 5.77 (d, J = 6.1 Hz, 1 H), 4.04 (s, 3H), 3.48 (s, 3H), 2.61 (s, 3H). MS (ES+, m/z) 424 (M+H).
Example 71
2-[4-({4-[(2,3-dimethyl-2r/-indazol-6-yl)(methyl)amino]pyrimidin-2- yl}amino)phenyl]ethanesulfonamide
Figure imgf000097_0002
1H NMR (300 MHz, deDMSO+NaHCOa) δ 9.10 (br s, 1 H), 7.83 (d, J = 6.0 Hz, 1 H), 7.75 (d, J = 8.7 Hz, 1 H), 7.67 (d, J = 8.5 Hz, 2H), 7.43 (d, J = 1.1 Hz, 1 H), 7.06 (d, J = 8.5 Hz, 2H), 6.86- 6.89 (m, 3H), 5.76 (d, J = 6.0 Hz, 1 H), 4.06 (s, 3H), 3.46 (s, 3H), 3.21 (m, 2H), 2.91 (m, 2H), 2.62 (s, 3H). MS (ES+, m/z) 452 (M+H).
Example 72 Λf1-(2,3-dimethyl-2f/-indazol-6-yl)-Λf1-methyl-/\ -{4- [(methyIsuIfonyl)methyI]phenyl}pyrimidine-2,4-diamine
Figure imgf000098_0001
1H NMR (300 MHz, deDMSO+NaHCOa) δ 9.37 (bs, 1 H). 7.88 (d, J = 6.1 Hz, I H), 7.78 (m, 3H), 7.47 (s, 1 H), 7.22 (d, J = 8.5 Hz, 2H), 6.91 (dd, J = 8.8, 1.5 Hz, 1 H), 5.84 (d, J = 6.1 Hz, 1 H), 4.37 (s, 2H), 4.09 (s, 3H), 3.51 (s, 3H), 2.88 (s, 3H), 2.65 (s, 3H). MS (ES+, m/z) 437 (M+H), 435 (M-H).
Example 73
3-({4-[[3-(hydroxymethyl)-2-methyl-2f/-indazol-6-yl](methyl)amino]pyrimidin-2- yl}amino)benzenesulfonamide
Figure imgf000098_0002
To a solution of 2,3-dimethyl-6-nitro-2 /-indazole (3.00 g, 15.69 mmol) in CCU
(500 mL) was added AIBN (0.51 g, 3.14 mmol) and NBS (3.06 g, 17.26 mmol). The mixture was heated to 80 °C for 5 hours then stirred at rt overnight. Approximately half of the solvent was removed in vacuo, and the mixture was filtered. The filtrate was cone, in vacuo, and the crude product was purified by silica gel column chromatography eluting with ethyl acetate and hexane to afford 3-(bromomethyl)-2-methyl-6-nitro-2f/-indazole with some succinimide present (4.41 g, 104% TY). 1H NMR (300 MHz, CDCIa) δ 8.68 (d, J = 2.1 HZ, 1 H), 7.98 (dd, J = 9.3, 2.1 Hz, 1 H). 7.74 (d, J = 9.3 Hz, 1 H), 4.87 (s, 2H). 4.28 (s, 3H). MS (ES+, m/z) 270, 272 (M+H). 3-(Bromomethyl)-2-methyl-6-nitro-2r/-indazole (4.20 g, ~14.9 mmol) in CHaCN (500 ml) and water (200 ml) was treated with NaOH to give pH~1 1. The solution was stirred at rt for 2 days then cone, in vacuo and repeatedly extracted with dichloromethane and chloroform. The combined organic extracts were evaporated, and the crude product was purified by silica gel column chromatography to give (2-methyl-6-nitro-2/V-indazol- 3-yl)methanol (1.03 g, 33% TY). MS (ES+, m/z) 208.
Under anhydrous conditions and nitrogen atmosphere, give (2-methyl-6-nitro-2 V- indazol-3-yl)methanol (1.03 g, 4.97 mmol) in CH2CI2 (50 ml) was treated with triethylamine (0.58 g, 5.47 mmol) and DMAP (64 mg, 0.50 mmol) followed by chlorotriphenylmethane (1.42 g, 5.07 mmol). The resulting solution was stirred under nitrogen at rt for 20 hours then diluted with CH2CI2 and washed with water. Concentration in vacuo followed by silica gel chromatography eluting with CH2CI2 provided 2-methyl-6-nitro-3-[(trityloxy)methyl]-2f/-indazole (1.09 g, 49% TY). 1H NMR (300 MHz, CDCIa) δ 8.66 (d, J = 2.1 HZ, 1 H), 7.88 (dd, J = 9.3, 2.1 Hz, 1 H), 7.55 (d, J = 9.3 Hz, 1 H), 7.50 (m, 6H). 7.1 -7-4 (m, 9H), 4.52 (s, 2H), 4.13 (s, 3H). MS (ES+, m/z) 450 (M+H).
To a solution of 2-methyl-6-nitro-3-[(trityloxy)methyl]-2r/-indazole (0.50 g, 1.1 1 mmol) in anhydrous THF under nitrogen atmosphere at 0 °C was added LiAIH4 (2.7 ml, 1.0 M in THF, 2.7 mmol). The solution was stirred at 0 °C for ~ 3 h then cooled to -78 °C and quenched with wet THF. The resulting mixture was cone, in vacuo then repeatedly triturated with CH3CN. The combined CH3CN was cone, in vacuo to give crude 2-methyl- 3-[(trityloxy)methyl]-2r/-indazol-6-amine (0.593 g, 108% TY). MS (ES+, m/z) 420 (M+H).
2-Methyl-3-[(trityloxy)methyI]-2f/-indazol-6-amine was utilized in the manner described above for Intermediate Example 12 and 13 and according to the general procedures set forth above for Example 69. Purification by preparative HPLC and isolation by lyophilization provided the trifluoroacetate salt of 3-({4-[[3-(hydroxymethyl)-2- methyl-2H-indazol-6-yl](methyl)amino]pyrimidin-2-yl}amino)-benzenesulfonamide as a tan solid. 1H NMR (300 MHz, deDMSO + NaHCOa) δ 9.53 (s, 1 H), 8.57 (s, 1 H), 7.85 (m, 2H), 7.79 (d, J = 7.2 Hz, 1 H), 7.51 (s. 1 H), 7.36 (m, 2H), 7.25 (s, 1 H), 6.95 (d, J = 8.9 Hz, 1 H), 5.78 (d, J = 6.0 Hz, 1 H), 5.47 (t, J = 5.4 Hz, 1 H), 4.92 (d, J = 5.4 Hz, 2H), 4.14 (s, 3H), 3.50 (s, 3H). MS (ES+, m/z) 440 (M+H), 438 (M-H).
Example 74
3-({4-[(1 ,2-dimethyl-1 H-benzimidazol-5-yl)(methyl)amino]pyrimidin-2- yl}amino)benzenesulfonamide
Figure imgf000100_0001
Intermediate Example 21 (200 mg) was combined with 100 mg of 3- aminobenenesulfonamide in 5.0 mL of isopropanol with 3 drops of aqueous HCI. The reaction was heated to 80 °C and followed by TLC. When the reaction was judged to be complete based upon consumption the Intermediate Example 21 , the reaction was quenched with solid sodium bicarbonate while warm, then allowed to cool to room temperature. The complete reaction mixture was then coated onto silica gel and chromatographed on silica gel using CH2CI2 and MeOH as eluent affording 223 mg of product. 1 H NMR (400 MHz, deDMSO) δ 9.50 (s, 1 H), 8.59 (s, 1 H), 7.80 (d, J = 6.06 Hz, 1 H), 7.77 (s, 1 H), 7.57 (d, J = 8.56 Hz, 1 H), 7.46 (d, J = 1.78 Hz, 1 H), 7.35 (m, 2H), 7.25 (s, 2H), 7.12 (dd, J = 8.38, 1.96 Hz, 1 H), 5.62 (d, J = 5.71 Hz, 1 H), 3.76 (s, 3H), 3.48 (s, 3H), 2.54 (s, 3H). MS (ESI) (M+H)+ 424.
Example 75
3-({4-[(2-benzyl-1-methyl-1 r/-benzimidazol-5-yl)(methyl)amino]pyrimidin-2- yl}amino)benzenesulfonamide
Figure imgf000101_0001
Example 75 was prepared by the similar procedure set forth at the Example 74 wherein Intermediate Example 18 was used instead of Intermediate Example 17 for the synthesis of Intermediate Example 21. I H NMR (400 MHz, deDMSO) δ 9.49 (s, 1 H) 8.57 (s, 1 H) 7.79 (d, J = 6.06 Hz, 1 H) 7.76 (m, 1 H) 7.57 (d, J = 8.56 Hz, 1 H) 7.52 (d, J = 178 Hz, 1 H) 7.30 (m, 5H) 7.22 (m, 4H) 7.14 [dd, J = 8.38, 1.96 Hz, 1 H) 5.64 (d, J = 5.71 Hz, 1 H) 4.31 (s, 2H) 3.72 (s, 3H) 3.47 (s, 3H).
Example 76
3-({4-[(2-ethyl-3-methyl-2 V-indazol-6-yl)(methyl)amino]pyrimidin-2- yl}amino)benzenesulfonamide
Figure imgf000101_0002
Example 76 was prepared according to the general procedure outlined in Example 69 wherein triethyloxonium hexafluorophosphate was used instead of trimethyloxonium tetrafluoroborate in the synthesis of Intermediate Example 1 1. 'H NMR (400 MHz, deDMSO) δ 8.39 (br s, 1 H), 7.83 (m, 2H), 7.73 (m, 1 H), 7.49-7.55 ( , 3H), 7.36 (s, 2H), 6.90 (d, J = 8.6 Hz, 1 H), 5.90 (m, 1 H), 4.38 (q, J = 7.1 Hz, 2H), 3.52 (s, 3H), 2.64 (s, 3H), 1.42 (t, J = 7.1 Hz, 3H). MS (ES+, m/z) 438 (M+H).
Example 77
3-({4-[[2-(3-chlorobenzyl)-3-methyl-2r/-indazol-6-yl](methyl)amino]pyrimidin-2- y|}amino)benzenesulfonamide
Figure imgf000102_0001
Intermediate Example 9 (10 g, 0.029 mol) was treated with excess trifluoroacetic acid (20 ml) at rt for 30 min. The reaction mixture was quenched with NaHQ- and extracted with ethyl acetate. The organic layer was separated, and the aqueous layer was thoroughly extracted with EtOAc. The combined organic layer was dried over anhydrous MgS0 , filtered and evaporated to give /V-(2-chloropyrimidin-4-yl)-Λ/,3-dimethyl-1 /V- indazol-6-amine as an off-white solid (7.3 g, 100%). 'H NMR (300 MHz, deDMSO) δ 12.80 (br s, 1 H), 7.94 (d, J = 6.0 Hz, 1 H), 7.82 (d, J = 8.5 Hz, 1 H), 7.44 (s, 1 H), 7.01 (m, 1 H), 6.25 (d, J = 6.0 Hz, 1 H). 3.42 (s, 3H). 2.50 (s, 3H). MS (ES+, m/z) 274 (M+H).
Λ/-(2-chloropyrimidin-4-yl)-Λ/,3-dimethyI-1 /-indazol-6-amine (2 g, 7.31 mmol) was dissolved in DMF (15 ml), and CS2CO3 (2 g, 14.6 mmol) and 3-chlorobenzyl bromide (1.25 ml, 9.5 mmol) were added at room temperature. Mixture was stirred at rt for overnight. The reaction mixture was diluted with ethyl acetate and washed with water. The organic layer was separated. The aqueous layer was thoroughly extracted with EtOAc. The combined organic layers were dried over anhydrous MgS04, filtered and evaporated to give 2-(3-chlorobenzyl)-Λ/-(2-chloropyrimidin-4-yl)-Λ/,3-dimethyl-2r/-indazol-6-amine as an off-white solid . Η NMR (300 MHz, deDMSO) δ 7.94 (d, J = 6.0 Hz, 1 H), 7.83 (d, J = 8.8 Hz, 1 H), 7.56 (d, J = 1.3 Hz, 1 H), 7.36-7.38 (m, 2H), 7.32 (br s, I H), 7.16 (m, 1 H), 6.91 (m, 1 H), 6.28 (d, J = 6.1 Hz, 1 H), 5.65 (s, 2H), 3.42 (s, 3H), 2.63(s, 3H). MS (ES+, m/z) 398 (M+H).
To a solution of 2-(3-chlorobenzyl)-Λ/-(2-chloropyrimidin-4-yl)-Λ/,3-dimethyl-2r/- indazol-6-amine (40 mg, 0.1 mmol) and 3-aminobenzenesulfonamide (17.3 mg, 0.1 mmol) in isopropanol (2 ml) was added 2 drops of cone. HCI. The mixture was heated to reflux overnight. The mixture was cooled to rt. Precipitate was collected via filtration and washed with EtOH. HCI salt of 3-({4-[[2-(3-chlorobenzyl)-3-methyl-2r/-indazol-6- yl](methyl)amino]-pyrimidin-2-yl}amino)benzenesulfonamide was isolated as off-white solid. 1H NMR (400 MHz, deDMSO+NaHCOa) δ 9.52 (br s, 1 H), 8.54 (br s, I H). 7.85 (d, J = 5.9 Hz, 1 H), 777-779 (m, 2H), 7.49 (s, 1 H), 7.30-7.36 (m, 5H), 7.22 (br s, 2H), 7.14 (br s, 1 H), 6.90 (d, J = 87 Hz, 1 H), 5.80 (d, J = 5.8 Hz, 1 H), 5.64 (s, 2H), 3.48 (s, 3H), 2.62 (s, 3H). MS (ES+, m/z) 534 (M+H).
Example 78
3-({4-[(2,3-dimethyl-2f/-indazol-6-yl)(methyl)amino]-1 ,3,5-triazin-2- yl}amino)benzenesulfonamide
Figure imgf000103_0001
Intermediate Example 15 (0.017 g, 0.06 mmol), and 3-aminobenzenesulfonamide (0.01 g, 0.06 mmol) were combined in EtOH. A 1 N solution of HCI in diethylether was added (0.06 mL, 0.06 mmol), and the solution was warmed to reflux for 18 h. The solution was cooled to RT, and the precipitate was filtered off, washed with EtOH, and dried, to give analytically pure product as a white solid (0.025 g). 'H NMR (300 MHz, deDMSO) δ 9.99 (br s, 1 H), 8.24 (br s, 1 H), 7.80 (d, J = 6.4 Hz, 1 H), 7.68 (d, J = 8.0 Hz, 1 H), 7.40-7.46 (m, 2H), 7.27-7.33 (m, 2H), 6.93 (d, J = 7.7 Hz, I H), 4.05 (s, 3H), 3.51 (s, 3H), 2.62 (s, 3H). MS (ES+, m/z) 425 (M+H).
Example 79
5-({4-[(2,3-dimethyl-2 /-indazol-6-yl)(methyI)amino]-1 ,3,5-triazin-2-yl}amino)-2- methylbenzenesulfonamide
Figure imgf000104_0001
Intermediate Example 15 (0.032 g, 0.1 1 mmol), and 3-amino-4- methylbenzenesulfonamide (0.021g, 0.1 1 mmol) where combined in EtOH. A 1 N solution of HCI in diethylether was added (0.06 mL, 0.06 mmol), and the solution was warmed to reflux for 18 h. The solution was cooled to RT, and the precipitate was filtered off, washed with EtOH, and dried, to give analytically pure product as a tan solid (0.033 g). 1H NMR (300 MHz, deDMSO) δ 9.88 (br s, I H), 8.19 (br s, 1 H), 770-7.65 (m, 2H), 7.41 (s, 1 H), 7.28 (brs, 2H), 6.90 (d, J = 8.8 Hz, 1 H), 4.04 (s, 3H), 3.50 (s, 3H), 2.61 (s, 3H), 2.49 (s, 3H). MS (ES+, m/z) 439 (M+H).
BIOLOGICAL DATA
The compounds of the present invention elicit important and measurable pharmacological responses. Each of the compounds described in the Examples section bind with high affinity (IC-o < 1 μM) to the kinase domain of VEGFR2 receptor, as described by the VEGFR2 HTRF assay below. In addition to binding to the kinase domain of VEGFR2, the exemplified compounds of the present invention also measurably and significantly inhibit the proliferation of endothelial cells that are stimulated for growth by activation with VEGF. Data for inhibition of cell proliferation are provided in Table 1 below.
VEGFR2 HTRF Assay
The assays were performed in 96-well black plates. 10 nM hVEGFR2 was used to phosphorylate 0.36 μM peptide (Biotin-Ahx-EEEEYFELVAKKKK) in the presence of 75 μM ATP, 5 mM MgCI2, 0.3 mM DTT, 0.1 mg/ml BSA, and 0.1 M HEPES (pH 7.5). 10 μl 0.5 M EDTA was added to reactions as negative controls. The 50 μl kinase reaction with or without inhibitors in 5% DMS0 was carried out at room temperature for 45 minutes, then stopped by 40 μl of 125 mM EDTA. 2.4 μg/ml Streptavidin-APC and 0.15 μg/ml Eu-α-pY, in the presence of 0.1 mg/ml BSA, 0.1 M HEPES (pH7.5), were added to a final volume of 140 μl. The plate was incubated for 10 min at room temperature (22°C) and read on the Victor with the time resolved fluorescence mode by exciting at 340 nm and reading the emission at 665 nm.
Reagent resources: Peptide from Synpep (Dublin, CA) ATP, MgCb, DTT. BSA, HEPES, EDTA, DMSO from Sigma Streptavidin-APC from Molecular Probes (Eugene, Oregon) Eu-α-pY from EGftG Wallac (Gaithersburg, MD) Abbreviations:
Figure imgf000105_0001
Human Umbilical Vein Endothelial Cell (HUVEC) Proliferation Assay (BrdU Incorporation)
Materials
HUVEC cells and EGM-MV (Endothelial cell growth medium - microvascular) were purchased from Clonetics (San Diego, CA). VEGF and bFGF were purchased from REtD Systems (Minneapolis, MN). Anti-BrdU antibody was obtained from Chemicon International (Temecula, CA).
Methods
HUVECs were routinely maintained in EGM-MV medium and were used within passage 7. HUVECs were plated at a density of 2500 cells/well in M 199 medium containing 5% FBS (Hyclone) in type I collagen coated plate (Becton Dickinson). The plate was incubated at 37 °C overnight. The medium was removed by aspiration, and test compounds were added to each well in a volume of 0.1 ml/well in serum-free M199 medium. Compound concentrations ranged from 1.5 nM to 30 micromolar. The plate was incubated for 30 min at 37°C. Another 0.1 ml of serum-free M 199 medium containing BSA and VEGF (or bFGF) was added to give a final concentration of 0.1% BSA and 10 ng/ml VEGF (0.3 ng/ml bFGF). The plate was incubated at 37°C for 72 hrs. BrdU was added to each well after the first 48 hrs to give a concentration of 10 micromolar. The colorimetric ELISA assay was performed according to manufacturer's (Roche Molecular Sciences) instructions, with detection by absorbance reading at 450 nm. Results were plotted as concentration of test compound vs. absorbance to give an ICso value for inhibition of BrdU incorporation.
Table 1 = Inhibition of HUVEC proliferation (IC∞ in nM; 1 -200nM = ++++; 201 -500nM = +++; 501-1000nM = ++; >1 ,000 = +)
TABLE 1
Figure imgf000107_0001
Figure imgf000108_0001
The application of which this description and claim(s) forms part may be used as a basis for priority in respect of any subsequent application. The claims of such subsequent application may be directed to any feature or combination of features described herein. They may take the form of product, composition, process or use claims and may include, by way of example and without limitation, one or more of the following claim(s):

Claims

We claim:
A compound of Formula (I):
Figure imgf000109_0001
(I) or a salt, solvate, or physiologically functional derivative thereof: wherein:
D is
Figure imgf000109_0002
Xi is hydrogen, Cι-C4 alkyl, G-C4 haloalkyl, or G-C hydroxyal yl; X2 is hydrogen, Cι-C4alkyl, G-C4 haloalkyl, C(0)R\ or aralkyl; X3 is hydrogen or halogen; X4 is hydrogen, G-C4 alkyl, G-C4 haloalkyl, heteroaralkyl, cyanoalkyl,
Figure imgf000110_0001
-(CH2)pC≡C(CH2)tH, or C3-C7 cycloalkyl; p is 1 , 2, or 3; t is 0 or 1 ;
W is N or C-R, wherein R is hydrogen, halogen, or cyano;
Qi is hydrogen, halogen, C1-C2 haloalkyl, C1-C2 alkyl, C1-C2 alkoxy, or C1-C2 haloalkoxy;
Q2 is A1 or A2;
Qa is A1 when Q2 is A2 and Qa is A2 when Q2 is A1; wherein
A1 is hydrogen, halogen, C1-C3 alkyl, C1-C3 haloalkyl, -OR1, and A2 is the group defined by -(Z)m-(Z1)-(Z2), wherein
Z is CH2 and m is 0, 1, 2, or 3, or
Z is NR2and m is 0 or 1, or
Z is oxygen and m is 0 or 1 , or
Figure imgf000110_0002
T is S(0)2, S(0), or C(0); and
Z2 is G-C4 alkyl, NR3R4, aryl, arylamino, aralkyl, aralkoxy, or heteroaryl, R' is C1-C4 alkyl;
R2, R3, and R4 are each independently selected from hydrogen, G-C4alkyl, C3-C7 cycloalkyl, S(0)2R5, and -C(0)R5; R5 is dialkyl, or C3-C7 cycloalkyl; and when Z is oxygen then Z1 is S(0)2 and when D is
Figure imgf000110_0003
then X2 is Cι-C4 alkyl, Cι-C4 haloalkyl,, C(0)R\ or aralkyl.
2. A compound as claimed in claim 1 wherein D is
Figure imgf000111_0001
A compound as claimed in claim 1 , wherein D is
Figure imgf000111_0002
A compound of claim 1 : wherein D is
Figure imgf000111_0003
A compound of formula (II):
Figure imgf000112_0001
or a salt, solvate, or physiologically functional derivative thereof: wherein:
Xi is hydrogen, G-C4 alkyl, G-C4 haloalkyl, or G-Gt hydroxyalkyl;
X2 is hydrogen, C1-C4 alkyl, Ci-C* haloalkyl, C(0)R1, or aralkyl;
X3 is hydrogen or halogen;
Figure imgf000112_0002
p is 1 , 2, or 3; t is 0 or 1 ;
W is N or C-R, wherein R is hydrogen, halogen, or cyano;
Qi is hydrogen, halogen, C1-C2 haloalkyl, C1-C2 alkyl, C1-C2 alkoxy, or C1-C2 haloalkoxy;
Q2 is A1 or A2;
Q3 is A1 when Q2 is A2 and Q3 is A2 when Q2 is A1; wherein
A1 is hydrogen, halogen, C1-C3 alkyl, C1-C3 haloalkyl, -OR1, and
A2 is the group defined by -(Z)m-(Z1)-(Z2), wherein
Z is CH2 and m is 0, 1 , 2, or 3, or
Z is NR2and m is 0 or 1 , or
Z is oxygen and m is 0 or 1 , or
Z is CH2NR2 and m is O or 1 ;
Z1 is S(0)2, S(0), or C(0); and
Z2 is C1-C4 alkyl, NR3R4, aryl, arylamino, aralkyl, aralkoxy, or heteroaryl, R1 is C1-C4 alkyl; R2, R3, and R4 are each independently selected from hydrogen, C1-C4 alkyl, C3-C7 cycloalkyl,
S(0)2R5, and -C(0)R5;
R5 is C1-C alkyl, or C3-C7 cycloalkyl; and when Z is oxygen then Z1 is S(0)2.
6. A compound of Formula (III):
Figure imgf000113_0001
or a salt, solvate, or physiologically functional derivative thereof: wherein:
Xi is hydrogen, G-Galkyl, G-G haloalkyl, or G-G hydroxyalkyl;
X2 is G-Galkyl, G-G haloalkyl. or C(0)R1;
X3 is hydrogen or halogen;
X is hydrogen, G-Galkyl, G-G haloalkyl, heteroaralkyl, cyanoalkyl,
Figure imgf000113_0002
-(CH2)PC≡C(CH2)tH, or G-G cycloalkyl; p is 1 , 2, or 3; t is O or 1 ;
W is N or C-R, wherein R is hydrogen, halogen, or cyano;
Qi is hydrogen, halogen, G-G haloalkyl, G-G alkyl, G-G alkoxy, or G-G haloalkoxy;
Q2 is A1 or A2;
Q3 is A1 when Q2 is A2 and Q3 is A2 when Q2 is A1; wherein
A1 is hydrogen, halogen, G-Galkyl, G-G haloalkyl, -OR1, and
A2 is the group defined by -(Z)m-(Z1)-(Z2), wherein Z is CH2 and m is 0, 1, 2, or 3, or Z is NR2 and m is 0 or 1 , or Z is oxygen and m is 0 or 1 , or
Z is CH2NR2 and m is O or 1 ;
Figure imgf000114_0001
Z2 is G-G alkyl, NR3R\ aryl, arylamino, aralkyl, aralkoxy, or heteroaryl, R1 is G-Galkyl;
R2, R3, and R4 are each independently selected from hydrogen, G-G alkyl, G-G cycloalkyl, S(0)2R5, and -C(0)R5; R5 is dialkyl, or G-G cycloalkyl; and when Z is oxygen then Z1 is S(0)2.
7. A compound of Formula (IV):
Figure imgf000114_0002
or a salt, solvate, or physiologically functional derivative thereof: wherein:
Xi is hydrogen, G-G alkyl, G-G haloalkyl, or G-Ghydroxyalkyl;
X2 is hydrogen, G-G alkyl, G-G haloalkyl, or C(0)R1, or aralkyl;
X3 is hydrogen or halogen;
X4 is hydrogen, G-G alkyl, G-G haloalkyl, heteroaralkyl, cyanoalkyl,
Figure imgf000114_0003
-(CH2)PC≡C(CH2)tH, or G-G cycloalkyl; p is 1 , 2, or 3; t is O or 1 ;
W is N or C-R, wherein R is hydrogen, halogen, or cyano;
Qi is hydrogen, halogen, G-G haloalkyl, G-G alkyl, G-G alkoxy, or G-G haloalkoxy;
Q2 is A1 or A2;
Q3 is A1 when Q2 is A2 and Q3 is A2 when Q2 is A1; wherein
A1 is hydrogen, halogen, G-G alkyl, G-G haloalkyl, -OR1, and A2 is the group defined by -(Z)m-(Z1)-(Z2), wherein
Z is CH2 and m is 0, 1, 2, or 3, or
Z is NR2 and m is 0 or 1 , or
Z is oxygen and m is 0 or 1 , or
Figure imgf000115_0001
Z1 is S(0)2, S(0), or C(0); and
Z2 is G-G alkyl, NR3R4, aryl, arylamino, aralkyl, aralkoxy, or heteroaryl, R1 is G-G alkyl ;
R2, R3, and R4 are each independently selected from hydrogen, G-G alkyl, G-G cycloalkyl, S(0)2R5, and -C(0)R5; R5 is G-Galkyl, or G-G cycloalkyl; and when Z is oxygen then Z1 is S(0)2.
8. A compound as claimed in claim 1 , wherein Xi is hydrogen or C1-4 alkyl.
9. A compound as claimed in claim 1 , wherein Xi is methyl or ethyl.
10. A compound as claimed in claim 1 , wherein Xi is methyl.
1 1. A compound as claimed in claim 1 , wherein X2 is hydrogen or C1-4 alkyl.
12. A compound as claimed in claim 1, wherein X2 is hydrogen or methyl.
13. A compound as claimed in claim 1 , wherein X2 is hydrogen.
14. A compound as claimed in claim 1 , wherein X2 is methyl.
15. A compound as claimed in claim 1 , wherein X3 is halogen.
16. A compound as claimed in claim 1 , wherein X3 is hydrogen.
17. A compound as claimed in claim 1 , wherein X4 is hydrogen, G-G alkyl, cyanoalkyl,
Figure imgf000116_0001
18. A compound as claimed in claim 1, wherein X4is hydrogen, methyl, ethyl, isopropyl, cyanomethyl, or -(CH2)PC≡C(CH2)tH, wherein p is 1 and t is 0.
19. A compound as claimed in claim 1 , wherein X4 is methyl.
20. A compound as claimed in claim 1 , wherein Xi is methyl or ethyl, X2 is hydrogen or methyl, X3 is hydrogen or halogen, and X4 is hydrogen, methyl, ethyl, isopropyl, cyanomethyl, or -(CH2)PC≡C(CH2)tH, wherein p is 1 and t is 0.
21. A compound as claimed in claim 1 , wherein Xi is methyl, X2 is hydrogen, X3 is hydrogen, and X4 is methyl.
22. A compound as claimed in claim 1 , wherein Xi is methyl, X2 is methyl, X3 is hydrogen, and X4 is methyl.
23. A compound as claimed in claim 1 , wherein D is:
Figure imgf000116_0002
and Xi is methyl, X2 is hydrogen, Xs is hydrogen, and X4is methyl.
24. A compound as claimed in claim 1 , wherein D is
Figure imgf000117_0001
and Xi is methyl, X2 is methyl, X3 is hydrogen, and X4 is methyl.
25. A compound as claimed in claim 1 , wherein W is N.
26. A compound as claimed in claim 1 , wherein W is C-R wherein R is H, F, Cl, or CN.
27. A compound as claimed in claim 1 , wherein W is N, C-H, or C-F.
28. A compound as claimed in claim 1, wherein W is C-F or C-H.
29. A compound as claimed in claim 1, wherein Qi is hydrogen, halogen, G-G alkyl or C1X2 alkoxy.
30. A compound as claimed in claim 1 , wherein Qi is hydrogen.
31. A compound as claimed in claim 1 , wherein Qi is chlorine.
32. A compound as claimed in claim 1 , wherein Qi is methyl.
33. A compound as claimed in claim 1 , wherein Qi is methoxy.
34. A compound as claimed in claim 1 , wherein Q2 is A1 and Q3 is A2.
35. A compound as claimed in claim 1 , wherein Q2 is A2 and Q3 is A1.
36. A compound as claimed in claim 1 , wherein Q2 is A2and Q3 is A1, wherein A1 is hydrogen, halogen, or G-G haloalkyl and A2 is the group defined by -(Z)m-(Z1)-(Z2), wherein Z is CH2 and m is 0, 1 , 2, or 3, or Z is NR2 and m is 0 or 1 , or Z is CH2NR2 and m is 0 or 1 ; Z1 is S(0)2, S(0), or C(0); and Z2 is G- alkyl or NR3R4 and wherein R2, R3, and R4 are each independently selected from hydrogen or G-Galkyl.
37. A compound as claimed in Claim 1 , wherein Q2 is A2 and Q3 is A1, wherein A1 is hydrogen or chlorine and A2 is the group defined by -(Z)m-(Z1)-(Z2), wherein Z is CH2 and m is 0, 1 , 2, or 3; Z1 is S(0)2; and Z2 is G- alkyl.
38. A compound as claimed in claim 1 , wherein Q2 is A1 and Q3 is A2, wherein A1 is hydrogen, halogen, or G-G alkyl and A2 is the group defined by -(Z)m-(Z1)-(Z2), wherein Z is CH2 and m is 0, 1 , 2, or 3, or Z is NR2 and m is 0 or 1 , or Z is CH2NR2 and m is 0 or 1 ; Z1 is S(0)2, S(0), or C(0); and Z2 is G-G alkyl or NR3R\ and wherein R2, R3, and R4 are each independently selected from hydrogen or G-Galkyl.
39. A compound as claimed in claim 1 , wherein Q2 is A1 and Q3 is A2, wherein A1 is hydrogen, methyl, or chlorine and A2 is the group defined by -(Z)m-(Z1)-(Z2), wherein Z is CH2 and m is 0, 1 , 2, or 3; Z1 is S(0)2; and Z2 is G-G alkyl or NR3R4, wherein R3 and R4 are each independently selected from hydrogen or G-Galkyl.
40. A compound as claimed in claim 1 , wherein Xi is hydrogen or C1-4 alkyl; X2 is hydrogen or G-4 alkyl; X3 is hydrogen or halogen; and X4 is hydrogen, G-G alkyl, cyanoalkyl, or -(CH2)PC≡C(CH2)tH; W is N; Qi is hydrogen, halogen, G-G alkyl or G-G alkoxy; and Q2 is A2 and Q3 is A1 , wherein A1 is hydrogen, halogen, or G-G haloalkyl and A2 is the group defined by -(Z)m-(Z1)-(Z2), wherein Z is CH2 and m is 0, 1 , 2, or 3, or Z is NR2 and m is 0 or 1 , or Z is CH2NR2 and m is 0 or 1 ; Z1 is S(0)2 or C(0); and Z2 is G-G alkyl or NR3R4 and wherein R2, R3, and R4 are each independently selected from hydrogen or G- Galkyl.
41. A compound as claimed in claim 1 , wherein Xi is hydrogen or CM alkyl ; X2 is hydrogen or G-4 alkyl; X3 is hydrogen or halogen; and X4 is hydrogen, G-G alkyl, cyanoalkyl, or -(CH2)PC≡C(CH2)tH; W is C-R wherein R is H, F, Cl, or CN; Qi is hydrogen, halogen, G-G alkyl or G-G alkoxy; and Q2 is A2 and Q3 is A1 , wherein A1 is hydrogen, halogen, or G-G haloalkyl and A2 is the group defined by -(Z)m-(Z1)-(Z2), wherein Z is CH2 and m is 0, 1 , 2, or 3, or Z is NR2 and m is 0 or 1 , or Z is CH2NR2 and m is 0 or 1 ; Z1 is S(0)2 or C(0); and Z2 is G-G alkyl or NR3R4 and wherein R2, R3, and R4 are each independently selected from hydrogen or G-Galkyl.
42. A compound as claimed in claim 1 , wherein Xi is hydrogen or G-4 alkyl; X2 is hydrogen or G-4 alkyl; X3 is hydrogen or halogen; and X4 is hydrogen, G-G alkyl, cyanoalkyl, or -(CH2)PC≡C(CH2)tH; W is N; Qi is hydrogen, halogen, G-G alkyl or G-G alkoxy; Q2 is A1 and Q3 is A2 , wherein A1 is hydrogen, halogen, or G-G alkyl and A2 is the group defined by -(Z)m-(Z1)-(Z2), wherein Z is CH2 and m is 0, 1, 2, or 3, or Z is NR2 and m is 0 or 1 , or Z is CH2NR2 and m is 0 or 1 ; Z1 is S(0)2, S(0), or C(0); and Z2 is G-G alkyl or NR3R4, and wherein R2, R3, and R4 are each independently selected from hydrogen or G-G alkyl.
43. A compound as claim in claim 1 , wherein Xi is hydrogen or C1-4 alkyl; X2 is hydrogen or G-4 alkyl; X3 is hydrogen or halogen; and X4 is hydrogen, G-G alkyl, cyanoalkyl, or ~(CH2)PC≡C(CH2)tH.; W is C-R wherein R is H, F, Cl, or CN; Qi is hydrogen, halogen, G-G alkyl or G-G alkoxy; Q2 is A1 and Q3 is A2 , wherein A1 is hydrogen, halogen, or G-G alkyl and A2 is the group defined by -(Z)m-(Z1)-(Z2), wherein Z is CH2 and m is 0, 1 , 2, or 3, or Z is R2 and m is 0 or 1 , or Z is CH2NR2 and m is O or 1 ; Z1 is S(0)2, S(0), or C(0); and Z2 is G-G alkyl or NR3R4, and wherein R2, R3, and R4 are each independently selected from hydrogen or G-G alkyl.
44. A compound as claimed in claim 1 , wherein Xi is methyl or ethyl; X2 is hydrogen or methyl; X3 is hydrogen; and X4 is hydrogen, methyl, ethyl, isopropyl, cyanomethyl, or - (CH2)PC≡C(CH2)tH, wherein p is 1 and t is 0.; W is N, C-H, C-F, or C-CN; Qi is hydrogen, chlorine, or methoxy; Q2 is A1 and Q3 is A2 , wherein A1 is hydrogen, methyl, or chlorine and A2 is the group defined by -(Z)m-(Z1)-(Z2), wherein Z is CH2 and m is 0, 1, 2, or 3, or Z is NR2 and m is 0 or 1 , or Z is CH2NR2 and m is 0 or 1 ; Z1 is S(0)2, S(0), or C(0); and Z2 is G-G alkyl or NR3R\ and wherein R2, R3, and R4 are each independently selected from hydrogen or G-Galkyl.
45. A compound as claimed in claim 1 , wherein Xi is methyl or ethyl; X2 is hydrogen or methyl; X3 is hydrogen; and X4 is hydrogen, methyl, ethyl, isopropyl, cyanomethyl, or - (CH2)PC≡C(CH2)tH, wherein p is 1 and t is 0.; W is C-H or C-F; Qi is hydrogen, chlorine, methyl, or methoxy; Q2 is A1 and Q3 is A2 , wherein A1 is hydrogen, methyl, or chlorine and A2 is the group defined by -(Z)m-(Z1)-(Z2), wherein Z is CH2 and m is 0, 1 , 2, or 3, or Z is NR2 and m is 0 or 1 , or Z is CH2NR2 and m is 0 or 1 ; Z1 is S(0)2, S(0), or C(0); and Z2 is G-G alkyl or NR3R\ and wherein R2, R3, and R4 are each independently selected from H or G-G alkyl.
46. A compound as claimed in claim 1 , wherein Xi is methyl; X2 is hydrogen; X3 is hydrogen; and X4 is methyl; W is C-H; Qi is hydrogen, chlorine, methyl, or methoxy; Q2 is A1 and Q3 is A2, wherein A1 is hydrogen, methyl, or chlorine and A2 is the group defined by - (Z)m-(Z1)-(Z2), wherein Z is CH2 and m is 0, 1 , 2, or 3, or Z is NR2 and m is 0 or 1 , or Z is CH2NR2 and m is 0 or 1 ; Z1 is S(0)2, S(0), or C(0); and Z2 is G-G alkyl or NR3R4, and wherein R2, R3, and R4 are each independently selected from hydrogen or G-Galkyl.
47. A compound as claimed in claim 1 , wherein Xi is methyl; X2 is methyl; X3 is hydrogen; and X4 is methyl; W is C-H; Qi is hydrogen, chlorine, methyl, or methoxy; Q2 is A1 and Q3 is A2, wherein A1 is hydrogen, methyl, or chlorine and A2 is the group defined by - (Z)m-(Z1)-(Z2), wherein Z is CH2 and m is 0, 1, 2, or 3, or Z is NR2 and m is 0 or 1, or Z is CH2NR2 and m is 0 or 1 ; Z1 is S(0)2, S(0), or C(0); and Z2 is G-G alkyl or NR3R\ and wherein R2, R3, and R4 are each independently selected from hydrogen or G-Galkyl.
48. A compound as claimed in claim 1 , wherein Xi is methyl; X2 is hydrogen; X3 is hydrogen; and X is methyl; W is C-F; Qi is hydrogen, chlorine, or methoxy; Q2 is A1 and Q3 is A2, wherein A1 is hydrogen, methyl, or chlorine and A2 is the group defined by -(Z)m-(Z1)- (Z2), wherein Z is CH2 and m is 0, 1 , 2, or 3, or Z is NR2 and m is 0 or 1 , or Z is CH2NR2 and m is 0 or 1 ; Z1 is S(0)2, S(0), or C(0); and Z2 is G- alkyl or NR3R\ and wherein R2, R3, and R4 are each independently selected from hydrogen or G-G alkyl.
49. A compound as claimed in claim 1 , wherein D is:
Figure imgf000121_0001
and Xi is methyl; X2 is hydrogen; X3 is hydrogen; and X4 is methyl; W is C-H; Qi is hydrogen, methyl, chlorine, or methoxy; Q2 is A1 and Q3 is A2 , wherein A1 is hydrogen, methyl, or chlorine and A2 is the group defined by -(Z)m-(Z1)-(Z2), wherein Z is CH2 and m is 0, 1 , 2, or 3, or Z is NR2 and m is 0 or 1 , or Z is CH2NR2 and m is 0 or 1 ; Z1 is S(0)2, S(O), or C(0); and Z2 is G-G alkyl or NR3R4, and wherein R2, R3, and R4 are each independently selected from hydrogen or G-Galkyl.
50. A compound as claimed in claim 1 , wherein D is
Figure imgf000121_0002
and Xi is methyl; X2 is methyl; X3 is hydrogen; and X4 is methyl; W is C-H; Qi is hydrogen, chlorine, methyl, or methoxy; Q2 is A1 and Q3 is A2 , wherein A1 is hydrogen, methyl, or chlorine and A2 is the group defined by -(Z) -(Z1)-(Z2), wherein Z is CH2 and m is 0, 1 , 2, or 3, or Z is NR2 and m is 0 or 1 , or Z is CH2NR2 and m is 0 or 1 ; Z1 is S(0)2, S(0), or C(0); and Z2 is G-G alkyl or NR3R4, and wherein R2, R3, and R4 are each independently selected from hydrogen or G-G alkyl.
51. A compound as claimed in claim 1 , selected from the group consisting of:
Λ/2-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-fluoro-Λ/4-methyl-Λ/4-(3-methyl-1 H-indazol-6- yl)-2,4-pyrimidinediamine;
3-({5-fluoro-4-[methyl(3-methyl-1 f/-indazol-6-yl)amino]-2-pyrimidinyl}amino)-4- methoxy-/V-methylbenzenesulfonamide; 5-fluoro-Λ/ -methyl-Λ/ -(3-methyl-1 r/-indazol-6-yl)-/V2-{3- [(methylsulfonyl)methyl]phenyl}-2,4-pyrimidinediamine;
3-({5-fluoro-4-[methyl(3-methyl-1 r/-indazol-6-yl)amino]-2-pyrimidinyl}amino)-Λ/- isopropylbenzenesulfdnamide;
5-fluoro-Λ/2-[5-(isopropylsulfonyl)-2-methoxyphenyl]-Λ/4-methyl-Λ/ -(3-methyl-1 r/- indazol-6-yl)-2,4-pyrimidinediamine;
N-[5-({5-fluoro-4-[methyl(3-methyl-1 f/-indazol-6-yl)amino]-2-pyrimidinyl}amino)-2- methylphenyI]methanesulfonamide;
5-fluoro-Λ/ -methyl-Λ/4-(3-methyl-1 H-indazol-6-yl)-Λ/2-[4-(methylsulfonyl)phenyl]-2,4- pyrimidinediamine;
Λ/4-(3-ethyl-1 r-indazol-6-yl)-5-fluoro-/v4-methyl-Λ/2-{3- [(methylsulfonyI)methyl]phenyl}-2,4-pyrimidinediamine;
4-({5-fluoro-4-[methyl(3-methyl-1 r/-indazol-6-yl)amino]-2- pyrimidinyl}amino)benzenesulfonamide;
N4-ethyl-5-fluoro-N2-[2-methoxy-5-(methylsulfonyl)phenyl]-N4-(3-methyl-l H-indazol-6- yl)-2,4-pyrimidinediamine;
[4-({5-fluoro-4-[methyl(3-methyl-1 r/-indazol-6-yl)amino]-2-pyrimidinyl}amino)phenyl]- Λ/-methylmethanesulfonamide;
5-fluoro-Λ/2-{3-[(isopropylsulfonyl)methyl]phenyl}-Λ/4-methyl-Λ/4-(3-methyl-1 f/-indazol- 6-yl)-2,4-pyrimidinediamine;
3-({5-fluoro-4-[methyI(3-methyl-1 f/-indazol-6-yl)amino]-2-pyrimidinyl}amino)-4- methoxybenzamide;
4-({5-fluoro-4-[methyl(3-methyl-1 /-indazol-6-yl)amino]-2-pyrimidinyl}amino)-3- methoxybenzenesulfonamide;
N2-(3-methyl-l H-indazol-6-yl)-N4-{3-[(methylsulfonyl)methyl]phenyl}-1 ,3,5-triazine- 2,4-diamine trifluoroacetate; N2-methyl-N2-(3-methyl-l H-indazol-6-yl)-N4-{3-[(methylsulfonyl)methyl]phenyl}-1 ,3,5- triazine-2,4-diamine;
Λ/2-[5-(ethylsulfonyl)-2-methoxyphenyl]-Λ/4-methyl-Λ/ -(3-methyl-1 r/-indazol-6-yl)-1 ,3,5- triazine-2,4-diamine;
Λ/-[2-methyl-5-({4-[methyI(3-methyl-1 r/-indazol-6-yl)amino]-1 ,3,5-triazin-2- yl}amino)phenyl]methanesulfonamide;
Λ/2-methyl-Λ/2-(3-methyl-1 f/-indazol-6-yl)-Λ/4-[3-(methylsulfonyl)phenyl]-1 ,3,5-triazine- 2,4-diamine;
Λ/-[4-({4-[methyl(3-methyl-1 r/-indazol-6-yl)amino]-1 ,3,5-triazin-2- yl}amino)phenyl]acetamide;
3-({4-[methyl(3-methyl-1 f/-indazol-6-yl)amino]-2- pyriιnidinyl}amino)benzenesulfonamide;
Λ/2-[5-(ethylsulfonyl)-2-methoxyphenyl]-/V4-methyl-Λ/4-(3-methyl-1 r/-indazol-6-yl)-2,4- pyrimidinediamine;
/V4-methyl-/V4-(3-methyl-l H-indazol-6-yl)-Λ/2-{3-[(methylsulfonyl)methyl]phenyl}-2,4- pyrimidinediamine;
Λ/-isopropyl-3-({4-[methyl(3-methyl-1 f/-indazol-6-yl)amino]-2- pyrimidinyl}amino)benzenesulfonamide;
Λ/-cyclopropyl-3-({4-[methyl(3-methyl-1 f/-indazol-6-yl)amino]-2- pyrimidinyl}amino)benzenesulfonamide;
Λ/ -ethyl-Λ^-[5-(ethyIsulfonyl)-2-methoxyphenyl]-/\/4-(3-methyl-1 r/-indazol-6-yl)-2,4- pyrimidinediamine;
Λ/-[3-({4-[methyl(3-methyl-1 r -indazol-6-yl)amino]-2- pyrimidinyl}amino)phenyl]methanesulfonamide;
Λ/2-{3-[(isopropylsulfonyl)methyl]phenyl}-Λ/4-methyl-Λ/4-(3-methyl-1 r/-indazol-6-yl)-2I4- pyrimidinediamine;
/V2-{4-[(isopropylsulfonyl)methyl]phenyl}-Λ/4-methyl-/V4-(3-methyl-1 H-indazol-6-yl)-2,4- pyrimidinediamine; Λ/2-[5-(isobutylsulfonyl)-2-methoxyphenyl]-Λ/4-(3-methyl-1 r/-indazol-6-yl)-2,4- pyrimidinediamine;
Λ/-[3-({4-[methyl(3-methyl-1 f/-indazoI-6-yl)amino]-2- pyrimidinyl}amino)phenyl]acetamide;
Λ/-[3-({4-[ethyl(3-methyl-1 f/-indazol-6-yl)amino]-2- pyrimidinyl}amino)phenyl]acetamide;
Λ/2-(2-methoxy-5-{[(5-methyl-3-isoxazolyl)methyl]sulfonyl}phenyl)-Λ/4-(3-methyl-l H- indazol-6-yl)-2,4-pyrimidinediamine;
4-methoxy-3-({4-[(3-methyl-1 f/-indazol-6-yl)amino]-2- pyrimidinyl}amino)benzenesulfonamide;
Λ/2-[5-(isopropylsulfonyl)-2-methoxyphenyl]-Λ/4-methyl-/V4-(3-methyl-l W-indazol-6-yl)- 2,4-pyrimidinediamine;
Λ/2-[5-(ethylsulfonyl)-2-methoxyphenyl]-Λ/4-isopropyl-Λ/ -(3-methyl-1 /-indazol-6-yl)-2,4- pyrimidinediamine;
Λ/4-(l r/-indazol-6-yl)-Λ/4-methyl-Λ/2-{3-[(methylsulfonyl)methyl]phenyl}-2,4- pyrimidinediamine;
/V4-(l ,3-dimethyl-1 /-indazol-6-yl)-Λ/4-methyl-Λ/2-{3-[(methylsulfonyl)methyl]phenyl}- 2,4-pyrimidinediamine;
Λ/4-(2,3-dimethyl-2r/-indazol-6-yl)-Λ/4-methyl-Λ/2-{3-[(methylsulfonyl)methyl]phenyl}- 2,4-pyrimidinediamine;
Λ/4-(2,3-dimethyl-2r/-indazol-6-yl)-Λ/2-[5-(ethylsulfonyl)-2-methoxyphenyl]-Λ/ -methyl- 2,4-pyrimidinediamine;
1 -[4-methoxy-3-({4-[(3-methyl-1 V-indazol-6-yl)amino]-2-pyrimidinyl}amino)phenyl]-1 - propanone;
4-methoxy-/V-[3-({4-[methyl(3-methyl-1 /-indazol-6-yl)amino]-2- pyrimidinyl}amino)phenyl]benzenesulfonamide;
4-methoxy-Λ/-methyl-3-({4-[(3-methyl-l H-indazol-6-yl)amino]-2- pyrimidinyl}amino)benzenesulfonamide; [(3-methyl-1 r/-indazoI-6-yl)(2-{4-[(methylsulfonyl)methyl]anilino}-4- pyrimidinyl)amino]acetonitrile;
[{2-[5-(ethylsulfonyl)-2-methoxyanilino]-4-pyrimidinyl}(3-methyl-1 /-indazol-6- yl)amino]acetonitrile;
[(3-methyl-1 r/-indazol-6-yl)(2-{3-[(methylsulfonyl)methyl]anilino}-4- pyrimidinyl)amino]acetonitrile;
4-methoxy-/V-methyl-3-({4-[methyl(3-methyl-1 /-indazol-6-yl)amino]-2- pyrimidinyl}amino)benzenesulfonamide;
4-({4-[methyl(3-methyI-1 V-indazol-6-yl)amino]-2-pyrimidinyl}amino)benzamide;
3-methoxy-4-({4-[methyl(3-methyl-1 r/-indazol-6-yl)amino]-2- pyrimidinyl}amino)benzenesulfonamide;
Λ/4-ethynyl-Λ/4-(3-methyl-1 r/-indazol-6-yl)-Λ/2-{3-[(methylsulfonyl)methyl]phenyl}-2,4- pyrimidinediamine;
3-({4-[(3-methyl-1 /-indazol-6-yl)(2-propynyl)amino]-2-pyrimidinyl}amino) benzenesulfonamide;
4-({4-[methyl(3-methyl-1 f/-indazol-6-yl)amino]-2-pyrimidinyl}amino) benzenesulfonamide;
Λ/4-methyl-/V4-(3-methyl-1 r/-indazol-6-yl)-/\/2-[3-(methylsulfonyl)phenyl]-2,4- pyrimidϊnediamine;
4-methoxy-3-({4-[methyl(3-methyl-1 V-indazol-6-yl)amino]-2- pyrimidinyl}amino)benzenesulfonamide;
/\r2-[5-(ethylsulfonyl)-2-methoxyphenyl]-Λ/4-(3-methyl-1 f/-indazol-6-yl)-2,4- pyrimidinediamine;
3-({4-[methyl(3-methyl-1 r/-indazol-6-yl)amino]-2-pyrimidinyl}amino)benzamide; Λ/2-[4-(ethylsulfonyl)phenyl]-/V4-methyl-Λ/4-(3-methyl-1 f/-indazol-6-yl)-2,4- pyrimidinediamine;
Λ/-[4-({4-[methyl(3-methyl-1 f/-indazol-6-yl)amino]-2-pyrimidinyl}amino) benzyljethanesulfonamide;
N-[3-({4-[methyl(3-methyl-l H-indazol-6-yl)amino]-2-pyrimidinly}amino)benzyl] methanesulfonamide;
2-chloro-5-({4-[methyl(3-methyl-1 t7-indazol-6-yl)amino]-2- pyrimidinyl}amino)benzenesulfonamide;
2-chloro-4-({4-[methyI(3-methyl-1 r/-indazol-6-yl)amino]-2- pyrimidinyl}amino)benzenesuIfonamide;
4-chloro-3-({4-[methyl(3-methyl-1 r/-indazol-6-yI)amino]-2- pyrimidinyl}amino)benzenesulfonamide;
3-methyl-4-({4-[methyl(3-methyl-l W-indazol-6-yl)amino]-2-pyrimidinyl}amino) benzenesulfonamide;
2-methyl-5-({4-[methyl(3-methyl-1 f/-indazol-6-yl)amino]-2- pyrimidinyl}amino)benzenesulfonamide;
4-methyl-3-({4-[methyl(3-methyl-1 r/-indazol-6-yl)amino]-2- pyrimidinyl}amino)benzenesulfonamide;
Λ/ -methyl-/V4-(3-methyl-1 f/-indazol-6-yl)-Λ/2-[3-(methylsulfinyl)phenyl]-2,4- pyrimidinediamine;
/V2-[2-fluoro-5-(methylsulfonyl)phenyl]-Λ/4-methyl-/V4-(3-methyl-1 /-indazol-6-yl)-2,4- pyrimidinediamine;
/V2-[2-methoxy-5-(methylsulfonyl)phenyl]-Λ/4-methyl-Λ/ -(3-methyl-1 r/-indazol-6-yl)-2,4- pyrimidinediamine;
5-({4-[(2,3-dimethyl-2r/-indazol-6-yl)(methyl)amino]pyrimidin-2-yl}amino)-2- methylbenzenesulfonamide;
3-({4-[(2,3-dimethyl-2r/-indazol-6-yl)(methyl)amino]pyrimidin-2- yl}amino)benzenesulfonamide; 2-[4-({4-[(2,3-dimethyl-2r/-indazol-6-yl)(methyI)amino]pyrimidin-2- yI}amino)phenyl]ethanesulfonamide;
Λ/4-(2,3-dimethyl-2/V-indazol-6-yl)-/\/4-methyl-/V2-{4-[(methylsulfonyl) methyl]phenyl}pyrimidine-2,4-diamine;
3-({4-[[3-(hydroxymethyl)-2-methyl-2r/-indazol-6-yl](methyl)amino]pyrimidin-2- yl}amino)benzenesulfonamide;
3-({4-[(l ,2-dimethyl-1 r/-benzimidazol-5-yl)(methyl)amino]pyrimidin-2- yl}amino)benzenesulfonamide;
3-({4-[(2-benzyl-1 -methyl- 1 /-benzimidazol-5-yl)(methyl)amino]pyrimidin-2- yl}amino)benzenesulfonamide;
3-({4-[(2-ethyl-3-methyl-2r/-indazol-6-yl)(methyl)amino]pyrimidin-2- yl}amino)benzenesulfonamide;
3-({4-[[2-(3-chlorobenzyl)-3-methyl-2r/-indazol-6-yl](methyl)amino]pyrimidin-2- yl}amino)benzenesulfonamide;
3-({4-[(2,3-dimethyl-2r/-indazol-6-yl)(methyl)amino]-1 ,3,5-triazin-2- yl}amino)benzenesulfonamide; and
5-({4-[(2,3-dimethyl-2 /-indazol-6-yl)(methyl)amino]-1 ,3,5-triazin-2-yl}amino)-2- methylbenzenesulfonamide;
or a salt, solvate, or physiologically functional derivative thereof.
52. A pharmaceutical composition, comprising: a therapeutically effective amount of a compound as claimed in any one of claims 1 to 51 , or a salt, solvate, or a physiologically functional derivative thereof and one or more of pharmaceutically acceptable carriers, diluents and excipients.
53. The pharmaceutical composition of claim 52, further comprising at least one additional anti-neoplastic agent.
54. The pharmaceutical composition of claim 52, further comprising an additional agent which inhibits angiogenesis.
55. A method of treating a disorder in a mammal, said disorder being mediated by inappropriate VEGFR2 activity, comprising: administering to said mammal a therapeutically effective amount of a compound as claimed in any one of claims 1 to 52, or a salt, solvate, or a physiologically functional derivative thereof.
56. The method of claim 55, wherein the disorder is cancer.
57. A compound as claimed in any of claims 1 to 51 , or a salt, solvate, or a physiologically functional derivative thereof for use in therapy.
58. Use of a compound as claimed in any of claims 1 to 51 , or a salt, solvate, or a physiologically functional derivative thereof in the preparation of a medicament for use in the treatment of a disorder mediated by inappropriate VEGFR2 activity.
59. The use of claim 58, wherein the disorder is cancer.
60. A method of treating cancer in a mammal, comprising: administering to said mammal a therapeutically effective amount of a compound as claimed in any one of claims 1 to 51 , or a salt, solvate, or a physiologically functional derivative thereof.
61. The method of claim 60, further comprising administering a therapeutically effective amount of at least one additional anti-cancer therapy.
62. The method of claim 61, wherein the additional anti-cancer therapy is administered concomitantly with the administration of the compound, salt, solvate or physiologically functional derivative as claimed in any one of claims 1 to 47.
63. The method of claim 61 , wherein the additional anti-cancer therapy is administered after the administration of the compound, salt, solvate or physiologically functional derivative as claimed in any one of claims 1 to 51.
64. The method of claim 61, wherein the additional anti-cancer therapy is administered before the administration of the compound, salt, solvate or physiologically functional derivative as claimed in any one of claims 1 to 51.
65. A method of treating a disorder in a mammal, said disorder being mediated by inappropriate VEGFR2 activity, comprising: administering to said mammal therapeutically effective amounts of (1) a compound as claimed in any one of claims 1 to 51 , or a salt, solvate or physiologically functional derivative thereof and (ii) an agent to inhibit growth factor receptor function.
66. The method of claim 65, wherein the agent to inhibit growth factor receptor function inhibits the function of platelet derived growth factor receptor.
67. The method of claim 65, wherein the agent to inhibit growth factor receptor function inhibits the function of epidermal growth factor receptor.
68. The method of claim 65, wherein the agent to inhibit growth factor receptor function inhibits the function of the erbB2 receptor.
69. The method of claim 65, wherein the agent to inhibit growth factor receptor function inhibits the function of a VEGF receptor.
70. The method of claim 65, wherein the agent to inhibit growth factor receptor function inhibits the function of the TIE-2 receptor.
71. The method of claim 65, wherein the agent to inhibit growth factor receptor function inhibits the function of the epidermal growth factor receptor and erbB2.
72. The method of claim 65, wherein the agent to inhibit growth factor receptor function inhibits the function of at least two of the epidermal growth factor receptor, erbB2, and erbB4.
73. The method of claim 65, wherein the agent to inhibit growth factor receptor function inhibits the function of the VEGF receptor and the TIE-2 receptor.
74. The method of claim 65, wherein the disorder is cancer.
75. A method of treating a disorder in a mammal, said disorder being characterized by inappropriate angiogenesis, comprising: administering to said mammal a therapeutically effective amount of a compound as claimed in any one of claims 1 to 51 , or a salt, solvate or physiologically functional derivative thereof.
76. The method of claim 75, wherein the inappropriate angiogenesis results from at least one of inappropriate VEGFR1 , VEGFR2, VEGFR3 or TIE-2 activity.
77. The method of claim 75, wherein the inappropriate angiogenesis results from inappropriate VEGFR2 and TIE-2 activity.
78. The method of claim 75, further comprising administering a therapeutically effective amount of a TIE-2 inhibitor.
79 The method of claim 75, further comprising administering an agent to inhibit growth factor receptor function.
80. The method of claim 75, wherein the disorder is cancer.
81. Use of a compound as claimed in any of claims 1 to 51 , or a salt, solvate, or a physiologically functional derivative thereof in the preparation of a medicament for use in the treatment of a disorder characterized by inappropriate angiogenesis.
PCT/US2001/049367 2000-12-21 2001-12-19 Pyrimidineamines as angiogenesis modulators WO2002059110A1 (en)

Priority Applications (34)

Application Number Priority Date Filing Date Title
MXPA03005696A MXPA03005696A (en) 2000-12-21 2001-12-19 Pyrimidineamines as angiogenesis modulators.
HUP0400691A HU230574B1 (en) 2000-12-21 2001-12-19 Pyrimidineamines as angiogenesis modulators and pharmaceutical compositions containing them
US10/451,305 US7105530B2 (en) 2000-12-21 2001-12-19 Pyrimidineamines as angiogenesis modulators
CNB018227503A CN1307173C (en) 2000-12-21 2001-12-19 Pyrimidineamines as angiogenesis modulators
JP2002559412A JP4253188B2 (en) 2000-12-21 2001-12-19 Pyrimidineamine as an angiogenesis regulator
CA2432000A CA2432000C (en) 2000-12-21 2001-12-19 Pyrimidineamines as angiogenesis modulators
KR1020037008349A KR100847169B1 (en) 2000-12-21 2001-12-19 Pyrimidineamines as angiogenesis modulators
DK01994315T DK1343782T3 (en) 2000-12-21 2001-12-19 Pyrimidinamines as angiogenesis modulators
PL363243A PL214667B1 (en) 2000-12-21 2001-12-19 Pyrimidineamines as angiogenesis modulators
AT01994315T ATE430742T1 (en) 2000-12-21 2001-12-19 PYRIMIDINAMINES AS ANGIOGENESIS MODULATORS
AU2002246723A AU2002246723B2 (en) 2000-12-21 2001-12-19 Pyrimidineamines as angiogenesis modulators
SI200130922T SI1343782T1 (en) 2000-12-21 2001-12-19 Pyrimidineamines as angiogenesis modulators
IL15630601A IL156306A0 (en) 2000-12-21 2001-12-19 Pyrimidineamines as angiogenesis modulators
DE60138645T DE60138645D1 (en) 2000-12-21 2001-12-19 PYRIMIDINAMINES AS ANGIOGENESIS MODULATORS
EP01994315A EP1343782B1 (en) 2000-12-21 2001-12-19 Pyrimidineamines as angiogenesis modulators
BR0116452-0A BR0116452A (en) 2000-12-21 2001-12-19 Compound, pharmaceutical composition, use of a compound
NZ526542A NZ526542A (en) 2000-12-21 2001-12-19 Pyrimidineamines as angiogenesis modulators
DE122010000038C DE122010000038I1 (en) 2000-12-21 2001-12-19 PYRIMIDINAMINES AS ANGIOGENESIS MODULATORS
IL156306A IL156306A (en) 2000-12-21 2003-06-04 5 - ({4 - [(2,3 - DIMETHYL l - 2H - INDAZOL - 6 - YL)(METHYL) AMINO] PYRIMIDIN - 2 - YL} AMINO) - 2 -
ZA2003/04482A ZA200304482B (en) 2000-12-21 2003-06-09 Pyrimidineamines as angiogenesis modulators
NO20032831A NO325987B1 (en) 2000-12-21 2003-06-20 Pyrimidinamines, their use and pharmaceutical preparations.
HK04101322.3A HK1059926A1 (en) 2000-12-21 2004-02-24 Pyrimidineamines as angiogenesis modulators
US11/383,229 US7262203B2 (en) 2000-12-21 2006-05-15 Pyrimidineamines as angiogenesis modulators
US11/830,024 US7858626B2 (en) 2000-12-21 2007-07-30 Pyrimidineamines as angiogenesis modulators
US11/830,608 US8114885B2 (en) 2000-12-21 2007-07-30 Chemical compounds
CY20091100644T CY1109160T1 (en) 2000-12-21 2009-06-18 PYRIDINOAMINES AS ANGIOGENESIS REGULATORS
US12/609,398 US20100105712A1 (en) 2000-12-21 2009-10-30 Chemical compounds
LU91710C LU91710I2 (en) 2000-12-21 2010-07-21 Pazopanib, optionally in the form of a pharmaceutically acceptable salt or solvate thereof
CY2010014C CY2010014I1 (en) 2000-12-21 2010-07-29 PYRIDINOAMINES AS ANGIOGENESIS REGULATORS
BE2010C030C BE2010C030I2 (en) 2000-12-21 2010-08-05
FR10C0037C FR10C0037I2 (en) 2000-12-21 2010-08-17 CHEMICAL COMPOUNDS
NO2010020C NO2010020I1 (en) 2000-12-21 2010-11-10 5 - {{4 - [(2,3-Dimethyl-2H-indazot-6-yl) (methyl) amino] pyrimidin-2-yl} amino) -2-methylbenzenesulfonamide Pazopanib.
US13/545,029 US20120277258A1 (en) 2000-12-21 2012-07-10 Chemical Compounds
NO2022001C NO2022001I1 (en) 2000-12-21 2022-01-06 Pazopanib

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US25752600P 2000-12-21 2000-12-21
US60/257,526 2000-12-21
US26240301P 2001-01-16 2001-01-16
US60/262,403 2001-01-16

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10451305 A-371-Of-International 2001-12-19
US11/383,229 Continuation US7262203B2 (en) 2000-12-21 2006-05-15 Pyrimidineamines as angiogenesis modulators

Publications (1)

Publication Number Publication Date
WO2002059110A1 true WO2002059110A1 (en) 2002-08-01

Family

ID=26946028

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/049367 WO2002059110A1 (en) 2000-12-21 2001-12-19 Pyrimidineamines as angiogenesis modulators

Country Status (28)

Country Link
US (6) US7105530B2 (en)
EP (2) EP1343782B1 (en)
JP (1) JP4253188B2 (en)
KR (1) KR100847169B1 (en)
CN (1) CN1307173C (en)
AT (1) ATE430742T1 (en)
AU (1) AU2002246723B2 (en)
BE (1) BE2010C030I2 (en)
BR (1) BR0116452A (en)
CA (1) CA2432000C (en)
CY (2) CY1109160T1 (en)
CZ (1) CZ304059B6 (en)
DE (2) DE60138645D1 (en)
DK (2) DK1343782T3 (en)
ES (2) ES2324981T3 (en)
FR (1) FR10C0037I2 (en)
HK (2) HK1059926A1 (en)
HU (2) HU230574B1 (en)
IL (2) IL156306A0 (en)
LU (1) LU91710I2 (en)
MX (1) MXPA03005696A (en)
NO (3) NO325987B1 (en)
NZ (1) NZ526542A (en)
PL (1) PL214667B1 (en)
PT (2) PT1343782E (en)
SI (2) SI2311825T1 (en)
WO (1) WO2002059110A1 (en)
ZA (1) ZA200304482B (en)

Cited By (182)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003018021A1 (en) * 2001-08-22 2003-03-06 Amgen Inc. 2,4-disubstituted pyrimidinyl derivatives for use as anticancer agents
WO2003074515A1 (en) * 2002-03-01 2003-09-12 Smithkline Beecham Corporation Diamino-pyrimidines and their use as angiogenesis inhibitors
WO2004009557A1 (en) * 2002-07-19 2004-01-29 Memory Pharmaceuticals Corporation 6-amino-1h-indazole and 4-aminobenzofuran compounds as phosphodiesterase 4 inhibitors
WO2004056786A2 (en) * 2002-12-20 2004-07-08 Pfizer Products Inc. Pyrimidine derivates for the treatment of abnormal cell growth
EP1515955A2 (en) * 2002-06-17 2005-03-23 SmithKline Beecham Corporation Chemical process
WO2005013996A3 (en) * 2003-08-07 2005-06-09 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and uses as anti-proliferative agents
JP2006503081A (en) * 2002-10-10 2006-01-26 スミスクライン ビーチャム コーポレーション Chemical compound
WO2005118544A3 (en) * 2004-05-18 2006-02-16 Rigel Pharmaceuticals Inc Cycloalkyl substituted pyrimidinediamine compounds and their uses
WO2006020564A1 (en) * 2004-08-09 2006-02-23 Smithkline Beecham Corporation Pyrimidin derivatives for the treatment of multiple myeloma
EP1659115A1 (en) 2004-11-16 2006-05-24 Yung Shin Pharm. Ind. Co., Ltd. Synthesis of substituted 2H-indazole derivatives as anti-angiogenic agents
WO2006055561A2 (en) * 2004-11-15 2006-05-26 Rigel Pharmaceuticals, Inc. Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses
WO2006060318A2 (en) 2004-11-30 2006-06-08 Amgen Inc. Quinolines and quinazoline analogs and their use as medicaments for treating cancer
WO2005105094A3 (en) * 2004-04-16 2006-06-15 Smithkline Beecham Corp Cancer treatment method
US7087625B2 (en) 2002-11-19 2006-08-08 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors
US7109335B2 (en) 2002-12-20 2006-09-19 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
US7109337B2 (en) 2002-12-20 2006-09-19 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
US7115617B2 (en) 2001-08-22 2006-10-03 Amgen Inc. Amino-substituted pyrimidinyl derivatives and methods of use
US7122542B2 (en) 2003-07-30 2006-10-17 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
US7145008B2 (en) 2004-05-14 2006-12-05 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
US7153871B2 (en) 2001-01-22 2006-12-26 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors, including aminoindazole and aminobenzofuran analogs
US7205320B2 (en) 2001-01-22 2007-04-17 Memory Pharmaceuticals Corp. Phosphodiesterase 4 inhibitors
US7208499B2 (en) 2004-05-14 2007-04-24 Pfizer Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
WO2007064753A2 (en) 2005-11-29 2007-06-07 Smithkline Beecham Corporation Cancer treatment method
US7235562B2 (en) 2004-05-14 2007-06-26 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
WO2007085833A2 (en) * 2006-01-26 2007-08-02 Astrazeneca Ab Pyrimidine derivatives
WO2007089445A2 (en) 2006-01-27 2007-08-09 Amgen Inc. Ang2 and vegf inhibitor combinations
WO2007098507A2 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
WO2007143483A2 (en) * 2006-06-01 2007-12-13 Smithkline Beecham Corporation Combination of pazopanib and lapatinib for treating cancer
WO2008049123A2 (en) 2006-10-19 2008-04-24 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine derivatives as inhibitors of jak kinases for the treatment of autoimmune diseases
WO2008079907A1 (en) * 2006-12-20 2008-07-03 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
WO2008079291A2 (en) 2006-12-20 2008-07-03 Amgen Inc. Substituted heterocycles and methods of use
WO2008086014A2 (en) 2007-01-09 2008-07-17 Amgen Inc. Bis-aryl amide derivatives useful for the treatment of cancer
US7405230B2 (en) 2002-07-19 2008-07-29 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors, including N-substituted aniline and diphenylamine analogs
WO2007064752A3 (en) * 2005-11-29 2008-08-14 Smithkline Beecham Corp Treatment of ocular neovascular disorders such as macular degeneration, angiod streaks, uveitis and macular edema
WO2008103277A2 (en) 2007-02-16 2008-08-28 Amgen Inc. Nitrogen-containing heterocyclyl ketones and their use as c-met inhibitors
US7491732B2 (en) 2005-06-08 2009-02-17 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
EP2058307A1 (en) * 2007-11-12 2009-05-13 Cellzome Ag Methods for the identification of JAK kinase interacting molecules and for the purification of JAK kinases
US7589200B2 (en) * 2002-02-01 2009-09-15 Rigel Pharmaceuticals, Inc. 5-Fluoro-4N-phenyl-4-pyrimidineamine compounds
WO2009136995A2 (en) 2008-04-16 2009-11-12 Portola Pharmaceuticals, Inc. Inhibitors of syk protein kinase
WO2010036796A1 (en) * 2008-09-26 2010-04-01 Concert Pharmaceuticals, Inc. Pyridineamine derivatives
WO2010092114A1 (en) 2009-02-13 2010-08-19 Guerbet Use of buffers for radionuclide complexation
US7812029B1 (en) 2002-07-29 2010-10-12 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
US7851480B2 (en) 2004-11-24 2010-12-14 Rigel Pharmaceuticals, Inc. Spiro 2,4-pyrimidinediamine compounds and their uses
US7868024B2 (en) 2007-01-19 2011-01-11 Sanofi-Aventis Derivatives of N-(heteroaryl)-1-heteroaryl-1H-indole-2-carboxamides, preparation thereof and therapeutic use thereof
WO2011039648A1 (en) 2009-09-30 2011-04-07 Glaxo Wellcome Manufacturing Pte Ltd. Methods of administration and treatment
WO2011058179A1 (en) 2009-11-16 2011-05-19 Ratiopharm Gmbh 5- (4- (n- (2, 3 -dimethyl- 2h- indazol- 6 -yl) -n-methylamino) pyrimidin- 2 -ylamino) -2 -methylbenzenesulfonamide
WO2011069053A1 (en) 2009-12-04 2011-06-09 Teva Pharmaceutical Industries Ltd. Process for the preparation of pazopanip hcl and crystalline forms of pazopanib hcl
EP2341067A1 (en) 2003-07-18 2011-07-06 Amgen, Inc Specific binding agents to hepatocyte growth factor
WO2011085007A1 (en) * 2010-01-06 2011-07-14 Glaxo Wellcome Manufacturing Pte Ltd Treatment method
US7989631B2 (en) 2006-02-10 2011-08-02 Amgen Inc. Hydrate forms of AMG706
US8044040B2 (en) 2001-06-26 2011-10-25 Bristol-Myers Squibb Company N-heterocyclic inhibitors of TNF-alpha expression
WO2011161217A2 (en) 2010-06-23 2011-12-29 Palacký University in Olomouc Targeting of vegfr2
WO2012027438A1 (en) 2010-08-26 2012-03-01 Glaxosmithkline Llc Pharmaceutical combination of a vegfr inhibitor and a mek inhibitor useful for treating cancer
US8138339B2 (en) 2008-04-16 2012-03-20 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
WO2012036919A2 (en) 2010-09-14 2012-03-22 Glaxosmithkline Llc Combination of braf and vegf inhibitors
WO2012061418A2 (en) 2010-11-01 2012-05-10 Portola Pharmaceuticals, Inc. Benzamides and nicotinamides as syk modulators
WO2012061415A1 (en) 2010-11-01 2012-05-10 Portola Pharmaceuticals, Inc. Oxypyrimidines as syk modulators
WO2012082337A2 (en) 2010-12-17 2012-06-21 Glaxo Wellcome Manufacturing Pte Ltd Combination
WO2012084981A1 (en) 2010-12-20 2012-06-28 Guerbet Chelate nanoemulsion for mri
US8227455B2 (en) 2005-04-18 2012-07-24 Rigel Pharmaceuticals, Inc. Methods of treating cell proliferative disorders
WO2012106302A1 (en) 2011-02-01 2012-08-09 Glaxo Wellcome Manufacturing Pte Ltd Combination
US8258144B2 (en) 2008-04-22 2012-09-04 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
WO2012129344A1 (en) 2011-03-23 2012-09-27 Amgen Inc. Fused tricyclic dual inhibitors of cdk 4/6 and flt3
WO2012143399A1 (en) * 2011-04-19 2012-10-26 Bayer Intellectual Property Gmbh Substituted 4-aryl-n-phenyl-1,3,5-triazin-2-amines
WO2013045333A1 (en) 2011-09-26 2013-04-04 Guerbet Nanoemulsions and use thereof as contrast agents
EP2575460A1 (en) * 2010-05-26 2013-04-10 GlaxoSmithKline LLC Combination
EP2578583A1 (en) 2006-07-14 2013-04-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
EP2589610A1 (en) 2007-08-21 2013-05-08 Amgen, Inc Human c-fms antigen binding proteins
EP2627179A1 (en) * 2010-10-14 2013-08-21 ARIAD Pharmaceuticals, Inc Methods for inhibiting cell proliferation in egfr-driven cancers
WO2013132044A1 (en) 2012-03-08 2013-09-12 F. Hoffmann-La Roche Ag Combination therapy of antibodies against human csf-1r and uses thereof
US8598156B2 (en) 2010-03-25 2013-12-03 Glaxosmithkline Llc Chemical compounds
US8648199B2 (en) 2005-12-23 2014-02-11 Amgen Inc. Process for making a solid-state form of AMG 706
WO2014036022A1 (en) 2012-08-29 2014-03-06 Amgen Inc. Quinazolinone compounds and derivatives thereof
WO2014108837A1 (en) 2013-01-09 2014-07-17 Glaxosmithkline Intellectual Property (No.2) Limited Combination
WO2014114724A1 (en) 2013-01-23 2014-07-31 Guerbet Vectorised magnetic emulsion
US8926945B2 (en) 2005-10-07 2015-01-06 Guerbet Compounds comprising a biological target recognizing part, coupled to a signal part capable of complexing gallium
US8952027B2 (en) 2008-04-16 2015-02-10 Portola Pharmaceuticals, Inc. Inhibitors of syk and JAK protein kinases
US8986650B2 (en) 2005-10-07 2015-03-24 Guerbet Complex folate-NOTA-Ga68
US9012462B2 (en) 2008-05-21 2015-04-21 Ariad Pharmaceuticals, Inc. Phosphorous derivatives as kinase inhibitors
WO2015056180A1 (en) 2013-10-15 2015-04-23 Glaxosmithkline Intellectual Property (No.2) Limited Indoline derivatives as inhibitors of perk
US9102625B2 (en) 2010-11-01 2015-08-11 Portola Pharmaceuticals, Inc. Nicotinamides as JAK kinase modulators
WO2015136463A1 (en) 2014-03-11 2015-09-17 Glaxosmithkline Intellectual Property (No.2) Limited Chemical compounds acting as perk inhibitors
US9266912B2 (en) 2005-01-19 2016-02-23 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
WO2016055935A1 (en) 2014-10-06 2016-04-14 Glaxosmithkline Intellectual Property (No.2) Limited Combination of lysine-specific demethylase 1 inhibitor and thrombopoietin agonist
US9359308B2 (en) 2011-11-23 2016-06-07 Portola Pharmaceuticals, Inc. Pyrazine kinase inhibitors
WO2016112111A1 (en) 2015-01-08 2016-07-14 The Board Of Trustees Of The Leland Stanford Junior University Factors and cells that provide for induction of bone, bone marrow, and cartilage
US20160280689A1 (en) * 2013-11-05 2016-09-29 Laurus Labs Private Limited An improved process for the preparation of pazopanib or a pharmaceutically acceptable salt thereof
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
US9650340B2 (en) 2012-11-15 2017-05-16 Bayer Pharma Aktiengesellschaft 5-fluoro-N-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfoximine group
US9650361B2 (en) 2012-11-15 2017-05-16 Bayer Pharam Aktiengesellschaft N-(pyridin-2-yl)pyrimidin-4-amine derivatives containing a sulfoximine group
EP3170824A1 (en) 2008-01-15 2017-05-24 Amgen, Inc 6-([1,2,4]triazolo[4,3-a]pyridin-3-ylmethyl)-1,6-naphthyridin-5(6h)-one derivatives as c-met inhibitors
US9669034B2 (en) 2011-05-24 2017-06-06 Bayer Intellectual Property Gmbh 4-aryl-N-phenyl-1,3,5-triazin-2-amines containing a sulfoximine group
US9670161B2 (en) 2012-10-18 2017-06-06 Bayer Pharma Aktiengesellschaft 5-fluoro-N-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfone group
US9676756B2 (en) 2012-10-08 2017-06-13 Portola Pharmaceuticals, Inc. Substituted pyrimidinyl kinase inhibitors
WO2017098421A1 (en) 2015-12-08 2017-06-15 Glaxosmithkline Intellectual Property Development Limited Benzothiadiazine compounds
US9708293B2 (en) 2012-10-18 2017-07-18 Bayer Pharma Aktiengesellschaft N-(pyridin-2-yl)pyrimidin-4-amine derivatives containing a sulfone group
US9745288B2 (en) 2011-08-16 2017-08-29 Indiana University Research And Technology Corporation Compounds and methods for treating cancer by inhibiting the urokinase receptor
WO2017153952A1 (en) 2016-03-10 2017-09-14 Glaxosmithkline Intellectual Property Development Limited 5-sulfamoyl-2-hydroxybenzamide derivatives
US9770445B2 (en) 2013-07-04 2017-09-26 Bayer Pharma Aktiengesellschaft Sulfoximine substituted 5-fluoro-N-(pyridin-2-yl)pyridin-2-amine derivatives and their use as CDK9 kinase inhibitors
EP3228630A1 (en) 2016-04-07 2017-10-11 IMBA-Institut für Molekulare Biotechnologie GmbH Combination of an apelin antagonist and an angiogenesis inhibitor for the treatment of cancer
US9790189B2 (en) 2014-04-01 2017-10-17 Bayer Pharma Aktiengesellschaft Disubstituted 5-fluoro pyrimidine derivatives containing a sulfondiimine group
US9834571B2 (en) 2012-05-05 2017-12-05 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in EGFR-driven cancers
US9834518B2 (en) 2011-05-04 2017-12-05 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in EGFR-driven cancers
WO2017212423A1 (en) 2016-06-08 2017-12-14 Glaxosmithkline Intellectual Property Development Limited Chemcical compounds
WO2017212425A1 (en) 2016-06-08 2017-12-14 Glaxosmithkline Intellectual Property Development Limited Chemical compounds as atf4 pathway inhibitors
US9856263B2 (en) 2014-04-28 2018-01-02 Pfizer Inc. Heteroaromatic compounds and their use as dopamine D1 ligands
US9856242B2 (en) 2014-03-13 2018-01-02 Bayer Pharma Aktiengesellscaft 5-fluoro-N-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfone group
WO2018015879A1 (en) 2016-07-20 2018-01-25 Glaxosmithkline Intellectual Property Development Limited Isoquinoline derivatives as perk inhibitors
US9884849B2 (en) 2014-10-16 2018-02-06 Bayer Pharma Aktiengesellschaft Fluorinated benzofuranyl-pyrimidine derivatives containing a sulfoximine group
US9902716B2 (en) 2014-10-16 2018-02-27 Bayer Pharma Aktiengesellschaft Fluorinated benzofuranyl-pyrimidine derivatives containing a sulfone group
US9963464B2 (en) 2014-04-11 2018-05-08 Bayer Pharma Aktiengesellschaft Macrocyclic compounds
WO2018100536A1 (en) 2016-12-01 2018-06-07 Glaxosmithkline Intellectual Property Development Limited Methods of treating cancer
WO2018119183A2 (en) 2016-12-22 2018-06-28 Amgen Inc. Kras g12c inhibitors and methods of using the same
WO2018217651A1 (en) 2017-05-22 2018-11-29 Amgen Inc. Kras g12c inhibitors and methods of using the same
WO2018225093A1 (en) 2017-06-07 2018-12-13 Glaxosmithkline Intellectual Property Development Limited Chemical compounds as atf4 pathway inhibitors
WO2019008506A1 (en) 2017-07-03 2019-01-10 Glaxosmithkline Intellectual Property Development Limited N-(3-(2-(4-chlorophenoxy)acetamido)bicyclo[1.1.1]pentan-1-yl)-2-cyclobutane-1-carboxamide derivatives and related compounds as atf4 inhibitors for treating cancer and other diseases
WO2019008507A1 (en) 2017-07-03 2019-01-10 Glaxosmithkline Intellectual Property Development Limited 2-(4-chlorophenoxy)-n-((1 -(2-(4-chlorophenoxy)ethynazetidin-3-yl)methyl)acetamide derivatives and related compounds as atf4 inhibitors for treating cancer and other diseases
WO2019021208A1 (en) 2017-07-27 2019-01-31 Glaxosmithkline Intellectual Property Development Limited Indazole derivatives useful as perk inhibitors
WO2019051291A1 (en) 2017-09-08 2019-03-14 Amgen Inc. Inhibitors of kras g12c and methods of using the same
WO2019049061A1 (en) 2017-09-07 2019-03-14 Glaxosmithkline Intellectual Property Development Limited 5-(1 h-benzo[d]imidazo-2-yl)-pyridin-2-amine and 5-(3h-imidazo[4,5-b]pyridin-6-yl)-pyridin-2-amine derivatives as c-myc and p300/cbp histone acetyltransferase inhibitors for treating cancer
WO2019053500A1 (en) 2018-04-17 2019-03-21 Alvogen Malta Operations (Row) Ltd Pharmaceutical composition of solid dosage form containing pazopanib and process for its preparation
WO2019053617A1 (en) 2017-09-12 2019-03-21 Glaxosmithkline Intellectual Property Development Limited Chemical compounds
WO2019193540A1 (en) 2018-04-06 2019-10-10 Glaxosmithkline Intellectual Property Development Limited Heteroaryl derivatives of formula (i) as atf4 inhibitors
WO2019193541A1 (en) 2018-04-06 2019-10-10 Glaxosmithkline Intellectual Property Development Limited Bicyclic aromatic ring derivatives of formula (i) as atf4 inhibitors
WO2019213526A1 (en) 2018-05-04 2019-11-07 Amgen Inc. Kras g12c inhibitors and methods of using the same
WO2019213516A1 (en) 2018-05-04 2019-11-07 Amgen Inc. Kras g12c inhibitors and methods of using the same
WO2019217691A1 (en) 2018-05-10 2019-11-14 Amgen Inc. Kras g12c inhibitors for the treatment of cancer
WO2019232419A1 (en) 2018-06-01 2019-12-05 Amgen Inc. Kras g12c inhibitors and methods of using the same
WO2019241157A1 (en) 2018-06-11 2019-12-19 Amgen Inc. Kras g12c inhibitors for treating cancer
WO2020007822A1 (en) 2018-07-02 2020-01-09 Conservatoire National Des Arts Et Metiers (Cnam) Bismuth metallic (0) nanoparticles, process of manufacturing and uses thereof
WO2020012339A1 (en) 2018-07-09 2020-01-16 Glaxosmithkline Intellectual Property Development Limited Chemical compounds
WO2020031107A1 (en) 2018-08-08 2020-02-13 Glaxosmithkline Intellectual Property Development Limited Chemical compounds
WO2020050890A2 (en) 2018-06-12 2020-03-12 Amgen Inc. Kras g12c inhibitors and methods of using the same
WO2020102730A1 (en) 2018-11-16 2020-05-22 Amgen Inc. Improved synthesis of key intermediate of kras g12c inhibitor compound
WO2020106640A1 (en) 2018-11-19 2020-05-28 Amgen Inc. Kras g12c inhibitors and methods of using the same
WO2020106647A2 (en) 2018-11-19 2020-05-28 Amgen Inc. Combination therapy including a krasg12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
WO2020110056A1 (en) 2018-11-30 2020-06-04 Glaxosmithkline Intellectual Property Development Limited Compounds useful in hiv therapy
WO2020132651A1 (en) 2018-12-20 2020-06-25 Amgen Inc. Kif18a inhibitors
WO2020132648A1 (en) 2018-12-20 2020-06-25 Amgen Inc. Kif18a inhibitors
WO2020132653A1 (en) 2018-12-20 2020-06-25 Amgen Inc. Heteroaryl amides useful as kif18a inhibitors
WO2020132649A1 (en) 2018-12-20 2020-06-25 Amgen Inc. Heteroaryl amides useful as kif18a inhibitors
WO2020180768A1 (en) 2019-03-01 2020-09-10 Revolution Medicines, Inc. Bicyclic heteroaryl compounds and uses thereof
WO2020180770A1 (en) 2019-03-01 2020-09-10 Revolution Medicines, Inc. Bicyclic heterocyclyl compounds and uses thereof
WO2021018941A1 (en) 2019-07-31 2021-02-04 Glaxosmithkline Intellectual Property Development Limited Methods of treating cancer
WO2021026101A1 (en) 2019-08-02 2021-02-11 Amgen Inc. Kif18a inhibitors
WO2021026098A1 (en) 2019-08-02 2021-02-11 Amgen Inc. Kif18a inhibitors
WO2021026099A1 (en) 2019-08-02 2021-02-11 Amgen Inc. Kif18a inhibitors
WO2021026100A1 (en) 2019-08-02 2021-02-11 Amgen Inc. Pyridine derivatives as kif18a inhibitors
EP3789027A1 (en) 2015-01-13 2021-03-10 Kyoto University Bosutinib, sunitinib, tivozanib, imatinib, nilotinib, rebastinib or bafetinib for preventing and/or treating amyotrophic lateral sclerosis
WO2021081212A1 (en) 2019-10-24 2021-04-29 Amgen Inc. Pyridopyrimidine derivatives useful as kras g12c and kras g12d inhibitors in the treatment of cancer
WO2021091982A1 (en) 2019-11-04 2021-05-14 Revolution Medicines, Inc. Ras inhibitors
WO2021091967A1 (en) 2019-11-04 2021-05-14 Revolution Medicines, Inc. Ras inhibitors
WO2021092115A1 (en) 2019-11-08 2021-05-14 Revolution Medicines, Inc. Bicyclic heteroaryl compounds and uses thereof
WO2021091956A1 (en) 2019-11-04 2021-05-14 Revolution Medicines, Inc. Ras inhibitors
WO2021097212A1 (en) 2019-11-14 2021-05-20 Amgen Inc. Improved synthesis of kras g12c inhibitor compound
WO2021097207A1 (en) 2019-11-14 2021-05-20 Amgen Inc. Improved synthesis of kras g12c inhibitor compound
WO2021108683A1 (en) 2019-11-27 2021-06-03 Revolution Medicines, Inc. Covalent ras inhibitors and uses thereof
WO2021142026A1 (en) 2020-01-07 2021-07-15 Revolution Medicines, Inc. Shp2 inhibitor dosing and methods of treating cancer
WO2021257736A1 (en) 2020-06-18 2021-12-23 Revolution Medicines, Inc. Methods for delaying, preventing, and treating acquired resistance to ras inhibitors
US11236091B2 (en) 2019-05-21 2022-02-01 Amgen Inc. Solid state forms
US11242356B2 (en) 2017-03-28 2022-02-08 Bayer Aktiengesellschaft PTEFb inhibiting macrocyclic compounds
US11254690B2 (en) 2017-03-28 2022-02-22 Bayer Pharma Aktiengesellschaft PTEFb inhibiting macrocyclic compounds
WO2022040446A1 (en) 2020-08-19 2022-02-24 Nanocopoeia, Llc Amorphous pazopanib particles and pharmaceutical compositions thereof
WO2022060836A1 (en) 2020-09-15 2022-03-24 Revolution Medicines, Inc. Indole derivatives as ras inhibitors in the treatment of cancer
WO2022060583A1 (en) 2020-09-03 2022-03-24 Revolution Medicines, Inc. Use of sos1 inhibitors to treat malignancies with shp2 mutations
WO2022140427A1 (en) 2020-12-22 2022-06-30 Qilu Regor Therapeutics Inc. Sos1 inhibitors and uses thereof
US11426404B2 (en) 2019-05-14 2022-08-30 Amgen Inc. Dosing of KRAS inhibitor for treatment of cancers
WO2022235864A1 (en) 2021-05-05 2022-11-10 Revolution Medicines, Inc. Ras inhibitors
WO2022235866A1 (en) 2021-05-05 2022-11-10 Revolution Medicines, Inc. Covalent ras inhibitors and uses thereof
WO2022235870A1 (en) 2021-05-05 2022-11-10 Revolution Medicines, Inc. Ras inhibitors for the treatment of cancer
WO2023060253A1 (en) 2021-10-08 2023-04-13 Revolution Medicines, Inc. Ras inhibitors
WO2023114954A1 (en) 2021-12-17 2023-06-22 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
US11701347B2 (en) 2018-02-13 2023-07-18 Bayer Aktiengesellschaft Use of 5-fluoro-4-(4-fluoro-2-methoxyphenyl)-N-{4-[(S-methylsulfonimidoyl)methyl]pyridin-2-yl}pyridin-2-amine for treating diffuse large B-cell lymphoma
EP4227307A1 (en) 2022-02-11 2023-08-16 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
WO2023172940A1 (en) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Methods for treating immune refractory lung cancer
WO2023230541A1 (en) 2022-05-27 2023-11-30 Viiv Healthcare Company Piperazine derivatives useful in hiv therapy
WO2023240263A1 (en) 2022-06-10 2023-12-14 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2024081916A1 (en) 2022-10-14 2024-04-18 Black Diamond Therapeutics, Inc. Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives
WO2024206858A1 (en) 2023-03-30 2024-10-03 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
WO2024211712A1 (en) 2023-04-07 2024-10-10 Revolution Medicines, Inc. Condensed macrocyclic compounds as ras inhibitors
WO2024211663A1 (en) 2023-04-07 2024-10-10 Revolution Medicines, Inc. Condensed macrocyclic compounds as ras inhibitors

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0301117A3 (en) * 2000-02-17 2004-01-28 Amgen Inc Thousand Oaks Imidazole derivatives kinase inhibitors, their use, process for their preparation and pharmaceutical compositions containing them
MXPA03005696A (en) * 2000-12-21 2003-10-06 Glaxo Group Ltd Pyrimidineamines as angiogenesis modulators.
DE50212771D1 (en) * 2001-10-17 2008-10-23 Boehringer Ingelheim Pharma PYRIMIDIN DERIVATIVES, MEDICAMENTS CONTAINING THESE COMPOUNDS, THEIR USE AND METHOD FOR THEIR PREPARATION
WO2003037877A1 (en) * 2001-11-01 2003-05-08 Janssen Pharmaceutica N.V. AMINOBENZAMIDE DERIVATIVES AS GLYCOGEN SYNTHASE KINASE 3β INHIBITORS
US20040167132A1 (en) * 2003-01-16 2004-08-26 Geetha Shankar Methods of treating conditions associted with an Edg-2 receptor
JP4634367B2 (en) 2003-02-20 2011-02-16 スミスクライン ビーチャム コーポレーション Pyrimidine compounds
CN1901903A (en) * 2003-11-06 2007-01-24 细胞基因公司 Methods of using and compositions comprising a jnk inhibitor for the treatment and management of asbestos-related diseases and disorders
AU2005295788A1 (en) * 2004-10-13 2006-04-27 Wyeth N-benzenesulfonyl substituted anilino-pyrimidine analogs
WO2006129100A1 (en) * 2005-06-03 2006-12-07 Glaxo Group Limited Novel compounds
PL2154967T3 (en) * 2007-04-16 2014-08-29 Hutchison Medipharma Entpr Ltd Pyrimidine derivatives
US20100029689A1 (en) * 2008-07-02 2010-02-04 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors
EP2490536A4 (en) * 2009-10-23 2013-04-17 Glaxo Wellcome Mfg Pte Ltd Compositions and processes
US10166142B2 (en) 2010-01-29 2019-01-01 Forsight Vision4, Inc. Small molecule delivery with implantable therapeutic device
KR20130031296A (en) 2010-05-21 2013-03-28 케밀리아 에이비 Novel pyrimidine derivatives
US8354420B2 (en) 2010-06-04 2013-01-15 Genentech, Inc. Aminopyrimidine derivatives as LRRK2 inhibitors
PL3124483T3 (en) 2010-11-10 2020-03-31 Genentech, Inc. Pyrazole aminopyrimidine derivatives as lrrk2 modulators
US20140031769A1 (en) 2010-11-19 2014-01-30 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
US9150547B2 (en) 2010-11-29 2015-10-06 Hetero Research Foundation Process for the preparation of pazopanib using novel intermediate
CN102093339B (en) * 2010-12-09 2013-06-12 天津药物研究院 Preparation method and application of pyrimidine derivatives
CN102060848B (en) * 2010-12-09 2013-09-18 天津药物研究院 Preparation and application of aromatic amine substituted pyrimidine derivatives
CN102093340B (en) * 2010-12-09 2013-07-17 天津药物研究院 Preparation method and application of 2-methylindazole derivatives
DK2688883T3 (en) 2011-03-24 2016-09-05 Noviga Res Ab pyrimidine
EP2755948B1 (en) * 2011-09-16 2016-05-25 Bayer Intellectual Property GmbH Disubstituted 5-fluoro pyrimidine derivatives containing a sulfoximine group
EP2773204A4 (en) 2011-10-31 2015-05-27 Glaxosmithkline Intellectual Property Ltd Pazopanib formulation
CN103159742B (en) * 2011-12-16 2015-08-12 北京韩美药品有限公司 5-chloropyrimide compounds and the application as EGFR tyrosine kinase inhibitor thereof
CN103373989B (en) * 2012-04-28 2016-04-13 上海医药工业研究院 The preparation method of the intermediate of pazopanib hydrochloride
CN103864764A (en) * 2012-12-11 2014-06-18 齐鲁制药有限公司 Indazole-substituted pyrimidinamine derivative, and preparation method and use thereof
WO2014097152A1 (en) 2012-12-17 2014-06-26 Ranbaxy Laboratories Limited Process for the preparation of pazopanib or salts thereof
US9802923B2 (en) * 2012-12-17 2017-10-31 Sun Pharmaceutical Industries Limited Process for the preparation of pazopanib or salts thereof
CN103910716A (en) * 2013-01-07 2014-07-09 华东理工大学 2,4-disubstituted-cycloalkyl[d]pyrimidine compound and its use
CA2905496A1 (en) 2013-03-14 2014-09-25 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
CN103214467B (en) * 2013-04-26 2015-09-30 中国人民解放军军事医学科学院微生物流行病研究所 5-[[4-[(2,3-dimethyl-2H-indazole-6-base) methylamino-]-2 pyrimidyl] are amino]-2-methyl-benzenesulfonyl sulfonamide derivatives and preparation method thereof and application
PT3039424T (en) 2013-08-28 2020-09-03 Crown Bioscience Inc Taicang Gene expression signatures predictive of subject response to a multi-kinase inhibitor and methods of using the same
CN103739550B (en) * 2014-01-02 2016-06-01 中国药科大学 2,3-dimethyl-6-urea-2H-indazole compounds and its preparation method and application
CN104829542B (en) * 2014-02-10 2018-02-02 中国科学院上海药物研究所 Aniline pyrimidine class compound, its preparation method and medical usage
CN107106551A (en) 2014-08-08 2017-08-29 弗赛特影像4股份有限公司 The stabilization of receptor tyrosine kinase inhibitors and solvable preparation and its preparation method
KR101705980B1 (en) * 2015-06-12 2017-02-13 중앙대학교 산학협력단 Novel pazopanib derivatives and pharmaceutical composition comprising the same
CN105237523B (en) * 2015-10-08 2018-06-01 深圳市博圣康生物科技有限公司 Pyrimidine derivatives and preparation method thereof, purposes
US11426406B2 (en) 2017-02-09 2022-08-30 Georgetown University Compositions and methods for treating lysosomal storage disorders
CA3060247A1 (en) 2017-04-17 2018-10-25 Yale University Compounds, compositions and methods of treating or preventing acute lung injury
CN107619407B (en) * 2017-08-10 2019-05-24 山东大学 Bis- target spot inhibitor of HDAC and VEGFR based on pazopanib structure and its preparation method and application
CN113292537B (en) 2018-06-15 2024-04-05 汉达癌症医药责任有限公司 Salts of kinase inhibitors and compositions thereof
US20220040324A1 (en) 2018-12-21 2022-02-10 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and kinase inhibitor
CN110746402B (en) * 2019-09-21 2021-01-15 温州医科大学 2-N-aryl-4-N-aryl-5-fluoropyrimidine compound and preparation method and application thereof
EP4149475A1 (en) 2020-05-22 2023-03-22 QX Therapeutics Inc. Compositions and methods for treating lung injuries associated with viral infections
WO2023081923A1 (en) 2021-11-08 2023-05-11 Frequency Therapeutics, Inc. Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof
WO2023228095A1 (en) 2022-05-24 2023-11-30 Daiichi Sankyo Company, Limited Dosage regimen of an anti-cdh6 antibody-drug conjugate

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000039101A1 (en) * 1998-12-24 2000-07-06 Astrazeneca Ab Pyrimidine compounds
WO2000073264A1 (en) * 1999-05-28 2000-12-07 Abbott Laboratories Cell proliferation inhibitors
WO2001009134A1 (en) * 1999-07-30 2001-02-08 Novartis Ag Purine derivatives inhibitors of tyrosine protein kinase syk
WO2001025220A1 (en) * 1999-10-07 2001-04-12 Amgen Inc. Triazine kinase inhibitors
WO2001040218A1 (en) * 1999-11-29 2001-06-07 Aventis Pharma S.A. Arylamine derivatives and their use as anti-telomerase agent
WO2002022601A1 (en) * 2000-09-15 2002-03-21 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5490121A (en) 1977-11-28 1979-07-17 Boettcher Barry Neutral copper bonded body and antiinflaming agent
UA41297C2 (en) 1991-11-25 2001-09-17 Пфайзер, Інк. Indole derivatives, a pharmaceutical composition and a method for treatment
CA2197298C (en) 1994-08-13 1999-10-19 Jong Wook Lee Novel pyrimidine derivatives and processes for the preparation thereof
US5730977A (en) 1995-08-21 1998-03-24 Mitsui Toatsu Chemicals, Inc. Anti-VEGF human monoclonal antibody
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
KR19990082463A (en) 1996-02-13 1999-11-25 돈 리사 로얄 Quinazolin derivatives as vascular endothelial growth factor inhibitors
CN1116286C (en) 1996-03-05 2003-07-30 曾尼卡有限公司 4-anilinoquinazoline derivatives
DE19610799C1 (en) 1996-03-19 1997-09-04 Siemens Ag Ignition device for triggering a restraint in a motor vehicle
GB9707800D0 (en) * 1996-05-06 1997-06-04 Zeneca Ltd Chemical compounds
GB9622363D0 (en) 1996-10-28 1997-01-08 Celltech Therapeutics Ltd Chemical compounds
JP2002501532A (en) 1997-05-30 2002-01-15 メルク エンド カンパニー インコーポレーテッド Novel angiogenesis inhibitors
WO1999010349A1 (en) * 1997-08-22 1999-03-04 Zeneca Limited Oxindolylquinazoline derivatives as angiogenesis inhibitors
EP1017682A4 (en) 1997-09-26 2000-11-08 Merck & Co Inc Novel angiogenesis inhibitors
KR100699514B1 (en) 1998-03-27 2007-03-26 얀센 파마슈티카 엔.브이. HIV inhibiting pyrimidine derivatives
WO1999060630A1 (en) 1998-05-15 1999-11-25 Glaxo Group Limited Infrared thermography
UA60365C2 (en) 1998-06-04 2003-10-15 Пфайзер Продактс Інк. Isothiazole derivatives, a method for preparing thereof, a pharmaceutical composition and a method for treatment of hyperproliferative disease of mammal
CA2336848A1 (en) 1998-07-10 2000-01-20 Merck & Co., Inc. Novel angiogenesis inhibitors
US6022307A (en) * 1998-07-14 2000-02-08 American Cyanamid Company Substituted dibenzothiophenes having antiangiogenic activity
AU5438299A (en) 1998-08-29 2000-03-21 Astrazeneca Ab Pyrimidine compounds
DE69932828T2 (en) 1998-08-29 2007-10-18 Astrazeneca Ab PYRIMIDINE COMPOUNDS
AU760020B2 (en) 1998-08-31 2003-05-08 Merck & Co., Inc. Novel angiogenesis inhibitors
EP1109823B1 (en) * 1998-09-08 2005-11-16 Agouron Pharmaceuticals, Inc. Modifications of the vegf receptor-2 protein and methods of use
CN1161352C (en) 1998-10-08 2004-08-11 阿斯特拉曾尼卡有限公司 Quinazoline derivatives
EP1144390A2 (en) 1999-01-22 2001-10-17 Amgen Inc., Kinase inhibitors
KR100838617B1 (en) 1999-02-10 2008-06-16 아스트라제네카 아베 Quinazoline derivatives as angiogenesis inhibitors
WO2000052470A1 (en) 1999-03-04 2000-09-08 Kyowa Hakko Kogyo Co., Ltd. Diagnostics and remedies for leukemia
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
US6245759B1 (en) 1999-03-11 2001-06-12 Merck & Co., Inc. Tyrosine kinase inhibitors
GB9907658D0 (en) 1999-04-06 1999-05-26 Zeneca Ltd Chemical compounds
CO5170501A1 (en) 1999-04-14 2002-06-27 Novartis Ag USEFUL REPLACED BLUES FOR THE TREATMENT OF DISEASES MEDIATED BY TNFa eIL-1 AND DISEASES OF THE OSEO METABOLISM
GB9914258D0 (en) * 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
JP2003523942A (en) 1999-06-30 2003-08-12 メルク エンド カムパニー インコーポレーテッド SRC kinase inhibitor compounds
GB9919778D0 (en) 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds
HUP0202682A3 (en) 1999-09-10 2003-03-28 Merck & Co Inc Tyrosine kinase inhibitors, pharmaceutical compositions containing them and their use
AU2735201A (en) 1999-12-28 2001-07-09 Pharmacopeia, Inc. Pyrimidine and triazine kinase inhibitors
HUP0301117A3 (en) * 2000-02-17 2004-01-28 Amgen Inc Thousand Oaks Imidazole derivatives kinase inhibitors, their use, process for their preparation and pharmaceutical compositions containing them
GB0004887D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004888D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
CZ20023518A3 (en) 2000-03-31 2004-04-14 Imclone Systems Incorporated Medicament for inhibition of growth of non-solid tumor cells
AUPR213700A0 (en) 2000-12-18 2001-01-25 Biota Scientific Management Pty Ltd Antiviral agents
MXPA03005696A (en) * 2000-12-21 2003-10-06 Glaxo Group Ltd Pyrimidineamines as angiogenesis modulators.

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000039101A1 (en) * 1998-12-24 2000-07-06 Astrazeneca Ab Pyrimidine compounds
WO2000073264A1 (en) * 1999-05-28 2000-12-07 Abbott Laboratories Cell proliferation inhibitors
WO2001009134A1 (en) * 1999-07-30 2001-02-08 Novartis Ag Purine derivatives inhibitors of tyrosine protein kinase syk
WO2001025220A1 (en) * 1999-10-07 2001-04-12 Amgen Inc. Triazine kinase inhibitors
WO2001040218A1 (en) * 1999-11-29 2001-06-07 Aventis Pharma S.A. Arylamine derivatives and their use as anti-telomerase agent
WO2002022601A1 (en) * 2000-09-15 2002-03-21 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors

Cited By (308)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7153871B2 (en) 2001-01-22 2006-12-26 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors, including aminoindazole and aminobenzofuran analogs
US7205320B2 (en) 2001-01-22 2007-04-17 Memory Pharmaceuticals Corp. Phosphodiesterase 4 inhibitors
US8044040B2 (en) 2001-06-26 2011-10-25 Bristol-Myers Squibb Company N-heterocyclic inhibitors of TNF-alpha expression
US6939874B2 (en) 2001-08-22 2005-09-06 Amgen Inc. Substituted pyrimidinyl derivatives and methods of use
US7115617B2 (en) 2001-08-22 2006-10-03 Amgen Inc. Amino-substituted pyrimidinyl derivatives and methods of use
WO2003018021A1 (en) * 2001-08-22 2003-03-06 Amgen Inc. 2,4-disubstituted pyrimidinyl derivatives for use as anticancer agents
US8334296B2 (en) 2002-02-01 2012-12-18 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US7820819B2 (en) 2002-02-01 2010-10-26 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US7803939B2 (en) 2002-02-01 2010-09-28 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US9346765B2 (en) 2002-02-01 2016-05-24 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US7589200B2 (en) * 2002-02-01 2009-09-15 Rigel Pharmaceuticals, Inc. 5-Fluoro-4N-phenyl-4-pyrimidineamine compounds
US10682350B2 (en) 2002-02-01 2020-06-16 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US9416112B2 (en) 2002-02-01 2016-08-16 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US9913842B2 (en) 2002-02-01 2018-03-13 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US8835430B2 (en) 2002-02-01 2014-09-16 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US10709703B2 (en) 2002-02-01 2020-07-14 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US7655797B2 (en) 2002-02-01 2010-02-02 Rigel Pharmaceuticals, Inc. Intermediates for making 2,4-pyrimidinediamine compounds
US9018204B1 (en) 2002-02-01 2015-04-28 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US7338959B2 (en) 2002-03-01 2008-03-04 Smithkline Beecham Corporation Diamino-pyrimidines and their use as angiogenesis inhibitors
WO2003074515A1 (en) * 2002-03-01 2003-09-12 Smithkline Beecham Corporation Diamino-pyrimidines and their use as angiogenesis inhibitors
EP1515955A4 (en) * 2002-06-17 2006-05-03 Smithkline Beecham Corp Chemical process
EP1515955A2 (en) * 2002-06-17 2005-03-23 SmithKline Beecham Corporation Chemical process
US7655802B2 (en) 2002-07-19 2010-02-02 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors, including aminoindazole and aminobenzofuran analogs
US7405230B2 (en) 2002-07-19 2008-07-29 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors, including N-substituted aniline and diphenylamine analogs
WO2004009557A1 (en) * 2002-07-19 2004-01-29 Memory Pharmaceuticals Corporation 6-amino-1h-indazole and 4-aminobenzofuran compounds as phosphodiesterase 4 inhibitors
US7825116B2 (en) 2002-07-29 2010-11-02 Rigel Pharmaceuticals, Inc. N2, N4-bis-aryl-5-fluoro-2,4-pyrimidinediamines
US7812029B1 (en) 2002-07-29 2010-10-12 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
JP2006503081A (en) * 2002-10-10 2006-01-26 スミスクライン ビーチャム コーポレーション Chemical compound
US7087625B2 (en) 2002-11-19 2006-08-08 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors
US7700631B2 (en) 2002-11-19 2010-04-20 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors
WO2004056786A2 (en) * 2002-12-20 2004-07-08 Pfizer Products Inc. Pyrimidine derivates for the treatment of abnormal cell growth
US7109337B2 (en) 2002-12-20 2006-09-19 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
US7109335B2 (en) 2002-12-20 2006-09-19 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
US7674796B2 (en) 2002-12-20 2010-03-09 Pfizer Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
NL1025071C2 (en) * 2002-12-20 2004-12-30 Pfizer Prod Inc Compounds for the treatment of abnormal cell growth.
WO2004056786A3 (en) * 2002-12-20 2004-10-21 Pfizer Prod Inc Pyrimidine derivates for the treatment of abnormal cell growth
US7351712B2 (en) 2002-12-20 2008-04-01 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
US7741336B2 (en) 2002-12-20 2010-06-22 Pfizer Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
EP2341067A1 (en) 2003-07-18 2011-07-06 Amgen, Inc Specific binding agents to hepatocyte growth factor
US8178671B2 (en) 2003-07-30 2012-05-15 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2, 4-pyrimidinediamine compounds
US9751893B2 (en) 2003-07-30 2017-09-05 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
US7122542B2 (en) 2003-07-30 2006-10-17 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
WO2005013996A3 (en) * 2003-08-07 2005-06-09 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and uses as anti-proliferative agents
US8809341B2 (en) 2003-08-07 2014-08-19 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and uses as anti-proliferative agents
US9598432B2 (en) 2003-08-07 2017-03-21 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and uses as anti-proliferative agents
US7884111B2 (en) 2003-08-07 2011-02-08 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and uses as anti-proliferative agents
WO2005105094A3 (en) * 2004-04-16 2006-06-15 Smithkline Beecham Corp Cancer treatment method
JP2007532658A (en) * 2004-04-16 2007-11-15 スミスクライン ビーチャム コーポレーション How to treat cancer
US7235562B2 (en) 2004-05-14 2007-06-26 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
US7145008B2 (en) 2004-05-14 2006-12-05 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
US7208499B2 (en) 2004-05-14 2007-04-24 Pfizer Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
US7754714B2 (en) 2004-05-18 2010-07-13 Rigel Pharmaceuticals, Inc. Cycloalkyl substituted pyrimidinediamine compounds and their uses
US8410093B2 (en) 2004-05-18 2013-04-02 Rigel Pharmaceuticals, Inc. Cycloalkyl substituted pyrimidinediamine compounds and their uses
US7868013B2 (en) 2004-05-18 2011-01-11 Rigel Pharmaceuticals, Inc. Cycloalkyl substituted pyrimidinediamine compounds and their uses
US7858633B2 (en) 2004-05-18 2010-12-28 Rigel Pharmaceuticals, Inc. Cycloalkyl substituted pyrimidinediamine compounds and their uses
US8546398B2 (en) 2004-05-18 2013-10-01 Rigel Pharmaceuticals, Inc. Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses
US9725419B2 (en) 2004-05-18 2017-08-08 Rigel Pharmaceuticals, Inc. Cycloalkyl substituted pyrimidinediamine compounds and their uses
WO2005118544A3 (en) * 2004-05-18 2006-02-16 Rigel Pharmaceuticals Inc Cycloalkyl substituted pyrimidinediamine compounds and their uses
WO2006020564A1 (en) * 2004-08-09 2006-02-23 Smithkline Beecham Corporation Pyrimidin derivatives for the treatment of multiple myeloma
WO2006055561A2 (en) * 2004-11-15 2006-05-26 Rigel Pharmaceuticals, Inc. Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses
US7863286B2 (en) 2004-11-15 2011-01-04 Rigel Pharmaceuticals, Inc. Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses
AU2005307849B2 (en) * 2004-11-15 2012-11-15 Rigel Pharmaceuticals, Inc. Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses
CN101171012B (en) * 2004-11-15 2013-04-17 里格尔药品股份有限公司 Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses
US8030483B2 (en) 2004-11-15 2011-10-04 Rigel Pharmaceuticals, Inc. Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses
WO2006055561A3 (en) * 2004-11-15 2008-05-22 Rigel Pharmaceuticals Inc Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses
US8101627B2 (en) 2004-11-15 2012-01-24 Rigel Pharmaceuticals, Inc. Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses
US8044054B2 (en) 2004-11-15 2011-10-25 Rigel Pharmaceuticals, Inc. Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses
US7514465B2 (en) 2004-11-16 2009-04-07 Yung Shin Pharm. Ind. Co., Ltd. Synthesis of N2-(substituted arylmethyl)-3-(substituted phenyl)indazoles as novel anti-angiogenic agents
EP1659115A1 (en) 2004-11-16 2006-05-24 Yung Shin Pharm. Ind. Co., Ltd. Synthesis of substituted 2H-indazole derivatives as anti-angiogenic agents
US7851480B2 (en) 2004-11-24 2010-12-14 Rigel Pharmaceuticals, Inc. Spiro 2,4-pyrimidinediamine compounds and their uses
WO2006060318A2 (en) 2004-11-30 2006-06-08 Amgen Inc. Quinolines and quinazoline analogs and their use as medicaments for treating cancer
US9532998B2 (en) 2005-01-19 2017-01-03 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
US10577381B2 (en) 2005-01-19 2020-03-03 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
US9266912B2 (en) 2005-01-19 2016-02-23 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
US8227455B2 (en) 2005-04-18 2012-07-24 Rigel Pharmaceuticals, Inc. Methods of treating cell proliferative disorders
US8481521B2 (en) 2005-04-18 2013-07-09 Rigel Pharmaceuticals, Inc. Methods of treating cell proliferative disorders
US9732073B2 (en) 2005-06-08 2017-08-15 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
US8415365B2 (en) 2005-06-08 2013-04-09 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
US9248190B2 (en) 2005-06-08 2016-02-02 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
US11198689B2 (en) 2005-06-08 2021-12-14 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
US11827628B2 (en) 2005-06-08 2023-11-28 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
US8399472B2 (en) 2005-06-08 2013-03-19 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
US9593082B2 (en) 2005-06-08 2017-03-14 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
US7491732B2 (en) 2005-06-08 2009-02-17 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
US10421752B2 (en) 2005-06-08 2019-09-24 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
US8986650B2 (en) 2005-10-07 2015-03-24 Guerbet Complex folate-NOTA-Ga68
US8926945B2 (en) 2005-10-07 2015-01-06 Guerbet Compounds comprising a biological target recognizing part, coupled to a signal part capable of complexing gallium
WO2007064753A2 (en) 2005-11-29 2007-06-07 Smithkline Beecham Corporation Cancer treatment method
WO2007064753A3 (en) * 2005-11-29 2007-11-29 Smithkline Beecham Corp Cancer treatment method
WO2007064752A3 (en) * 2005-11-29 2008-08-14 Smithkline Beecham Corp Treatment of ocular neovascular disorders such as macular degeneration, angiod streaks, uveitis and macular edema
EA016227B1 (en) * 2005-11-29 2012-03-30 Смитклайн Бичем Корпорейшн Method of treating ocular neovascular disorders
EP2380572A1 (en) 2005-11-29 2011-10-26 Glaxosmithkline LLC Cancer treatment method
AU2006320535B2 (en) * 2005-11-29 2010-09-23 Glaxosmithkline Llc Treatment method
EP2329821A1 (en) 2005-11-29 2011-06-08 GlaxoSmithKline LLC Treatment of ocular neovascular disorders such as macular degeneration, angiod streaks, uveitis and macular edema
US8648199B2 (en) 2005-12-23 2014-02-11 Amgen Inc. Process for making a solid-state form of AMG 706
WO2007085833A3 (en) * 2006-01-26 2007-09-27 Astrazeneca Ab Pyrimidine derivatives
WO2007085833A2 (en) * 2006-01-26 2007-08-02 Astrazeneca Ab Pyrimidine derivatives
AU2007209126B2 (en) * 2006-01-26 2012-01-19 Astrazeneca Ab Pyrimidine derivatives
WO2007089445A2 (en) 2006-01-27 2007-08-09 Amgen Inc. Ang2 and vegf inhibitor combinations
US7989631B2 (en) 2006-02-10 2011-08-02 Amgen Inc. Hydrate forms of AMG706
US11667611B2 (en) 2006-02-24 2023-06-06 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
US8962643B2 (en) 2006-02-24 2015-02-24 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
WO2007098507A2 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
WO2007143483A2 (en) * 2006-06-01 2007-12-13 Smithkline Beecham Corporation Combination of pazopanib and lapatinib for treating cancer
WO2007143483A3 (en) * 2006-06-01 2008-02-07 Smithkline Beecham Corp Combination of pazopanib and lapatinib for treating cancer
EP2578583A1 (en) 2006-07-14 2013-04-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
EP3093289A1 (en) 2006-07-14 2016-11-16 Amgen, Inc [1,2,4]triazolo[4,3-a]pyridine derivatives useful as inhibitors of the hepatocyte growth factor receptor
US8729087B2 (en) 2006-10-19 2014-05-20 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
WO2008049123A2 (en) 2006-10-19 2008-04-24 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine derivatives as inhibitors of jak kinases for the treatment of autoimmune diseases
WO2008049123A3 (en) * 2006-10-19 2008-06-19 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine derivatives as inhibitors of jak kinases for the treatment of autoimmune diseases
US9040543B2 (en) 2006-10-19 2015-05-26 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
US8193197B2 (en) 2006-10-19 2012-06-05 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
WO2008079291A2 (en) 2006-12-20 2008-07-03 Amgen Inc. Substituted heterocycles and methods of use
WO2008079907A1 (en) * 2006-12-20 2008-07-03 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
WO2008086014A2 (en) 2007-01-09 2008-07-17 Amgen Inc. Bis-aryl amide derivatives useful for the treatment of cancer
US7868024B2 (en) 2007-01-19 2011-01-11 Sanofi-Aventis Derivatives of N-(heteroaryl)-1-heteroaryl-1H-indole-2-carboxamides, preparation thereof and therapeutic use thereof
WO2008103277A2 (en) 2007-02-16 2008-08-28 Amgen Inc. Nitrogen-containing heterocyclyl ketones and their use as c-met inhibitors
EP2589610A1 (en) 2007-08-21 2013-05-08 Amgen, Inc Human c-fms antigen binding proteins
EP2592093A1 (en) 2007-08-21 2013-05-15 Amgen, Inc Human c-fms antigen binding proteins
EP3330292A1 (en) 2007-08-21 2018-06-06 Amgen, Inc Human c-fms antigen binding proteins
EP2058307A1 (en) * 2007-11-12 2009-05-13 Cellzome Ag Methods for the identification of JAK kinase interacting molecules and for the purification of JAK kinases
US8349861B2 (en) 2007-11-12 2013-01-08 Cellzome Ag Methods for identification of JAK kinase interacting molecules and for the purification of JAK kinases
WO2009062658A1 (en) * 2007-11-12 2009-05-22 Cellzome Ag Methods for identification of jak kinase interacting molecules and for the purification of jak kinases
EP3170824A1 (en) 2008-01-15 2017-05-24 Amgen, Inc 6-([1,2,4]triazolo[4,3-a]pyridin-3-ylmethyl)-1,6-naphthyridin-5(6h)-one derivatives as c-met inhibitors
US8501944B2 (en) 2008-04-16 2013-08-06 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
US9579320B2 (en) 2008-04-16 2017-02-28 Portola Pharmaceuticals, Inc. Inhibitors of syk and JAK protein kinases
WO2009136995A2 (en) 2008-04-16 2009-11-12 Portola Pharmaceuticals, Inc. Inhibitors of syk protein kinase
US10533001B2 (en) 2008-04-16 2020-01-14 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
US11414410B2 (en) 2008-04-16 2022-08-16 Alexion Pharmaceuticals, Inc. Inhibitors of protein kinases
US9868729B2 (en) 2008-04-16 2018-01-16 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
US8937070B2 (en) 2008-04-16 2015-01-20 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
US8952027B2 (en) 2008-04-16 2015-02-10 Portola Pharmaceuticals, Inc. Inhibitors of syk and JAK protein kinases
US8138339B2 (en) 2008-04-16 2012-03-20 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
US8258144B2 (en) 2008-04-22 2012-09-04 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
US9139581B2 (en) 2008-04-22 2015-09-22 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
US9012462B2 (en) 2008-05-21 2015-04-21 Ariad Pharmaceuticals, Inc. Phosphorous derivatives as kinase inhibitors
US20110301113A1 (en) * 2008-09-26 2011-12-08 Concert Pharmaceuticals Inc. Pyridineamine derivatives
WO2010036796A1 (en) * 2008-09-26 2010-04-01 Concert Pharmaceuticals, Inc. Pyridineamine derivatives
WO2010092114A1 (en) 2009-02-13 2010-08-19 Guerbet Use of buffers for radionuclide complexation
WO2011039648A1 (en) 2009-09-30 2011-04-07 Glaxo Wellcome Manufacturing Pte Ltd. Methods of administration and treatment
WO2011058179A1 (en) 2009-11-16 2011-05-19 Ratiopharm Gmbh 5- (4- (n- (2, 3 -dimethyl- 2h- indazol- 6 -yl) -n-methylamino) pyrimidin- 2 -ylamino) -2 -methylbenzenesulfonamide
WO2011069053A1 (en) 2009-12-04 2011-06-09 Teva Pharmaceutical Industries Ltd. Process for the preparation of pazopanip hcl and crystalline forms of pazopanib hcl
WO2011085007A1 (en) * 2010-01-06 2011-07-14 Glaxo Wellcome Manufacturing Pte Ltd Treatment method
US8598156B2 (en) 2010-03-25 2013-12-03 Glaxosmithkline Llc Chemical compounds
US20130237554A1 (en) * 2010-05-26 2013-09-12 Rakesh Kumar Combination
US20150094283A1 (en) * 2010-05-26 2015-04-02 Glaxosmithkline Llc Combination
EP2575460A4 (en) * 2010-05-26 2013-10-16 Glaxosmithkline Llc Combination
EP2575460A1 (en) * 2010-05-26 2013-04-10 GlaxoSmithKline LLC Combination
WO2011161217A2 (en) 2010-06-23 2011-12-29 Palacký University in Olomouc Targeting of vegfr2
WO2012027438A1 (en) 2010-08-26 2012-03-01 Glaxosmithkline Llc Pharmaceutical combination of a vegfr inhibitor and a mek inhibitor useful for treating cancer
WO2012036919A2 (en) 2010-09-14 2012-03-22 Glaxosmithkline Llc Combination of braf and vegf inhibitors
EP2627179A1 (en) * 2010-10-14 2013-08-21 ARIAD Pharmaceuticals, Inc Methods for inhibiting cell proliferation in egfr-driven cancers
EP2627179A4 (en) * 2010-10-14 2014-04-02 Ariad Pharma Inc Methods for inhibiting cell proliferation in egfr-driven cancers
WO2012061415A1 (en) 2010-11-01 2012-05-10 Portola Pharmaceuticals, Inc. Oxypyrimidines as syk modulators
US9102625B2 (en) 2010-11-01 2015-08-11 Portola Pharmaceuticals, Inc. Nicotinamides as JAK kinase modulators
EP3176154A1 (en) 2010-11-01 2017-06-07 Portola Pharmaceuticals, Inc. Benzamides and nicotinamides as syk modulators
WO2012061418A2 (en) 2010-11-01 2012-05-10 Portola Pharmaceuticals, Inc. Benzamides and nicotinamides as syk modulators
US8709420B2 (en) 2010-12-17 2014-04-29 Glaxosmithkline Intellectual Property Limited Pharmaceutical combination of pazopanib and topotecan to treat neuroblastoma, osteosarcoma, and rhabdomyosarcoma in a human
WO2012082337A2 (en) 2010-12-17 2012-06-21 Glaxo Wellcome Manufacturing Pte Ltd Combination
WO2012082337A3 (en) * 2010-12-17 2013-12-27 Glaxosmithkline Intellectual Property Limited Combination
US9770520B2 (en) 2010-12-20 2017-09-26 Guerbet Chelate nanoemulsion for MRI
WO2012084981A1 (en) 2010-12-20 2012-06-28 Guerbet Chelate nanoemulsion for mri
WO2012106302A1 (en) 2011-02-01 2012-08-09 Glaxo Wellcome Manufacturing Pte Ltd Combination
EP2937349A1 (en) 2011-03-23 2015-10-28 Amgen Inc. Fused tricyclic dual inhibitors of cdk 4/6 and flt3
WO2012129344A1 (en) 2011-03-23 2012-09-27 Amgen Inc. Fused tricyclic dual inhibitors of cdk 4/6 and flt3
CN103476759A (en) * 2011-04-19 2013-12-25 拜耳知识产权有限责任公司 Substituted 4-aryl-n-phenyl-1,3,5-triazin-2-amines
WO2012143399A1 (en) * 2011-04-19 2012-10-26 Bayer Intellectual Property Gmbh Substituted 4-aryl-n-phenyl-1,3,5-triazin-2-amines
CN103476759B (en) * 2011-04-19 2016-03-16 拜耳知识产权有限责任公司 4-aryl-N-phenyl-1,3,5-triazines-2-the amine replaced
US9834518B2 (en) 2011-05-04 2017-12-05 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in EGFR-driven cancers
US9669034B2 (en) 2011-05-24 2017-06-06 Bayer Intellectual Property Gmbh 4-aryl-N-phenyl-1,3,5-triazin-2-amines containing a sulfoximine group
US9962389B2 (en) 2011-05-24 2018-05-08 Bayer Intellectual Property Gmbh 4-aryl-N-phenyl-1,3,5-triazin-2-amines containing a sulfoximine group
US9745288B2 (en) 2011-08-16 2017-08-29 Indiana University Research And Technology Corporation Compounds and methods for treating cancer by inhibiting the urokinase receptor
WO2013045333A1 (en) 2011-09-26 2013-04-04 Guerbet Nanoemulsions and use thereof as contrast agents
US9359308B2 (en) 2011-11-23 2016-06-07 Portola Pharmaceuticals, Inc. Pyrazine kinase inhibitors
WO2013132044A1 (en) 2012-03-08 2013-09-12 F. Hoffmann-La Roche Ag Combination therapy of antibodies against human csf-1r and uses thereof
US9834571B2 (en) 2012-05-05 2017-12-05 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in EGFR-driven cancers
WO2014036022A1 (en) 2012-08-29 2014-03-06 Amgen Inc. Quinazolinone compounds and derivatives thereof
US9676756B2 (en) 2012-10-08 2017-06-13 Portola Pharmaceuticals, Inc. Substituted pyrimidinyl kinase inhibitors
US9708293B2 (en) 2012-10-18 2017-07-18 Bayer Pharma Aktiengesellschaft N-(pyridin-2-yl)pyrimidin-4-amine derivatives containing a sulfone group
US9670161B2 (en) 2012-10-18 2017-06-06 Bayer Pharma Aktiengesellschaft 5-fluoro-N-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfone group
US9650340B2 (en) 2012-11-15 2017-05-16 Bayer Pharma Aktiengesellschaft 5-fluoro-N-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfoximine group
US9650361B2 (en) 2012-11-15 2017-05-16 Bayer Pharam Aktiengesellschaft N-(pyridin-2-yl)pyrimidin-4-amine derivatives containing a sulfoximine group
US9877954B2 (en) 2012-11-15 2018-01-30 Bayer Pharma Aktiengesellschaft 5-fluoro-N-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfoximine group
WO2014108837A1 (en) 2013-01-09 2014-07-17 Glaxosmithkline Intellectual Property (No.2) Limited Combination
WO2014114724A1 (en) 2013-01-23 2014-07-31 Guerbet Vectorised magnetic emulsion
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
US9770445B2 (en) 2013-07-04 2017-09-26 Bayer Pharma Aktiengesellschaft Sulfoximine substituted 5-fluoro-N-(pyridin-2-yl)pyridin-2-amine derivatives and their use as CDK9 kinase inhibitors
WO2015056180A1 (en) 2013-10-15 2015-04-23 Glaxosmithkline Intellectual Property (No.2) Limited Indoline derivatives as inhibitors of perk
US11299477B2 (en) 2013-11-05 2022-04-12 Laurus Labs Limited Process for the preparation of Pazopanib or a pharmaceutically acceptable salt thereof
US11427570B2 (en) 2013-11-05 2022-08-30 Laurus Labs Limited Process for the preparation of pazopanib or a pharmaceutically acceptable salt thereof
US10730859B2 (en) * 2013-11-05 2020-08-04 Laurus Labs Limited Process for the preparation of pazopanib or a pharmaceutically acceptable salt thereof
US20160280689A1 (en) * 2013-11-05 2016-09-29 Laurus Labs Private Limited An improved process for the preparation of pazopanib or a pharmaceutically acceptable salt thereof
WO2015136463A1 (en) 2014-03-11 2015-09-17 Glaxosmithkline Intellectual Property (No.2) Limited Chemical compounds acting as perk inhibitors
US9856242B2 (en) 2014-03-13 2018-01-02 Bayer Pharma Aktiengesellscaft 5-fluoro-N-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfone group
US9790189B2 (en) 2014-04-01 2017-10-17 Bayer Pharma Aktiengesellschaft Disubstituted 5-fluoro pyrimidine derivatives containing a sulfondiimine group
US9963464B2 (en) 2014-04-11 2018-05-08 Bayer Pharma Aktiengesellschaft Macrocyclic compounds
US9856263B2 (en) 2014-04-28 2018-01-02 Pfizer Inc. Heteroaromatic compounds and their use as dopamine D1 ligands
WO2016055935A1 (en) 2014-10-06 2016-04-14 Glaxosmithkline Intellectual Property (No.2) Limited Combination of lysine-specific demethylase 1 inhibitor and thrombopoietin agonist
US9884849B2 (en) 2014-10-16 2018-02-06 Bayer Pharma Aktiengesellschaft Fluorinated benzofuranyl-pyrimidine derivatives containing a sulfoximine group
US9902716B2 (en) 2014-10-16 2018-02-27 Bayer Pharma Aktiengesellschaft Fluorinated benzofuranyl-pyrimidine derivatives containing a sulfone group
WO2016112111A1 (en) 2015-01-08 2016-07-14 The Board Of Trustees Of The Leland Stanford Junior University Factors and cells that provide for induction of bone, bone marrow, and cartilage
EP3789027A1 (en) 2015-01-13 2021-03-10 Kyoto University Bosutinib, sunitinib, tivozanib, imatinib, nilotinib, rebastinib or bafetinib for preventing and/or treating amyotrophic lateral sclerosis
WO2017098421A1 (en) 2015-12-08 2017-06-15 Glaxosmithkline Intellectual Property Development Limited Benzothiadiazine compounds
WO2017153952A1 (en) 2016-03-10 2017-09-14 Glaxosmithkline Intellectual Property Development Limited 5-sulfamoyl-2-hydroxybenzamide derivatives
WO2017174758A1 (en) 2016-04-07 2017-10-12 Imba - Institut Für Molekulare Biotechnologie Gmbh Combination of an apelin antagonist and an angiogenesis inhibitor for the treatment of cancer
EP3228630A1 (en) 2016-04-07 2017-10-11 IMBA-Institut für Molekulare Biotechnologie GmbH Combination of an apelin antagonist and an angiogenesis inhibitor for the treatment of cancer
WO2017212423A1 (en) 2016-06-08 2017-12-14 Glaxosmithkline Intellectual Property Development Limited Chemcical compounds
WO2017212425A1 (en) 2016-06-08 2017-12-14 Glaxosmithkline Intellectual Property Development Limited Chemical compounds as atf4 pathway inhibitors
WO2018015879A1 (en) 2016-07-20 2018-01-25 Glaxosmithkline Intellectual Property Development Limited Isoquinoline derivatives as perk inhibitors
WO2018100536A1 (en) 2016-12-01 2018-06-07 Glaxosmithkline Intellectual Property Development Limited Methods of treating cancer
US10532042B2 (en) 2016-12-22 2020-01-14 Amgen Inc. KRAS G12C inhibitors and methods of using the same
US11285135B2 (en) 2016-12-22 2022-03-29 Amgen Inc. KRAS G12C inhibitors and methods of using the same
WO2018119183A2 (en) 2016-12-22 2018-06-28 Amgen Inc. Kras g12c inhibitors and methods of using the same
EP4001269A1 (en) 2016-12-22 2022-05-25 Amgen Inc. Benzoisothiazole, isothiazolo[3,4-b]pyridine, quinazoline, phthalazine, pyrido[2,3-d]pyridazine and pyrido[2,3-d]pyrimidine derivatives as kras g12c inhibitors for treating lung, pancreatic or colorectal cancer
US11242356B2 (en) 2017-03-28 2022-02-08 Bayer Aktiengesellschaft PTEFb inhibiting macrocyclic compounds
US11691986B2 (en) 2017-03-28 2023-07-04 Bayer Aktiengesellschaft PTEFB inhibiting macrocyclic compounds
US11254690B2 (en) 2017-03-28 2022-02-22 Bayer Pharma Aktiengesellschaft PTEFb inhibiting macrocyclic compounds
WO2018217651A1 (en) 2017-05-22 2018-11-29 Amgen Inc. Kras g12c inhibitors and methods of using the same
US10519146B2 (en) 2017-05-22 2019-12-31 Amgen Inc. KRAS G12C inhibitors and methods of using the same
EP3974429A1 (en) 2017-05-22 2022-03-30 Amgen Inc. Precursors of kras g12c inhibitors
US11905281B2 (en) 2017-05-22 2024-02-20 Amgen Inc. KRAS G12C inhibitors and methods of using the same
WO2018225093A1 (en) 2017-06-07 2018-12-13 Glaxosmithkline Intellectual Property Development Limited Chemical compounds as atf4 pathway inhibitors
WO2019008506A1 (en) 2017-07-03 2019-01-10 Glaxosmithkline Intellectual Property Development Limited N-(3-(2-(4-chlorophenoxy)acetamido)bicyclo[1.1.1]pentan-1-yl)-2-cyclobutane-1-carboxamide derivatives and related compounds as atf4 inhibitors for treating cancer and other diseases
WO2019008507A1 (en) 2017-07-03 2019-01-10 Glaxosmithkline Intellectual Property Development Limited 2-(4-chlorophenoxy)-n-((1 -(2-(4-chlorophenoxy)ethynazetidin-3-yl)methyl)acetamide derivatives and related compounds as atf4 inhibitors for treating cancer and other diseases
WO2019021208A1 (en) 2017-07-27 2019-01-31 Glaxosmithkline Intellectual Property Development Limited Indazole derivatives useful as perk inhibitors
WO2019049061A1 (en) 2017-09-07 2019-03-14 Glaxosmithkline Intellectual Property Development Limited 5-(1 h-benzo[d]imidazo-2-yl)-pyridin-2-amine and 5-(3h-imidazo[4,5-b]pyridin-6-yl)-pyridin-2-amine derivatives as c-myc and p300/cbp histone acetyltransferase inhibitors for treating cancer
US10640504B2 (en) 2017-09-08 2020-05-05 Amgen Inc. Inhibitors of KRAS G12C and methods of using the same
US11306087B2 (en) 2017-09-08 2022-04-19 Amgen Inc. Inhibitors of KRAS G12C and methods of using the same
WO2019051291A1 (en) 2017-09-08 2019-03-14 Amgen Inc. Inhibitors of kras g12c and methods of using the same
EP4403175A2 (en) 2017-09-08 2024-07-24 Amgen Inc. Inhibitors of kras g12c and methods of using the same
US11993597B2 (en) 2017-09-08 2024-05-28 Amgen Inc. Inhibitors of KRAS G12C and methods of using the same
EP4141005A1 (en) 2017-09-08 2023-03-01 Amgen Inc. Inhibitors of kras g12c and methods of using the same
WO2019053617A1 (en) 2017-09-12 2019-03-21 Glaxosmithkline Intellectual Property Development Limited Chemical compounds
US11701347B2 (en) 2018-02-13 2023-07-18 Bayer Aktiengesellschaft Use of 5-fluoro-4-(4-fluoro-2-methoxyphenyl)-N-{4-[(S-methylsulfonimidoyl)methyl]pyridin-2-yl}pyridin-2-amine for treating diffuse large B-cell lymphoma
WO2019193540A1 (en) 2018-04-06 2019-10-10 Glaxosmithkline Intellectual Property Development Limited Heteroaryl derivatives of formula (i) as atf4 inhibitors
WO2019193541A1 (en) 2018-04-06 2019-10-10 Glaxosmithkline Intellectual Property Development Limited Bicyclic aromatic ring derivatives of formula (i) as atf4 inhibitors
WO2019053500A1 (en) 2018-04-17 2019-03-21 Alvogen Malta Operations (Row) Ltd Pharmaceutical composition of solid dosage form containing pazopanib and process for its preparation
WO2019213516A1 (en) 2018-05-04 2019-11-07 Amgen Inc. Kras g12c inhibitors and methods of using the same
US11045484B2 (en) 2018-05-04 2021-06-29 Amgen Inc. KRAS G12C inhibitors and methods of using the same
WO2019213526A1 (en) 2018-05-04 2019-11-07 Amgen Inc. Kras g12c inhibitors and methods of using the same
US11090304B2 (en) 2018-05-04 2021-08-17 Amgen Inc. KRAS G12C inhibitors and methods of using the same
US11766436B2 (en) 2018-05-04 2023-09-26 Amgen Inc. KRAS G12C inhibitors and methods of using the same
US10988485B2 (en) 2018-05-10 2021-04-27 Amgen Inc. KRAS G12C inhibitors and methods of using the same
WO2019217691A1 (en) 2018-05-10 2019-11-14 Amgen Inc. Kras g12c inhibitors for the treatment of cancer
WO2019232419A1 (en) 2018-06-01 2019-12-05 Amgen Inc. Kras g12c inhibitors and methods of using the same
US11096939B2 (en) 2018-06-01 2021-08-24 Amgen Inc. KRAS G12C inhibitors and methods of using the same
EP4268898A2 (en) 2018-06-11 2023-11-01 Amgen Inc. Kras g12c inhibitors for treating cancer
WO2019241157A1 (en) 2018-06-11 2019-12-19 Amgen Inc. Kras g12c inhibitors for treating cancer
WO2020050890A2 (en) 2018-06-12 2020-03-12 Amgen Inc. Kras g12c inhibitors and methods of using the same
US11285156B2 (en) 2018-06-12 2022-03-29 Amgen Inc. Substituted piperazines as KRAS G12C inhibitors
US12083121B2 (en) 2018-06-12 2024-09-10 Amgen Inc. Substituted piperazines as KRAS G12C inhibitors
WO2020007822A1 (en) 2018-07-02 2020-01-09 Conservatoire National Des Arts Et Metiers (Cnam) Bismuth metallic (0) nanoparticles, process of manufacturing and uses thereof
WO2020012339A1 (en) 2018-07-09 2020-01-16 Glaxosmithkline Intellectual Property Development Limited Chemical compounds
WO2020031107A1 (en) 2018-08-08 2020-02-13 Glaxosmithkline Intellectual Property Development Limited Chemical compounds
EP4234546A2 (en) 2018-11-16 2023-08-30 Amgen Inc. Improved synthesis of key intermediate of kras g12c inhibitor compound
US11299491B2 (en) 2018-11-16 2022-04-12 Amgen Inc. Synthesis of key intermediate of KRAS G12C inhibitor compound
WO2020102730A1 (en) 2018-11-16 2020-05-22 Amgen Inc. Improved synthesis of key intermediate of kras g12c inhibitor compound
WO2020106640A1 (en) 2018-11-19 2020-05-28 Amgen Inc. Kras g12c inhibitors and methods of using the same
US11053226B2 (en) 2018-11-19 2021-07-06 Amgen Inc. KRAS G12C inhibitors and methods of using the same
US11439645B2 (en) 2018-11-19 2022-09-13 Amgen Inc. Combination therapy including a KRASG12C inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
US11918584B2 (en) 2018-11-19 2024-03-05 Amgen Inc. Combination therapy including a KRASG12C inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
WO2020106647A2 (en) 2018-11-19 2020-05-28 Amgen Inc. Combination therapy including a krasg12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
WO2020110056A1 (en) 2018-11-30 2020-06-04 Glaxosmithkline Intellectual Property Development Limited Compounds useful in hiv therapy
EP4342473A2 (en) 2018-11-30 2024-03-27 GlaxoSmithKline Intellectual Property Development Limited Compounds useful in hiv therapy
WO2020132648A1 (en) 2018-12-20 2020-06-25 Amgen Inc. Kif18a inhibitors
WO2020132649A1 (en) 2018-12-20 2020-06-25 Amgen Inc. Heteroaryl amides useful as kif18a inhibitors
WO2020132653A1 (en) 2018-12-20 2020-06-25 Amgen Inc. Heteroaryl amides useful as kif18a inhibitors
US11236069B2 (en) 2018-12-20 2022-02-01 Amgen Inc. KIF18A inhibitors
WO2020132651A1 (en) 2018-12-20 2020-06-25 Amgen Inc. Kif18a inhibitors
US12054476B2 (en) 2018-12-20 2024-08-06 Amgen Inc. KIF18A inhibitors
WO2020180770A1 (en) 2019-03-01 2020-09-10 Revolution Medicines, Inc. Bicyclic heterocyclyl compounds and uses thereof
WO2020180768A1 (en) 2019-03-01 2020-09-10 Revolution Medicines, Inc. Bicyclic heteroaryl compounds and uses thereof
US11426404B2 (en) 2019-05-14 2022-08-30 Amgen Inc. Dosing of KRAS inhibitor for treatment of cancers
US11827635B2 (en) 2019-05-21 2023-11-28 Amgen Inc. Solid state forms
US11236091B2 (en) 2019-05-21 2022-02-01 Amgen Inc. Solid state forms
WO2021018941A1 (en) 2019-07-31 2021-02-04 Glaxosmithkline Intellectual Property Development Limited Methods of treating cancer
WO2021026099A1 (en) 2019-08-02 2021-02-11 Amgen Inc. Kif18a inhibitors
WO2021026098A1 (en) 2019-08-02 2021-02-11 Amgen Inc. Kif18a inhibitors
WO2021026101A1 (en) 2019-08-02 2021-02-11 Amgen Inc. Kif18a inhibitors
WO2021026100A1 (en) 2019-08-02 2021-02-11 Amgen Inc. Pyridine derivatives as kif18a inhibitors
WO2021081212A1 (en) 2019-10-24 2021-04-29 Amgen Inc. Pyridopyrimidine derivatives useful as kras g12c and kras g12d inhibitors in the treatment of cancer
WO2021091956A1 (en) 2019-11-04 2021-05-14 Revolution Medicines, Inc. Ras inhibitors
WO2021091982A1 (en) 2019-11-04 2021-05-14 Revolution Medicines, Inc. Ras inhibitors
WO2021091967A1 (en) 2019-11-04 2021-05-14 Revolution Medicines, Inc. Ras inhibitors
WO2021092115A1 (en) 2019-11-08 2021-05-14 Revolution Medicines, Inc. Bicyclic heteroaryl compounds and uses thereof
WO2021097212A1 (en) 2019-11-14 2021-05-20 Amgen Inc. Improved synthesis of kras g12c inhibitor compound
WO2021097207A1 (en) 2019-11-14 2021-05-20 Amgen Inc. Improved synthesis of kras g12c inhibitor compound
WO2021108683A1 (en) 2019-11-27 2021-06-03 Revolution Medicines, Inc. Covalent ras inhibitors and uses thereof
WO2021142026A1 (en) 2020-01-07 2021-07-15 Revolution Medicines, Inc. Shp2 inhibitor dosing and methods of treating cancer
WO2021257736A1 (en) 2020-06-18 2021-12-23 Revolution Medicines, Inc. Methods for delaying, preventing, and treating acquired resistance to ras inhibitors
WO2022040446A1 (en) 2020-08-19 2022-02-24 Nanocopoeia, Llc Amorphous pazopanib particles and pharmaceutical compositions thereof
WO2022060583A1 (en) 2020-09-03 2022-03-24 Revolution Medicines, Inc. Use of sos1 inhibitors to treat malignancies with shp2 mutations
WO2022060836A1 (en) 2020-09-15 2022-03-24 Revolution Medicines, Inc. Indole derivatives as ras inhibitors in the treatment of cancer
WO2022140427A1 (en) 2020-12-22 2022-06-30 Qilu Regor Therapeutics Inc. Sos1 inhibitors and uses thereof
WO2022235870A1 (en) 2021-05-05 2022-11-10 Revolution Medicines, Inc. Ras inhibitors for the treatment of cancer
WO2022235866A1 (en) 2021-05-05 2022-11-10 Revolution Medicines, Inc. Covalent ras inhibitors and uses thereof
WO2022235864A1 (en) 2021-05-05 2022-11-10 Revolution Medicines, Inc. Ras inhibitors
WO2023060253A1 (en) 2021-10-08 2023-04-13 Revolution Medicines, Inc. Ras inhibitors
WO2023114954A1 (en) 2021-12-17 2023-06-22 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
EP4227307A1 (en) 2022-02-11 2023-08-16 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
WO2023172940A1 (en) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Methods for treating immune refractory lung cancer
WO2023230541A1 (en) 2022-05-27 2023-11-30 Viiv Healthcare Company Piperazine derivatives useful in hiv therapy
WO2023240263A1 (en) 2022-06-10 2023-12-14 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2024081916A1 (en) 2022-10-14 2024-04-18 Black Diamond Therapeutics, Inc. Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives
WO2024206858A1 (en) 2023-03-30 2024-10-03 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
WO2024211712A1 (en) 2023-04-07 2024-10-10 Revolution Medicines, Inc. Condensed macrocyclic compounds as ras inhibitors
WO2024211663A1 (en) 2023-04-07 2024-10-10 Revolution Medicines, Inc. Condensed macrocyclic compounds as ras inhibitors

Also Published As

Publication number Publication date
ES2324981T3 (en) 2009-08-21
CA2432000C (en) 2011-03-15
EP2311825A1 (en) 2011-04-20
US20070292513A1 (en) 2007-12-20
KR20040011448A (en) 2004-02-05
EP1343782B1 (en) 2009-05-06
HUP0400691A3 (en) 2010-03-29
US20070015756A1 (en) 2007-01-18
HUS1700003I1 (en) 2020-09-28
CZ304059B6 (en) 2013-09-11
NO20032831L (en) 2003-08-15
HK1149930A1 (en) 2011-10-21
CY1109160T1 (en) 2012-01-25
IL156306A0 (en) 2004-01-04
US7262203B2 (en) 2007-08-28
BE2010C030I2 (en) 2021-06-17
JP4253188B2 (en) 2009-04-08
DE122010000038I1 (en) 2011-01-27
HK1059926A1 (en) 2004-07-23
CN1307173C (en) 2007-03-28
US7858626B2 (en) 2010-12-28
US20120277258A1 (en) 2012-11-01
PL363243A1 (en) 2004-11-15
CY2010014I2 (en) 2012-01-25
US7105530B2 (en) 2006-09-12
NO2022001I1 (en) 2022-01-06
FR10C0037I2 (en) 2011-04-29
PL214667B1 (en) 2013-08-30
CN1549813A (en) 2004-11-24
NZ526542A (en) 2005-01-28
US20070270427A1 (en) 2007-11-22
DE60138645D1 (en) 2009-06-18
HU230574B1 (en) 2023-11-28
NO325987B1 (en) 2008-08-25
BR0116452A (en) 2003-09-30
FR10C0037I1 (en) 2010-10-15
NO2010020I2 (en) 2012-02-13
ZA200304482B (en) 2005-11-30
KR100847169B1 (en) 2008-07-17
PT2311825E (en) 2016-01-22
SI2311825T1 (en) 2016-02-29
CA2432000A1 (en) 2002-08-01
HUP0400691A2 (en) 2004-07-28
DK1343782T3 (en) 2009-08-24
NO20032831D0 (en) 2003-06-20
LU91710I2 (en) 2010-09-21
EP2311825B1 (en) 2015-10-07
US20100105712A1 (en) 2010-04-29
US8114885B2 (en) 2012-02-14
LU91710I9 (en) 2019-01-03
AU2002246723B2 (en) 2005-07-14
PT1343782E (en) 2009-06-29
US20040242578A1 (en) 2004-12-02
MXPA03005696A (en) 2003-10-06
SI1343782T1 (en) 2009-10-31
IL156306A (en) 2010-12-30
CZ20031748A3 (en) 2004-04-14
JP2004517925A (en) 2004-06-17
EP1343782A1 (en) 2003-09-17
NO2010020I1 (en) 2010-11-22
ES2556946T3 (en) 2016-01-21
DK2311825T3 (en) 2016-01-18
ATE430742T1 (en) 2009-05-15
CY2010014I1 (en) 2012-01-25

Similar Documents

Publication Publication Date Title
EP2311825B1 (en) Pyrimidineamines as angiogenesis modulators
AU2002246723A1 (en) Pyrimidineamines as angiogenesis modulators
AU2003276125B2 (en) Chemical process
EP1487824A1 (en) Diamino-pyrimidines and their use as angiogenesis inhibitors
CA2476281A1 (en) Pyrimidine compounds
WO2002044156A2 (en) Benzimidazole derivatives useful as tie-2 and/or vegfr-2 inhibitors
JP2009506040A (en) Pyrimidinyl-pyrazole inhibitors of Aurora kinase
WO2004112714A2 (en) Chemical compounds

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 156306

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2003/04482

Country of ref document: ZA

Ref document number: 200304482

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2001994315

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2432000

Country of ref document: CA

Ref document number: 2002246723

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 03051479A

Country of ref document: CO

Ref document number: 03051479

Country of ref document: CO

Ref document number: 526542

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2002559412

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: PV2003-1748

Country of ref document: CZ

Ref document number: 1-2003-500531

Country of ref document: PH

Ref document number: 1020037008349

Country of ref document: KR

Ref document number: PA/a/2003/005696

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 018227503

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2001994315

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1020037008349

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: PV2003-1748

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 10451305

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 526542

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 526542

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 2002246723

Country of ref document: AU